data_5zv6_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5zv6 _Structure_validation_residue.Date_analyzed 2019-05-10 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.235 0.323 0 CA-C-O 120.536 0.208 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 83.3 m -91.84 146.28 23.88 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.234 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -114.11 110.6 32.71 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.958 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 56.02 27.15 10.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 123.975 0.91 . . . . 0.0 112.382 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.3 21.49 38.0 Favored Glycine 0 C--N 1.338 0.689 0 CA-C-N 115.818 -0.628 . . . . 0.0 113.42 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 76.8 mtp180 -134.3 122.7 23.04 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-O 120.645 0.26 . . . . 0.0 110.796 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.523 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.5 t -136.58 115.92 10.72 Favored Pre-proline 0 CA--C 1.54 0.565 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.787 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -80.95 -161.93 0.17 Allowed 'Trans proline' 0 C--N 1.37 1.689 0 C-N-CA 122.362 2.041 . . . . 0.0 112.845 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.22 -30.6 7.48 Favored Glycine 0 C--N 1.34 0.78 0 O-C-N 123.421 0.451 . . . . 0.0 113.04 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.61 43.33 3.42 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 121.599 -0.334 . . . . 0.0 112.728 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.722 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -132.93 -170.33 2.43 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.487 0.315 . . . . 0.0 110.843 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 72.5 m -95.0 154.45 17.16 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 120.759 0.314 . . . . 0.0 111.844 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 42.5 t -129.02 126.56 39.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.837 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 36.8 p -92.24 144.88 24.96 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.603 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.18 -20.82 7.46 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -76.03 -6.66 52.07 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.337 0.255 . . . . 0.0 111.379 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.77 48.12 2.79 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.609 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.489 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 88.3 m-85 -137.86 160.47 39.2 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -179.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.722 ' HB3' HD12 ' A' ' 13' ' ' LEU . 13.2 m -123.34 152.2 41.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.616 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 177.16 159.24 22.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.951 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.8 m -116.39 143.74 45.17 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 122.405 0.282 . . . . 0.0 110.925 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.18 -175.39 29.56 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.414 -0.659 . . . . 0.0 112.876 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -77.43 63.01 7.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 123.092 2.528 . . . . 0.0 112.49 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.11 -46.05 0.43 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.107 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -118.45 -2.68 11.02 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.121 178.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.7 m . . . . . 0 C--N 1.344 0.341 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.521 -179.777 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 . . . . . 0 N--CA 1.465 0.314 0 CA-C-O 120.526 0.203 . . . . 0.0 110.981 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.3 m -94.31 151.81 19.14 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.263 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -125.66 113.35 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 36.5 ttt180 55.95 26.23 9.63 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.998 0.919 . . . . 0.0 112.594 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.57 26.28 39.49 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.89 -0.595 . . . . 0.0 113.66 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -131.82 116.14 16.85 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 110.753 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.8 t -142.54 107.92 5.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.851 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.42 -160.61 0.12 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.462 2.108 . . . . 0.0 112.846 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.26 -32.12 7.28 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.285 0.365 . . . . 0.0 113.038 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.02 42.11 2.49 Favored Glycine 0 C--N 1.338 0.662 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.641 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.631 HD13 ' SG ' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -131.77 -169.52 2.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 122.683 0.393 . . . . 0.0 110.599 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 26.2 p -108.5 156.03 19.95 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.55 0.214 . . . . 0.0 111.296 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.406 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 47.6 t -126.21 131.7 51.92 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.642 -179.514 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.4 t -89.58 144.88 25.66 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.253 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -56.04 -19.38 12.57 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -178.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -77.66 -5.6 50.98 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 123.095 0.247 . . . . 0.0 111.497 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 48.36 2.45 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.615 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 83.6 m-85 -135.93 161.3 36.01 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.593 0.235 . . . . 0.0 111.571 -179.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.631 ' SG ' HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -134.11 145.93 49.79 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.574 179.748 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.582 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -175.75 -179.55 46.32 Favored Glycine 0 C--N 1.341 0.838 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.056 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 35.2 p -129.62 136.93 50.36 Favored 'General case' 0 C--O 1.236 0.372 0 O-C-N 123.723 0.307 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.63 -176.71 28.91 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 119.433 -0.649 . . . . 0.0 112.68 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -77.51 64.54 8.04 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 123.006 2.471 . . . . 0.0 112.364 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -137.49 -46.49 0.55 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.098 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -120.41 -6.22 9.81 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.059 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 38.1 m . . . . . 0 C--N 1.345 0.386 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.62 -179.385 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 N--CA 1.466 0.33 0 CA-C-O 120.58 0.229 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.421 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.8 m -94.88 137.51 33.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.163 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 14.6 p -105.28 109.95 29.41 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.724 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 68.4 mtp180 55.1 26.14 7.89 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 123.984 0.914 . . . . 0.0 112.732 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.64 26.56 24.66 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.871 -0.604 . . . . 0.0 113.408 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -134.89 117.4 15.82 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.668 0.27 . . . . 0.0 110.742 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.421 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 42.7 t -140.51 110.38 6.85 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.928 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.93 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.372 2.048 . . . . 0.0 112.723 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.93 -31.87 6.89 Favored Glycine 0 C--N 1.34 0.784 0 O-C-N 123.384 0.428 . . . . 0.0 112.995 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.75 2.68 Favored Glycine 0 C--N 1.338 0.675 0 C-N-CA 121.608 -0.33 . . . . 0.0 112.784 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.589 HD13 ' SG ' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -132.0 -171.48 2.64 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 122.578 0.351 . . . . 0.0 110.786 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 92.7 m -96.46 154.51 17.23 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.747 0.308 . . . . 0.0 111.689 -178.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 51.8 t -130.48 126.08 35.99 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.017 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.7 t -90.29 144.03 26.22 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.469 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.71 -20.11 13.28 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -76.87 -6.09 50.99 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.389 0.275 . . . . 0.0 111.508 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.18 48.19 2.47 Favored Glycine 0 C--N 1.343 0.941 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.644 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.423 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.8 m-85 -136.22 160.55 38.34 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.687 0.28 . . . . 0.0 111.716 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.589 ' SG ' HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -132.21 147.99 52.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.83 179.927 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.55 163.87 28.51 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.216 -0.516 . . . . 0.0 112.737 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -113.28 149.6 33.65 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.3 -179.35 32.13 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.336 -0.702 . . . . 0.0 112.827 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -77.36 63.12 7.79 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.98 2.454 . . . . 0.0 112.458 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.89 -46.64 0.44 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.198 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -114.82 -2.62 12.9 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.08 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.0 m . . . . . 0 C--N 1.344 0.357 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.508 -179.77 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 N--CA 1.464 0.269 0 CA-C-O 120.589 0.233 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.482 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 82.5 m -94.41 151.81 19.09 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.338 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -125.55 111.3 26.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.942 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 56.56 26.16 10.7 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 123.928 0.891 . . . . 0.0 112.795 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.5 22.7 39.32 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.561 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.33 120.8 21.48 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.692 0.282 . . . . 0.0 110.813 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.0 t -138.54 114.36 8.79 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.861 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -81.72 -161.53 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.678 0 C-N-CA 122.403 2.069 . . . . 0.0 112.732 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.05 -30.46 7.56 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 123.364 0.415 . . . . 0.0 113.054 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.57 43.22 3.21 Favored Glycine 0 C--N 1.337 0.635 0 C-N-CA 121.616 -0.326 . . . . 0.0 112.785 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.551 HD13 ' SG ' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -132.97 -171.84 2.78 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 122.465 0.306 . . . . 0.0 110.799 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.404 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 80.2 m -96.66 158.41 15.44 Favored 'General case' 0 C--N 1.344 0.341 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -178.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 54.1 t -129.84 125.48 35.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.044 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.1 t -88.2 144.68 26.31 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.426 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -55.12 -21.43 13.01 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -76.29 -6.02 49.61 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 123.13 0.269 . . . . 0.0 111.396 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.28 48.33 2.63 Favored Glycine 0 C--N 1.342 0.896 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.519 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.42 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 88.6 m-85 -136.85 163.05 31.56 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.632 0.253 . . . . 0.0 111.638 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.551 ' SG ' HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -129.2 148.57 51.15 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.941 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.26 167.05 33.24 Favored Glycine 0 C--N 1.342 0.87 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.561 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.0 t -119.96 148.28 43.72 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-O 120.626 0.25 . . . . 0.0 111.108 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 110.21 178.65 20.84 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-O 119.305 -0.719 . . . . 0.0 112.904 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.59 64.22 8.58 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.952 2.435 . . . . 0.0 112.373 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -148.1 -45.05 0.16 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.776 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -99.77 -10.25 22.06 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.867 178.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.344 0.338 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.347 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.236 0.342 0 CA-C-O 120.595 0.235 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.509 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 5.2 t -97.28 151.45 19.87 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.869 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -117.92 109.49 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.346 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 53.88 27.19 6.92 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.124 0.97 . . . . 0.0 113.008 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.536 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 87.34 28.65 24.38 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-N 115.944 -0.571 . . . . 0.0 113.328 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.468 ' C ' ' HG ' ' A' ' 4' ' ' CYS . 99.1 mtt180 -137.26 116.36 12.49 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 122.499 0.32 . . . . 0.0 110.479 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.509 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 6.1 t -138.73 119.8 10.02 Favored Pre-proline 0 CA--C 1.539 0.526 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.938 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -80.1 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 122.338 2.026 . . . . 0.0 112.849 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.4 -30.59 8.03 Favored Glycine 0 C--N 1.341 0.832 0 O-C-N 123.361 0.413 . . . . 0.0 113.073 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.74 38.22 2.08 Favored Glycine 0 C--N 1.338 0.671 0 C-N-CA 121.567 -0.349 . . . . 0.0 112.742 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.747 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -134.85 -169.92 2.45 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.637 0.375 . . . . 0.0 110.609 -179.978 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.465 ' HG ' ' H ' ' A' ' 15' ' ' CYS . 11.8 t -106.83 161.65 14.5 Favored 'General case' 0 C--N 1.344 0.332 0 CA-C-O 120.631 0.253 . . . . 0.0 111.653 -178.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.536 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 40.4 t -118.75 129.26 55.16 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.982 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 t -88.52 142.23 27.88 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.388 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.43 -21.83 10.89 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -77.26 -5.62 50.08 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.639 0.257 . . . . 0.0 111.45 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.72 47.8 2.87 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.449 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -137.59 166.46 23.86 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.747 ' HB3' HD12 ' A' ' 13' ' ' LEU . 12.2 m -117.86 152.03 36.2 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.753 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.406 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . 166.12 152.26 7.15 Favored Glycine 0 C--N 1.34 0.803 0 C-N-CA 121.266 -0.493 . . . . 0.0 112.532 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -108.07 143.38 36.88 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 122.286 0.234 . . . . 0.0 110.866 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.28 -178.19 31.52 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.854 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -79.2 64.72 8.87 Favored 'Trans proline' 0 C--N 1.371 1.719 0 C-N-CA 123.017 2.478 . . . . 0.0 112.443 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.5 -47.67 0.38 Allowed 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.932 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.406 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 85.1 m-85 -111.99 -5.81 14.27 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.074 178.554 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.235 0.307 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.409 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.7 tt0 . . . . . 0 N--CA 1.486 1.351 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.421 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.0 m -93.8 148.01 22.52 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.286 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.37 115.94 43.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.053 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 57.81 24.9 11.31 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 123.972 0.909 . . . . 0.0 112.815 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.76 19.45 57.98 Favored Glycine 0 C--N 1.339 0.731 0 CA-C-N 115.758 -0.655 . . . . 0.0 113.647 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -131.31 121.1 24.13 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.693 0.283 . . . . 0.0 110.804 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.421 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.6 t -138.33 112.26 8.59 Favored Pre-proline 0 CA--C 1.54 0.594 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.819 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -82.25 -161.66 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.365 2.044 . . . . 0.0 112.758 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.35 -31.21 7.28 Favored Glycine 0 C--N 1.34 0.787 0 O-C-N 123.341 0.4 . . . . 0.0 113.041 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.34 2.76 Favored Glycine 0 C--N 1.338 0.688 0 C-N-CA 121.54 -0.362 . . . . 0.0 112.741 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.56 HD12 ' SG ' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.39 -172.52 2.97 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.609 0.363 . . . . 0.0 110.743 -179.994 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.0 m -97.06 157.73 15.77 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.727 0.298 . . . . 0.0 111.737 -178.556 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.406 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 49.0 t -129.59 126.0 37.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.991 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.7 t -90.44 144.46 25.78 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.497 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -55.58 -20.75 14.43 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -76.6 -6.16 50.81 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 123.139 0.274 . . . . 0.0 111.525 179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.93 48.12 2.53 Favored Glycine 0 C--N 1.342 0.874 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.581 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 84.9 m-85 -136.09 161.49 35.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.697 0.284 . . . . 0.0 111.691 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.56 ' SG ' HD12 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -131.31 145.03 51.69 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.679 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.444 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . 177.81 157.7 19.2 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.664 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 41.2 p -107.98 149.04 28.87 Favored 'General case' 0 C--O 1.235 0.332 0 O-C-N 123.612 0.242 . . . . 0.0 111.165 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.99 -179.86 31.39 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-O 119.361 -0.688 . . . . 0.0 112.834 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.99 63.01 7.58 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 122.976 2.451 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.34 -46.39 0.42 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.242 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.444 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.5 m-85 -114.06 -2.35 13.51 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.079 178.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.5 m . . . . . 0 C--N 1.343 0.32 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.557 -179.77 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 . . . . . 0 N--CA 1.465 0.286 0 CA-C-O 120.492 0.187 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.487 ' HG ' ' H ' ' A' ' 8' ' ' ARG . 8.8 t -109.95 141.64 42.42 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.637 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -104.32 95.23 3.65 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 54.62 26.23 7.19 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.999 0.919 . . . . 0.0 112.777 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.739 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 89.02 46.54 4.44 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.028 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.487 ' H ' ' HG ' ' A' ' 4' ' ' CYS . 63.3 mtp180 -132.76 116.19 16.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.923 0.392 . . . . 0.0 111.218 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -141.65 156.88 66.15 Favored Pre-proline 0 CA--C 1.539 0.535 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.398 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.53 ' HG2' HD22 ' A' ' 13' ' ' LEU . 55.6 Cg_endo -67.84 -159.0 0.04 OUTLIER 'Trans proline' 0 C--N 1.375 1.934 0 C-N-CA 122.472 2.115 . . . . 0.0 113.189 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.92 35.28 4.97 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 123.266 0.354 . . . . 0.0 112.977 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -122.92 -45.77 0.29 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 121.587 -0.34 . . . . 0.0 112.578 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.53 HD22 ' HG2' ' A' ' 10' ' ' PRO . 1.0 OUTLIER -113.51 -176.59 2.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.452 0.301 . . . . 0.0 110.995 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -124.08 156.03 37.31 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.584 0.23 . . . . 0.0 111.432 -178.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.739 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 52.7 t -117.04 133.36 56.1 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.127 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.503 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 40.0 p -96.69 145.39 25.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.446 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.61 -18.78 8.41 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -76.45 -7.04 54.25 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.674 0.273 . . . . 0.0 111.409 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.01 47.42 2.65 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.606 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.503 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 87.4 m-85 -136.93 155.74 49.36 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.495 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -137.52 130.06 29.77 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.598 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.529 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -164.82 173.11 40.69 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.529 0.518 . . . . 0.0 112.974 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.3 m -112.63 152.06 29.39 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 122.368 0.267 . . . . 0.0 111.257 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.09 177.68 26.54 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.895 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -79.31 64.61 8.86 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.943 2.428 . . . . 0.0 112.379 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.25 -47.89 0.35 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.135 -0.939 . . . . 0.0 109.947 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.13 -8.14 18.62 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.94 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.5 m . . . . . 0 C--N 1.343 0.324 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.436 179.905 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.236 0.343 0 CA-C-O 120.466 0.174 . . . . 0.0 110.937 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 96.4 m -91.97 149.56 21.47 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.314 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.2 t -115.82 106.52 20.59 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.917 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 7.8 mpt_? 55.46 27.52 10.31 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.972 0.909 . . . . 0.0 112.668 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.1 20.38 36.26 Favored Glycine 0 C--N 1.339 0.728 0 CA-C-N 115.903 -0.589 . . . . 0.0 113.457 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.89 121.09 21.23 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.651 0.262 . . . . 0.0 110.743 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.517 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 40.6 t -136.44 116.67 11.05 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.825 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -80.92 -161.57 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.335 2.024 . . . . 0.0 112.859 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.85 -30.71 7.64 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.435 0.459 . . . . 0.0 113.068 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.31 42.29 3.25 Favored Glycine 0 C--N 1.338 0.687 0 C-N-CA 121.545 -0.36 . . . . 0.0 112.66 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.732 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -133.87 -170.31 2.48 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 122.582 0.353 . . . . 0.0 110.784 -179.974 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -97.04 158.17 15.56 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 120.728 0.299 . . . . 0.0 111.735 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 t -125.8 125.97 43.78 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.6 t -88.55 143.15 27.14 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.425 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -54.78 -20.99 9.71 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -77.29 -5.91 51.22 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.355 0.262 . . . . 0.0 111.4 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.04 48.08 2.73 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.587 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -137.34 163.6 30.61 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.732 ' HB3' HD13 ' A' ' 13' ' ' LEU . 17.9 m -123.79 149.76 45.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.533 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.55 157.13 18.57 Favored Glycine 0 C--N 1.342 0.866 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.837 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.6 m -109.74 135.08 51.23 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 122.356 0.262 . . . . 0.0 111.128 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.8 -177.73 24.6 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.422 -0.654 . . . . 0.0 112.915 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -79.14 64.69 8.86 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.115 2.543 . . . . 0.0 112.493 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -48.49 0.47 Allowed 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.12 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -110.65 -5.26 15.07 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.999 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.236 0.358 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.397 -179.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 . . . . . 0 N--CA 1.465 0.32 0 CA-C-O 120.631 0.253 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 78.9 m -89.26 148.99 23.28 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.324 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -114.92 112.03 38.31 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.968 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 56.33 26.53 10.71 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.964 0.906 . . . . 0.0 112.696 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.69 16.42 56.64 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 115.827 -0.624 . . . . 0.0 113.56 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -132.54 124.63 28.84 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.618 0.247 . . . . 0.0 110.746 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.534 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.4 t -134.67 116.43 12.71 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.796 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -80.72 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.709 0 C-N-CA 122.342 2.028 . . . . 0.0 112.859 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.08 -30.51 8.0 Favored Glycine 0 C--N 1.342 0.87 0 O-C-N 123.392 0.433 . . . . 0.0 113.043 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.71 42.7 3.06 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.542 -0.361 . . . . 0.0 112.607 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.742 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -134.38 -171.58 2.8 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.62 0.368 . . . . 0.0 110.796 -179.94 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.3 m -95.84 156.88 16.15 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.745 0.307 . . . . 0.0 111.754 -178.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 41.6 t -128.22 125.21 38.51 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.847 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 66.5 m -88.04 144.13 26.69 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.601 179.126 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -54.78 -20.86 9.43 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -77.46 -6.68 54.37 Favored 'General case' 0 CA--C 1.54 0.582 0 O-C-N 123.106 0.254 . . . . 0.0 111.13 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.06 48.53 2.42 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.573 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.431 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 21.4 m-85 -136.45 159.92 40.32 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.742 ' HB3' HD13 ' A' ' 13' ' ' LEU . 13.6 m -122.32 149.89 43.13 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.557 179.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.425 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . 176.86 154.5 11.99 Favored Glycine 0 C--N 1.341 0.836 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.746 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -111.76 145.15 39.86 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 123.665 0.273 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.96 -178.0 30.54 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-O 119.412 -0.66 . . . . 0.0 112.78 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.91 62.91 7.48 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 123.034 2.489 . . . . 0.0 112.467 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.27 -45.93 0.42 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.178 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.425 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.0 m-85 -116.82 -1.76 11.97 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.174 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 C--N 1.344 0.366 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.519 -179.795 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 . . . . . 0 N--CA 1.466 0.372 0 CA-C-O 120.546 0.212 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.563 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 99.5 m -93.17 149.55 21.14 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.236 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.9 108.01 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 56.06 27.27 11.13 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 123.952 0.901 . . . . 0.0 112.658 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.65 16.66 48.09 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.626 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -132.88 124.83 28.64 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.716 0.258 . . . . 0.0 110.796 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.563 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 41.2 t -133.92 119.26 14.65 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.989 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -80.42 -161.63 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 122.405 2.07 . . . . 0.0 112.782 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.42 -30.61 7.56 Favored Glycine 0 C--N 1.342 0.878 0 CA-C-N 116.397 -0.365 . . . . 0.0 113.033 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.67 42.77 2.83 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 121.614 -0.327 . . . . 0.0 112.739 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.738 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -134.84 -168.25 2.13 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.502 0.321 . . . . 0.0 110.804 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 70.2 m -100.9 160.2 14.57 Favored 'General case' 0 C--N 1.343 0.308 0 CA-C-O 120.673 0.273 . . . . 0.0 111.651 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.7 t -128.5 128.76 44.97 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.881 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.5 p -90.84 146.36 24.0 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.761 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -53.58 -20.16 4.75 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -178.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.78 -5.44 48.22 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 122.381 0.273 . . . . 0.0 111.272 179.132 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.35 45.57 4.33 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-N 115.758 -0.655 . . . . 0.0 112.175 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -134.46 161.37 35.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.646 0.26 . . . . 0.0 111.699 -179.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.738 ' HB3' HD13 ' A' ' 13' ' ' LEU . 11.2 m -116.84 152.6 34.11 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.675 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 175.16 160.38 22.95 Favored Glycine 0 C--N 1.343 0.936 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.759 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -115.58 143.4 45.39 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.605 0.238 . . . . 0.0 111.005 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.1 -178.8 32.14 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.888 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.07 64.55 8.85 Favored 'Trans proline' 0 C--N 1.37 1.675 0 C-N-CA 123.052 2.501 . . . . 0.0 112.412 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -47.23 0.46 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.114 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 -5.31 12.68 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.016 178.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.235 0.322 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.461 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 . . . . . 0 N--CA 1.466 0.355 0 CA-C-O 120.467 0.175 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 73.7 m -95.1 118.18 31.46 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.042 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 8.4 t -129.69 84.59 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.472 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 55.12 29.18 12.08 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.847 0.859 . . . . 0.0 112.428 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.73 -38.95 0.05 OUTLIER Glycine 0 C--N 1.34 0.756 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.984 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 61.47 162.5 0.07 Allowed 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 124.037 0.935 . . . . 0.0 112.67 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 77.2 m -87.0 151.87 52.53 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.352 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.52 -155.59 0.03 OUTLIER 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.838 2.358 . . . . 0.0 113.265 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.8 26.87 6.24 Favored Glycine 0 C--N 1.344 1.016 0 C-N-CA 121.76 -0.257 . . . . 0.0 113.393 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.66 -48.98 1.87 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 121.577 -0.344 . . . . 0.0 112.388 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -119.61 -173.4 2.52 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.558 0.343 . . . . 0.0 110.711 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.9 m -115.1 153.16 31.25 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.344 -179.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -122.33 131.7 54.03 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.05 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.9 m -92.56 143.0 26.78 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.497 179.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -57.6 -18.04 17.63 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -78.13 -7.17 56.68 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.33 0.252 . . . . 0.0 111.077 179.246 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 97.64 48.29 1.99 Allowed Glycine 0 C--N 1.341 0.855 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.67 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -138.03 160.47 39.26 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.737 0.303 . . . . 0.0 111.78 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 0.1 OUTLIER -134.65 144.18 47.7 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.96 179.721 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.455 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . -179.32 161.63 27.84 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.982 -0.554 . . . . 0.0 112.538 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.7 t -109.61 148.53 31.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 120.602 0.239 . . . . 0.0 111.141 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.39 179.19 26.04 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-O 119.328 -0.707 . . . . 0.0 112.882 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -77.91 63.45 8.13 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 123.024 2.483 . . . . 0.0 112.412 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.48 -47.83 0.43 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.21 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.455 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 97.1 m-85 -107.67 -3.35 19.29 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.03 178.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.7 m . . . . . 0 C--O 1.235 0.338 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.574 -179.869 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 . . . . . 0 C--O 1.235 0.317 0 CA-C-O 120.51 0.195 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.492 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.5 m -93.58 149.17 21.45 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.285 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.437 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.1 t -119.84 105.58 17.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.747 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . 0.437 HH11 ' CG1' ' A' ' 5' ' ' VAL . 8.3 mpt_? 55.99 27.18 10.84 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.848 0.859 . . . . 0.0 112.603 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.93 26.67 18.68 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.435 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -136.11 117.68 14.88 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-O 120.682 0.277 . . . . 0.0 110.803 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.492 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.1 t -138.98 114.57 8.49 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.719 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -81.35 -161.87 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.36 2.04 . . . . 0.0 112.844 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.57 -30.85 7.34 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.447 0.467 . . . . 0.0 113.013 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.47 43.44 3.43 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 121.697 -0.287 . . . . 0.0 112.707 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.709 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.41 -171.31 2.67 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 122.473 0.309 . . . . 0.0 110.807 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.9 m -93.82 155.07 17.4 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -125.84 125.2 42.48 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.712 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 75.6 m -90.9 143.57 26.59 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.735 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.83 -21.15 10.38 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -76.25 -6.81 53.09 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.381 0.273 . . . . 0.0 111.371 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.67 47.89 2.63 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.501 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -138.05 164.15 29.82 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.709 ' HB3' HD12 ' A' ' 13' ' ' LEU . 20.0 m -126.93 151.57 48.3 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.634 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 177.11 158.6 20.71 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.843 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.9 m -112.91 144.03 43.17 Favored 'General case' 0 C--O 1.235 0.318 0 O-C-N 123.659 0.27 . . . . 0.0 110.969 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.21 -177.56 31.23 Favored Glycine 0 CA--C 1.529 0.925 0 CA-C-O 119.393 -0.671 . . . . 0.0 112.776 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.76 62.99 7.39 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.996 2.464 . . . . 0.0 112.524 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.48 -46.36 0.46 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.25 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -116.72 -1.54 12.07 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.12 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 83.0 m . . . . . 0 C--N 1.344 0.344 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.528 -179.829 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 . . . . . 0 N--CA 1.466 0.366 0 CA-C-O 120.607 0.241 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.816 ' HG ' ' HB2' ' A' ' 21' ' ' CYS . 66.0 m -96.34 137.11 35.9 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.298 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.7 t -101.16 95.11 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 59.63 24.12 12.93 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 123.745 0.818 . . . . 0.0 112.234 -179.366 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.87 52.75 3.04 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.015 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 -135.59 121.75 20.22 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 120.814 0.34 . . . . 0.0 111.507 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.551 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 26.0 m -143.71 152.39 55.91 Favored Pre-proline 0 N--CA 1.469 0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.491 179.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -69.5 -159.39 0.05 OUTLIER 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 122.591 2.194 . . . . 0.0 113.075 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.59 37.46 3.8 Favored Glycine 0 C--N 1.341 0.829 0 O-C-N 123.324 0.39 . . . . 0.0 112.894 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.67 -40.57 0.52 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 121.548 -0.358 . . . . 0.0 112.68 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.591 HD12 ' SG ' ' A' ' 21' ' ' CYS . 1.5 pt? -123.96 178.39 5.31 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 122.4 0.28 . . . . 0.0 110.884 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.442 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 68.9 m -110.57 157.96 19.08 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.678 -0.237 . . . . 0.0 111.569 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.551 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 49.9 t -120.84 129.25 53.46 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.231 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.418 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 38.5 p -94.61 144.56 25.5 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.435 179.226 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -56.0 -17.75 7.59 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -76.4 -7.36 54.87 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.701 0.286 . . . . 0.0 111.282 179.132 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 46.84 2.76 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.629 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.418 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 95.0 m-85 -139.57 156.88 46.62 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.504 0.192 . . . . 0.0 111.489 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.816 ' HB2' ' HG ' ' A' ' 4' ' ' CYS . 0.7 OUTLIER -137.81 133.73 34.35 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.55 179.395 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.414 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . -164.88 166.97 38.39 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.667 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.2 t -105.94 148.32 27.79 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.664 0.268 . . . . 0.0 111.063 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.22 177.81 25.3 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.405 -0.664 . . . . 0.0 112.807 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -79.57 64.51 8.86 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.948 2.432 . . . . 0.0 112.468 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.61 -48.77 0.39 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.053 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.414 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 98.6 m-85 -103.66 -5.63 22.41 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.021 178.654 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 86.0 m . . . . . 0 C--N 1.345 0.375 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.491 -179.982 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 . . . . . 0 N--CA 1.465 0.317 0 CA-C-O 120.573 0.225 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.516 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 93.0 m -91.52 150.26 21.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.276 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -121.95 112.53 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.922 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 77.1 mtp180 57.62 25.84 12.16 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.859 0.863 . . . . 0.0 112.626 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.55 18.49 54.85 Favored Glycine 0 C--N 1.338 0.662 0 CA-C-N 115.779 -0.646 . . . . 0.0 113.531 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -133.02 124.39 27.59 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.634 0.254 . . . . 0.0 110.822 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.516 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.2 t -135.55 116.57 11.88 Favored Pre-proline 0 CA--C 1.54 0.571 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.844 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -80.82 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 122.36 2.04 . . . . 0.0 112.859 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.05 -30.69 7.75 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.388 0.43 . . . . 0.0 113.013 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.93 42.27 3.11 Favored Glycine 0 C--N 1.338 0.639 0 C-N-CA 121.617 -0.325 . . . . 0.0 112.685 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.71 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -134.71 -171.24 2.73 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 122.578 0.351 . . . . 0.0 110.729 -179.952 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.401 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 99.6 m -96.08 156.76 16.2 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 111.895 0.331 . . . . 0.0 111.895 -178.404 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -126.69 127.4 45.08 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.8 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.476 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 35.5 p -93.61 143.67 26.09 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.61 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -54.24 -20.43 6.97 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 -178.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -76.08 -6.88 53.17 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.356 0.263 . . . . 0.0 111.321 179.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.79 47.15 3.0 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.558 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.476 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 89.5 m-85 -138.25 161.98 35.49 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.483 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.71 ' HB3' HD12 ' A' ' 13' ' ' LEU . 15.1 m -123.54 151.68 42.61 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.685 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.458 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . 176.31 155.32 12.97 Favored Glycine 0 C--N 1.34 0.804 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.84 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -110.67 145.1 38.56 Favored 'General case' 0 C--O 1.235 0.34 0 O-C-N 123.723 0.308 . . . . 0.0 110.822 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 100.58 -178.71 28.92 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-O 119.368 -0.684 . . . . 0.0 112.809 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -76.83 62.75 7.38 Favored 'Trans proline' 0 C--N 1.371 1.721 0 C-N-CA 122.974 2.449 . . . . 0.0 112.508 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.9 -46.22 0.4 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.135 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.458 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.7 m-85 -114.32 -2.62 13.26 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.158 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.6 m . . . . . 0 C--N 1.344 0.332 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.544 -179.827 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 120.452 0.168 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.741 ' HG ' ' HB2' ' A' ' 21' ' ' CYS . 58.2 m -98.64 130.89 45.17 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 123.675 0.61 . . . . 0.0 111.115 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.4 t -101.76 95.26 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 58.24 24.69 11.75 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.815 0.846 . . . . 0.0 112.322 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 87.41 47.44 4.62 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-N 115.662 -0.699 . . . . 0.0 112.965 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.72 119.0 18.76 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 120.86 0.362 . . . . 0.0 111.28 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 54.8 m -141.25 151.78 62.53 Favored Pre-proline 0 CA--C 1.536 0.437 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.626 179.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . 0.408 ' HG2' HD22 ' A' ' 13' ' ' LEU . 59.7 Cg_endo -70.36 -159.23 0.06 OUTLIER 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.46 2.107 . . . . 0.0 113.007 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.82 37.7 3.68 Favored Glycine 0 C--N 1.34 0.794 0 O-C-N 123.341 0.401 . . . . 0.0 112.864 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.97 -44.14 0.38 Allowed Glycine 0 C--N 1.338 0.647 0 C-N-CA 121.655 -0.307 . . . . 0.0 112.539 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.606 HD12 ' SG ' ' A' ' 21' ' ' CYS . 1.3 pt? -118.62 178.84 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 122.478 0.311 . . . . 0.0 110.87 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 69.1 m -109.87 152.43 25.79 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 123.103 0.252 . . . . 0.0 111.43 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.561 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 46.4 t -109.82 128.37 55.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.146 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 57.9 m -95.92 138.7 33.18 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.529 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -54.3 -22.1 11.05 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 -178.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -76.27 -6.81 53.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.418 0.287 . . . . 0.0 111.229 179.158 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.96 44.35 3.61 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.51 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -143.03 123.61 14.04 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.629 0.252 . . . . 0.0 111.373 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.741 ' HB2' ' HG ' ' A' ' 4' ' ' CYS . 0.6 OUTLIER -106.05 140.41 39.08 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.66 179.92 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -170.83 167.9 41.04 Favored Glycine 0 C--N 1.338 0.691 0 O-C-N 123.603 0.565 . . . . 0.0 112.668 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 p -105.37 150.75 24.95 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.604 0.24 . . . . 0.0 111.369 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.77 176.35 26.96 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.276 -0.735 . . . . 0.0 112.876 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -78.53 63.79 8.5 Favored 'Trans proline' 0 C--N 1.371 1.754 0 C-N-CA 122.945 2.43 . . . . 0.0 112.375 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.4 -48.27 0.44 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.158 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -105.62 -3.7 21.97 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.026 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.2 m . . . . . 0 C--N 1.343 0.298 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.499 -179.817 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 . . . . . 0 C--O 1.235 0.308 0 CA-C-O 120.507 0.194 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 97.5 m -92.02 150.12 21.16 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.339 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -123.46 110.62 26.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.785 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 57.46 25.76 11.79 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 123.88 0.872 . . . . 0.0 112.68 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.07 21.76 37.83 Favored Glycine 0 C--N 1.339 0.732 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.524 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -134.79 123.55 23.75 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 120.654 0.264 . . . . 0.0 110.787 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.529 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 48.2 t -136.82 116.96 10.77 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.815 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -80.77 -161.84 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.69 0 C-N-CA 122.37 2.047 . . . . 0.0 112.877 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.99 -30.39 7.62 Favored Glycine 0 C--N 1.341 0.815 0 O-C-N 123.344 0.403 . . . . 0.0 113.057 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.43 42.74 3.36 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.582 -0.342 . . . . 0.0 112.675 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.716 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.86 -170.26 2.47 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 122.532 0.333 . . . . 0.0 110.796 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.9 m -95.42 154.55 17.15 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.766 0.317 . . . . 0.0 111.725 -178.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.8 t -123.89 128.95 50.21 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.792 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.469 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 46.9 p -96.78 141.65 29.74 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.46 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -54.94 -19.32 6.45 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -178.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -76.33 -7.25 54.56 Favored 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.141 0.275 . . . . 0.0 111.239 179.116 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.58 46.64 2.92 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.607 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.469 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 93.3 m-85 -139.6 164.25 30.4 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.716 ' HB3' HD13 ' A' ' 13' ' ' LEU . 19.8 m -126.4 152.64 46.07 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.752 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.565 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . 179.51 153.41 11.77 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.641 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 53.1 m -103.62 137.51 41.57 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.271 0.228 . . . . 0.0 111.324 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.59 179.95 22.14 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.36 -0.689 . . . . 0.0 112.953 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -80.13 65.94 8.85 Favored 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 123.101 2.534 . . . . 0.0 112.378 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.06 -49.34 0.42 Allowed 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.124 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.565 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 94.1 m-85 -101.11 -5.88 25.08 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.087 178.628 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.343 0.305 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.484 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 . . . . . 0 C--O 1.234 0.271 0 CA-C-O 120.608 0.242 . . . . 0.0 110.937 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.512 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 72.4 m -90.38 148.89 22.53 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.239 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -117.68 112.1 37.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.889 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 57.04 25.87 11.27 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 123.912 0.885 . . . . 0.0 112.688 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.98 20.39 46.74 Favored Glycine 0 C--N 1.339 0.705 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.478 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -133.91 123.68 25.1 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.594 0.235 . . . . 0.0 110.813 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.512 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 38.7 t -136.38 116.43 11.05 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.7 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -80.73 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.369 1.634 0 C-N-CA 122.348 2.032 . . . . 0.0 112.883 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.04 -30.65 7.8 Favored Glycine 0 C--N 1.34 0.798 0 O-C-N 123.377 0.423 . . . . 0.0 113.038 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.51 42.97 3.04 Favored Glycine 0 C--N 1.339 0.695 0 C-N-CA 121.588 -0.339 . . . . 0.0 112.588 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.727 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -134.38 -171.68 2.82 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 122.649 0.38 . . . . 0.0 110.778 -179.86 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 74.9 m -97.03 158.36 15.46 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.685 0.279 . . . . 0.0 111.744 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 43.0 t -128.6 127.2 41.79 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.089 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -89.22 144.85 25.8 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.394 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -53.94 -22.36 10.03 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -178.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -76.2 -5.72 48.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.622 0.248 . . . . 0.0 111.511 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.57 48.48 2.75 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.631 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.435 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.1 m-85 -136.23 160.96 37.1 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -179.503 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.727 ' HB3' HD12 ' A' ' 13' ' ' LEU . 15.4 m -121.9 151.15 41.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.776 179.729 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.58 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . 175.98 150.09 7.87 Favored Glycine 0 C--N 1.341 0.857 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.658 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.5 t -108.85 145.53 35.14 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.628 0.251 . . . . 0.0 110.804 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.71 -177.49 29.33 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.369 -0.684 . . . . 0.0 112.77 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.16 62.76 7.6 Favored 'Trans proline' 0 C--N 1.37 1.707 0 C-N-CA 122.962 2.441 . . . . 0.0 112.596 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.54 -45.81 0.37 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.083 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.58 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.0 m-85 -114.7 -3.43 12.85 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.12 178.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.0 m . . . . . 0 C--N 1.343 0.322 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.568 -179.779 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 . . . . . 0 C--O 1.235 0.321 0 CA-C-O 120.499 0.19 . . . . 0.0 110.901 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 62.3 m -98.68 136.42 38.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -116.41 114.6 46.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.284 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 54.97 26.25 7.76 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.953 0.901 . . . . 0.0 112.957 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.64 27.49 29.41 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.974 -0.557 . . . . 0.0 113.515 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -129.59 113.96 15.47 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 120.89 0.376 . . . . 0.0 110.694 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 46.7 t -146.96 115.36 4.35 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.768 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -81.04 -162.86 0.2 Allowed 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.373 2.049 . . . . 0.0 112.626 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.84 -30.17 6.82 Favored Glycine 0 C--N 1.34 0.795 0 O-C-N 123.38 0.425 . . . . 0.0 112.975 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.2 46.1 2.67 Favored Glycine 0 C--N 1.339 0.717 0 C-N-CA 121.674 -0.298 . . . . 0.0 112.873 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.585 HD13 ' SG ' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -134.19 -172.43 3.0 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 122.486 0.315 . . . . 0.0 110.81 179.951 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.664 ' HG ' ' H ' ' A' ' 15' ' ' CYS . 16.5 t -104.86 170.18 8.02 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -178.085 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.664 ' H ' ' HG ' ' A' ' 14' ' ' CYS . 50.3 m -122.08 130.53 53.34 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.613 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 t -91.46 142.51 27.59 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.312 178.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -55.1 -20.97 11.19 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -77.65 -5.31 49.94 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.384 0.274 . . . . 0.0 111.461 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.07 46.64 3.04 Favored Glycine 0 C--N 1.343 0.924 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.462 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -136.92 169.62 17.46 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.6 0.238 . . . . 0.0 111.602 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.585 ' SG ' HD13 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -127.07 141.54 51.75 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.621 179.86 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.469 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . -179.54 150.84 9.6 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 123.514 0.509 . . . . 0.0 112.361 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -100.94 143.38 31.16 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.618 0.246 . . . . 0.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.38 -179.66 32.14 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 119.376 -0.68 . . . . 0.0 112.943 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -79.97 65.41 8.89 Favored 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 123.007 2.471 . . . . 0.0 112.425 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.19 -49.54 0.42 Allowed 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.986 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.469 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 86.1 m-85 -106.52 -6.51 18.05 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.015 178.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.235 0.296 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.355 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 . . . . . 0 C--O 1.235 0.325 0 CA-C-O 120.538 0.209 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.544 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 86.2 m -91.46 150.47 21.22 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.394 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -118.46 112.66 39.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.871 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 56.86 26.03 11.13 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.891 0.876 . . . . 0.0 112.782 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.82 17.13 57.1 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.817 -0.628 . . . . 0.0 113.581 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -133.09 125.7 30.17 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.748 0.274 . . . . 0.0 110.824 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.544 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.7 t -134.94 117.92 12.97 Favored Pre-proline 0 CA--C 1.539 0.555 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.824 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -80.27 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.72 0 C-N-CA 122.43 2.087 . . . . 0.0 112.92 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.75 -30.37 8.01 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.437 0.46 . . . . 0.0 113.015 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.61 41.8 3.07 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 121.559 -0.353 . . . . 0.0 112.637 -179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.743 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.86 -170.96 2.61 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 122.644 0.377 . . . . 0.0 110.788 -179.938 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -98.36 160.03 14.56 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.648 0.261 . . . . 0.0 111.656 -178.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -127.73 128.6 45.67 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.058 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.9 t -90.26 143.66 26.56 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.3 179.151 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.46 -21.55 10.24 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -178.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -76.99 -5.72 49.76 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 123.152 0.282 . . . . 0.0 111.47 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.78 48.72 2.65 Favored Glycine 0 C--N 1.341 0.839 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.622 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -136.78 160.99 37.2 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.718 0.294 . . . . 0.0 111.752 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.743 ' HB3' HD13 ' A' ' 13' ' ' LEU . 16.2 m -120.85 148.95 43.33 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.627 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.513 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . 179.51 149.51 8.45 Favored Glycine 0 C--N 1.341 0.849 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.55 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.3 p -103.83 134.13 47.65 Favored 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.635 0.256 . . . . 0.0 111.225 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.55 -178.89 21.9 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.908 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -80.03 65.2 8.91 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 123.101 2.534 . . . . 0.0 112.417 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.75 -48.83 0.43 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.129 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.513 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.6 m-85 -105.74 -5.5 19.87 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.029 178.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.236 0.365 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.422 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 . . . . . 0 C--O 1.236 0.348 0 CA-C-O 120.498 0.19 . . . . 0.0 110.991 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 85.4 m -88.35 148.79 24.09 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.319 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.1 t -113.21 107.2 22.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 56.12 26.71 10.5 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.932 0.893 . . . . 0.0 112.647 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.4 20.89 33.71 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.465 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.1 mtp180 -134.2 121.86 21.98 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 116.72 0.26 . . . . 0.0 110.771 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.54 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.2 t -137.06 115.72 10.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.824 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.93 -161.46 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 122.393 2.062 . . . . 0.0 112.912 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.69 -31.18 7.44 Favored Glycine 0 C--N 1.34 0.771 0 O-C-N 123.317 0.386 . . . . 0.0 113.016 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.15 42.56 2.99 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.544 -179.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.743 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.59 -169.45 2.29 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.588 0.355 . . . . 0.0 110.695 -179.883 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -98.0 155.61 17.02 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.715 0.293 . . . . 0.0 111.58 -178.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 40.4 t -126.38 127.98 46.33 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.934 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.7 m -92.07 141.82 28.19 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.419 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -55.22 -19.78 9.0 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -77.07 -6.16 51.7 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.458 0.303 . . . . 0.0 111.361 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.49 48.28 2.59 Favored Glycine 0 C--N 1.343 0.936 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.702 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -138.83 161.14 38.0 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.743 ' HB3' HD12 ' A' ' 13' ' ' LEU . 14.5 m -123.96 151.15 43.96 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.65 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.526 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . 177.47 153.46 11.04 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.694 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 42.0 p -106.36 140.78 38.74 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 122.325 0.25 . . . . 0.0 111.253 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.53 -178.98 24.41 Favored Glycine 0 CA--C 1.529 0.923 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.867 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.46 65.86 8.87 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.086 2.524 . . . . 0.0 112.409 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.97 -49.45 0.43 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.996 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' TYR . . . . . 0.526 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.4 m-85 -103.57 -7.24 20.95 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.958 178.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.343 0.314 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.314 0 CA-C-O 120.485 0.184 . . . . 0.0 111.047 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.09 93.55 2.17 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.447 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -128.75 147.79 50.8 Favored 'General case' 0 C--O 1.235 0.323 0 O-C-N 123.668 0.275 . . . . 0.0 110.88 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 83.3 m -91.84 146.28 23.88 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.234 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -114.11 110.6 32.71 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.958 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 56.02 27.15 10.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 123.975 0.91 . . . . 0.0 112.382 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.3 21.49 38.0 Favored Glycine 0 C--N 1.338 0.689 0 CA-C-N 115.818 -0.628 . . . . 0.0 113.42 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 76.8 mtp180 -134.3 122.7 23.04 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-O 120.645 0.26 . . . . 0.0 110.796 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.523 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.5 t -136.58 115.92 10.72 Favored Pre-proline 0 CA--C 1.54 0.565 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.787 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -80.95 -161.93 0.17 Allowed 'Trans proline' 0 C--N 1.37 1.689 0 C-N-CA 122.362 2.041 . . . . 0.0 112.845 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.22 -30.6 7.48 Favored Glycine 0 C--N 1.34 0.78 0 O-C-N 123.421 0.451 . . . . 0.0 113.04 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.61 43.33 3.42 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 121.599 -0.334 . . . . 0.0 112.728 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.722 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -132.93 -170.33 2.43 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.487 0.315 . . . . 0.0 110.843 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 72.5 m -95.0 154.45 17.16 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 120.759 0.314 . . . . 0.0 111.844 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 42.5 t -129.02 126.56 39.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.837 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 36.8 p -92.24 144.88 24.96 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.603 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.18 -20.82 7.46 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -76.03 -6.66 52.07 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.337 0.255 . . . . 0.0 111.379 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.77 48.12 2.79 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.609 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.489 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 88.3 m-85 -137.86 160.47 39.2 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -179.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.722 ' HB3' HD12 ' A' ' 13' ' ' LEU . 13.2 m -123.34 152.2 41.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.616 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 177.16 159.24 22.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.951 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.8 m -116.39 143.74 45.17 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 122.405 0.282 . . . . 0.0 110.925 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.18 -175.39 29.56 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.414 -0.659 . . . . 0.0 112.876 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -77.43 63.01 7.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 123.092 2.528 . . . . 0.0 112.49 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.11 -46.05 0.43 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.107 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -118.45 -2.68 11.02 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.121 178.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.7 m -95.98 -43.25 7.89 Favored 'General case' 0 C--N 1.344 0.341 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.521 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.73 -76.76 0.29 Allowed Glycine 0 C--N 1.34 0.795 0 O-C-N 123.396 0.435 . . . . 0.0 112.473 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.34 -1.255 . . . . 0.0 112.49 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.323 0 CA-C-O 120.524 0.202 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 129.53 55.07 0.1 Allowed Glycine 0 C--N 1.337 0.625 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.477 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -108.72 151.71 25.82 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 122.364 0.266 . . . . 0.0 110.981 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.3 m -94.31 151.81 19.14 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.263 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -125.66 113.35 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 36.5 ttt180 55.95 26.23 9.63 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.998 0.919 . . . . 0.0 112.594 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.57 26.28 39.49 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.89 -0.595 . . . . 0.0 113.66 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -131.82 116.14 16.85 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 110.753 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.8 t -142.54 107.92 5.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.851 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.42 -160.61 0.12 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.462 2.108 . . . . 0.0 112.846 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.26 -32.12 7.28 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.285 0.365 . . . . 0.0 113.038 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.02 42.11 2.49 Favored Glycine 0 C--N 1.338 0.662 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.641 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.631 HD13 ' SG ' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -131.77 -169.52 2.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 122.683 0.393 . . . . 0.0 110.599 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 26.2 p -108.5 156.03 19.95 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.55 0.214 . . . . 0.0 111.296 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.406 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 47.6 t -126.21 131.7 51.92 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.642 -179.514 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.4 t -89.58 144.88 25.66 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.253 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -56.04 -19.38 12.57 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -178.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -77.66 -5.6 50.98 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 123.095 0.247 . . . . 0.0 111.497 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 48.36 2.45 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.615 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 83.6 m-85 -135.93 161.3 36.01 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.593 0.235 . . . . 0.0 111.571 -179.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.631 ' SG ' HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -134.11 145.93 49.79 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.574 179.748 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.582 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -175.75 -179.55 46.32 Favored Glycine 0 C--N 1.341 0.838 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.056 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 35.2 p -129.62 136.93 50.36 Favored 'General case' 0 C--O 1.236 0.372 0 O-C-N 123.723 0.307 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.63 -176.71 28.91 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 119.433 -0.649 . . . . 0.0 112.68 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -77.51 64.54 8.04 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 123.006 2.471 . . . . 0.0 112.364 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -137.49 -46.49 0.55 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.098 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -120.41 -6.22 9.81 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.059 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 38.1 m -92.14 -44.24 8.91 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.62 -179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -143.43 -107.14 0.58 Allowed Glycine 0 C--N 1.34 0.783 0 O-C-N 123.385 0.428 . . . . 0.0 112.51 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.394 -1.226 . . . . 0.0 112.674 -179.975 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.325 0 CA-C-O 120.465 0.174 . . . . 0.0 111.038 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 115.06 -54.53 0.57 Allowed Glycine 0 C--N 1.336 0.567 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.539 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -117.75 149.97 39.89 Favored 'General case' 0 N--CA 1.466 0.33 0 O-C-N 123.631 0.253 . . . . 0.0 110.85 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.421 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.8 m -94.88 137.51 33.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.163 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 14.6 p -105.28 109.95 29.41 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.724 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 68.4 mtp180 55.1 26.14 7.89 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 123.984 0.914 . . . . 0.0 112.732 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.64 26.56 24.66 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.871 -0.604 . . . . 0.0 113.408 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -134.89 117.4 15.82 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.668 0.27 . . . . 0.0 110.742 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.421 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 42.7 t -140.51 110.38 6.85 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.928 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.93 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.372 2.048 . . . . 0.0 112.723 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.93 -31.87 6.89 Favored Glycine 0 C--N 1.34 0.784 0 O-C-N 123.384 0.428 . . . . 0.0 112.995 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.75 2.68 Favored Glycine 0 C--N 1.338 0.675 0 C-N-CA 121.608 -0.33 . . . . 0.0 112.784 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.589 HD13 ' SG ' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -132.0 -171.48 2.64 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 122.578 0.351 . . . . 0.0 110.786 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 92.7 m -96.46 154.51 17.23 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.747 0.308 . . . . 0.0 111.689 -178.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.423 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 51.8 t -130.48 126.08 35.99 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.017 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.7 t -90.29 144.03 26.22 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.469 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.71 -20.11 13.28 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -76.87 -6.09 50.99 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.389 0.275 . . . . 0.0 111.508 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.18 48.19 2.47 Favored Glycine 0 C--N 1.343 0.941 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.644 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.423 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.8 m-85 -136.22 160.55 38.34 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.687 0.28 . . . . 0.0 111.716 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.589 ' SG ' HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -132.21 147.99 52.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.83 179.927 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.55 163.87 28.51 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.216 -0.516 . . . . 0.0 112.737 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -113.28 149.6 33.65 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.3 -179.35 32.13 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.336 -0.702 . . . . 0.0 112.827 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -77.36 63.12 7.79 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.98 2.454 . . . . 0.0 112.458 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.89 -46.64 0.44 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.198 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -114.82 -2.62 12.9 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.08 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.0 m -93.85 -42.11 9.27 Favored 'General case' 0 C--N 1.344 0.357 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.508 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -133.17 -140.46 4.4 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.5 0.5 . . . . 0.0 112.542 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.352 -1.249 . . . . 0.0 112.421 179.995 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.465 0.174 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 139.2 -58.96 0.6 Allowed Glycine 0 C--N 1.338 0.663 0 O-C-N 123.685 0.616 . . . . 0.0 112.531 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -113.65 148.17 36.78 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 123.634 0.255 . . . . 0.0 110.928 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.482 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 82.5 m -94.41 151.81 19.09 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.338 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -125.55 111.3 26.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.942 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 56.56 26.16 10.7 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 123.928 0.891 . . . . 0.0 112.795 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.5 22.7 39.32 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.561 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.33 120.8 21.48 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.692 0.282 . . . . 0.0 110.813 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.482 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.0 t -138.54 114.36 8.79 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.861 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -81.72 -161.53 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.678 0 C-N-CA 122.403 2.069 . . . . 0.0 112.732 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.05 -30.46 7.56 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 123.364 0.415 . . . . 0.0 113.054 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.57 43.22 3.21 Favored Glycine 0 C--N 1.337 0.635 0 C-N-CA 121.616 -0.326 . . . . 0.0 112.785 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.551 HD13 ' SG ' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -132.97 -171.84 2.78 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 122.465 0.306 . . . . 0.0 110.799 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.404 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 80.2 m -96.66 158.41 15.44 Favored 'General case' 0 C--N 1.344 0.341 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -178.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 54.1 t -129.84 125.48 35.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.044 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.1 t -88.2 144.68 26.31 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.426 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -55.12 -21.43 13.01 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -76.29 -6.02 49.61 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 123.13 0.269 . . . . 0.0 111.396 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.28 48.33 2.63 Favored Glycine 0 C--N 1.342 0.896 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.519 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.42 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 88.6 m-85 -136.85 163.05 31.56 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.632 0.253 . . . . 0.0 111.638 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.551 ' SG ' HD13 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -129.2 148.57 51.15 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.941 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 174.26 167.05 33.24 Favored Glycine 0 C--N 1.342 0.87 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.561 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.0 t -119.96 148.28 43.72 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-O 120.626 0.25 . . . . 0.0 111.108 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 110.21 178.65 20.84 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-O 119.305 -0.719 . . . . 0.0 112.904 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.59 64.22 8.58 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.952 2.435 . . . . 0.0 112.373 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -148.1 -45.05 0.16 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.776 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -99.77 -10.25 22.06 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.867 178.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -126.51 -41.86 1.84 Allowed 'General case' 0 C--N 1.344 0.338 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.347 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -98.35 93.01 1.3 Allowed Glycine 0 C--N 1.339 0.737 0 O-C-N 123.483 0.489 . . . . 0.0 112.486 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.507 -1.163 . . . . 0.0 112.543 179.952 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.524 0.202 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 148.55 -55.54 0.5 Allowed Glycine 0 C--N 1.338 0.648 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.482 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -100.53 151.2 21.86 Favored 'General case' 0 C--O 1.236 0.342 0 O-C-N 123.648 0.264 . . . . 0.0 110.95 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.509 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 5.2 t -97.28 151.45 19.87 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.869 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -117.92 109.49 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.346 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 53.88 27.19 6.92 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.124 0.97 . . . . 0.0 113.008 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.536 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 87.34 28.65 24.38 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-N 115.944 -0.571 . . . . 0.0 113.328 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.468 ' C ' ' HG ' ' A' ' 4' ' ' CYS . 99.1 mtt180 -137.26 116.36 12.49 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 122.499 0.32 . . . . 0.0 110.479 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.509 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 6.1 t -138.73 119.8 10.02 Favored Pre-proline 0 CA--C 1.539 0.526 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.938 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -80.1 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 122.338 2.026 . . . . 0.0 112.849 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.4 -30.59 8.03 Favored Glycine 0 C--N 1.341 0.832 0 O-C-N 123.361 0.413 . . . . 0.0 113.073 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.74 38.22 2.08 Favored Glycine 0 C--N 1.338 0.671 0 C-N-CA 121.567 -0.349 . . . . 0.0 112.742 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.747 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -134.85 -169.92 2.45 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.637 0.375 . . . . 0.0 110.609 -179.978 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.465 ' HG ' ' H ' ' A' ' 15' ' ' CYS . 11.8 t -106.83 161.65 14.5 Favored 'General case' 0 C--N 1.344 0.332 0 CA-C-O 120.631 0.253 . . . . 0.0 111.653 -178.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.536 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 40.4 t -118.75 129.26 55.16 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.982 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 t -88.52 142.23 27.88 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.388 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.43 -21.83 10.89 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -77.26 -5.62 50.08 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.639 0.257 . . . . 0.0 111.45 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.72 47.8 2.87 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.449 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -137.59 166.46 23.86 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.747 ' HB3' HD12 ' A' ' 13' ' ' LEU . 12.2 m -117.86 152.03 36.2 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.753 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.406 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . 166.12 152.26 7.15 Favored Glycine 0 C--N 1.34 0.803 0 C-N-CA 121.266 -0.493 . . . . 0.0 112.532 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -108.07 143.38 36.88 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 122.286 0.234 . . . . 0.0 110.866 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.28 -178.19 31.52 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.854 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -79.2 64.72 8.87 Favored 'Trans proline' 0 C--N 1.371 1.719 0 C-N-CA 123.017 2.478 . . . . 0.0 112.443 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.5 -47.67 0.38 Allowed 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.932 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.406 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 85.1 m-85 -111.99 -5.81 14.27 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.074 178.554 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.58 -42.68 4.48 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.409 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -115.52 132.3 10.21 Favored Glycine 0 C--N 1.34 0.792 0 O-C-N 123.424 0.452 . . . . 0.0 112.489 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.374 -1.237 . . . . 0.0 112.585 179.978 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.328 0 CA-C-O 120.503 0.192 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.82 105.79 2.7 Favored Glycine 0 C--N 1.337 0.595 0 CA-C-N 115.826 -0.625 . . . . 0.0 112.459 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.7 tt0 63.97 145.21 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 124.009 0.923 . . . . 0.0 111.934 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.421 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.0 m -93.8 148.01 22.52 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.286 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.37 115.94 43.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.053 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 57.81 24.9 11.31 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 123.972 0.909 . . . . 0.0 112.815 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.76 19.45 57.98 Favored Glycine 0 C--N 1.339 0.731 0 CA-C-N 115.758 -0.655 . . . . 0.0 113.647 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -131.31 121.1 24.13 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.693 0.283 . . . . 0.0 110.804 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.421 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.6 t -138.33 112.26 8.59 Favored Pre-proline 0 CA--C 1.54 0.594 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.819 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -82.25 -161.66 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.365 2.044 . . . . 0.0 112.758 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.35 -31.21 7.28 Favored Glycine 0 C--N 1.34 0.787 0 O-C-N 123.341 0.4 . . . . 0.0 113.041 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.34 2.76 Favored Glycine 0 C--N 1.338 0.688 0 C-N-CA 121.54 -0.362 . . . . 0.0 112.741 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.56 HD12 ' SG ' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.39 -172.52 2.97 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.609 0.363 . . . . 0.0 110.743 -179.994 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.406 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.0 m -97.06 157.73 15.77 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.727 0.298 . . . . 0.0 111.737 -178.556 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.406 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 49.0 t -129.59 126.0 37.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.991 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.7 t -90.44 144.46 25.78 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.497 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -55.58 -20.75 14.43 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -76.6 -6.16 50.81 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 123.139 0.274 . . . . 0.0 111.525 179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.93 48.12 2.53 Favored Glycine 0 C--N 1.342 0.874 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.581 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.406 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 84.9 m-85 -136.09 161.49 35.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.697 0.284 . . . . 0.0 111.691 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.56 ' SG ' HD12 ' A' ' 13' ' ' LEU . 0.1 OUTLIER -131.31 145.03 51.69 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.679 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.444 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . 177.81 157.7 19.2 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.664 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 41.2 p -107.98 149.04 28.87 Favored 'General case' 0 C--O 1.235 0.332 0 O-C-N 123.612 0.242 . . . . 0.0 111.165 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.99 -179.86 31.39 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-O 119.361 -0.688 . . . . 0.0 112.834 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.99 63.01 7.58 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 122.976 2.451 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.34 -46.39 0.42 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.242 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.444 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.5 m-85 -114.06 -2.35 13.51 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.079 178.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.5 m -93.64 -42.41 9.2 Favored 'General case' 0 C--N 1.343 0.32 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.557 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -137.84 -149.81 5.59 Favored Glycine 0 C--N 1.341 0.824 0 O-C-N 123.423 0.452 . . . . 0.0 112.527 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.433 -1.204 . . . . 0.0 112.527 179.984 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.275 0 CA-C-O 120.456 0.169 . . . . 0.0 111.109 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.2 65.91 0.15 Allowed Glycine 0 C--N 1.337 0.626 0 O-C-N 123.656 0.598 . . . . 0.0 112.48 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -119.73 139.45 52.25 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 122.323 0.249 . . . . 0.0 110.873 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.487 ' HG ' ' H ' ' A' ' 8' ' ' ARG . 8.8 t -109.95 141.64 42.42 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.637 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -104.32 95.23 3.65 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 54.62 26.23 7.19 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.999 0.919 . . . . 0.0 112.777 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.739 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 89.02 46.54 4.44 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.028 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.487 ' H ' ' HG ' ' A' ' 4' ' ' CYS . 63.3 mtp180 -132.76 116.19 16.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.923 0.392 . . . . 0.0 111.218 -179.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -141.65 156.88 66.15 Favored Pre-proline 0 CA--C 1.539 0.535 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.398 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.53 ' HG2' HD22 ' A' ' 13' ' ' LEU . 55.6 Cg_endo -67.84 -159.0 0.04 OUTLIER 'Trans proline' 0 C--N 1.375 1.934 0 C-N-CA 122.472 2.115 . . . . 0.0 113.189 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.92 35.28 4.97 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 123.266 0.354 . . . . 0.0 112.977 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -122.92 -45.77 0.29 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 121.587 -0.34 . . . . 0.0 112.578 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.53 HD22 ' HG2' ' A' ' 10' ' ' PRO . 1.0 OUTLIER -113.51 -176.59 2.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.452 0.301 . . . . 0.0 110.995 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -124.08 156.03 37.31 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.584 0.23 . . . . 0.0 111.432 -178.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.739 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 52.7 t -117.04 133.36 56.1 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.127 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.503 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 40.0 p -96.69 145.39 25.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.446 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.61 -18.78 8.41 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -76.45 -7.04 54.25 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.674 0.273 . . . . 0.0 111.409 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.01 47.42 2.65 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.606 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.503 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 87.4 m-85 -136.93 155.74 49.36 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.495 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -137.52 130.06 29.77 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.598 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.529 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -164.82 173.11 40.69 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.529 0.518 . . . . 0.0 112.974 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.3 m -112.63 152.06 29.39 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 122.368 0.267 . . . . 0.0 111.257 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.09 177.68 26.54 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.895 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -79.31 64.61 8.86 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.943 2.428 . . . . 0.0 112.379 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.25 -47.89 0.35 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.135 -0.939 . . . . 0.0 109.947 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.13 -8.14 18.62 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.94 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.5 m -98.64 -42.96 7.02 Favored 'General case' 0 C--N 1.343 0.324 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.436 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.1 121.55 7.27 Favored Glycine 0 C--N 1.34 0.804 0 O-C-N 123.465 0.478 . . . . 0.0 112.569 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.09 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.598 179.994 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.51 0.195 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.26 73.64 0.22 Allowed Glycine 0 C--N 1.336 0.567 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.537 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -128.86 148.37 50.89 Favored 'General case' 0 C--O 1.236 0.343 0 O-C-N 123.66 0.271 . . . . 0.0 110.937 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 96.4 m -91.97 149.56 21.47 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.314 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.2 t -115.82 106.52 20.59 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.917 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 7.8 mpt_? 55.46 27.52 10.31 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.972 0.909 . . . . 0.0 112.668 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.1 20.38 36.26 Favored Glycine 0 C--N 1.339 0.728 0 CA-C-N 115.903 -0.589 . . . . 0.0 113.457 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.89 121.09 21.23 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.651 0.262 . . . . 0.0 110.743 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.517 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 40.6 t -136.44 116.67 11.05 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.825 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -80.92 -161.57 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.335 2.024 . . . . 0.0 112.859 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.85 -30.71 7.64 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.435 0.459 . . . . 0.0 113.068 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.31 42.29 3.25 Favored Glycine 0 C--N 1.338 0.687 0 C-N-CA 121.545 -0.36 . . . . 0.0 112.66 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.732 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -133.87 -170.31 2.48 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 122.582 0.353 . . . . 0.0 110.784 -179.974 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -97.04 158.17 15.56 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 120.728 0.299 . . . . 0.0 111.735 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 t -125.8 125.97 43.78 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.6 t -88.55 143.15 27.14 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.425 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -54.78 -20.99 9.71 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -77.29 -5.91 51.22 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.355 0.262 . . . . 0.0 111.4 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.04 48.08 2.73 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.587 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -137.34 163.6 30.61 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.732 ' HB3' HD13 ' A' ' 13' ' ' LEU . 17.9 m -123.79 149.76 45.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.533 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 178.55 157.13 18.57 Favored Glycine 0 C--N 1.342 0.866 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.837 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.6 m -109.74 135.08 51.23 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 122.356 0.262 . . . . 0.0 111.128 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.8 -177.73 24.6 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.422 -0.654 . . . . 0.0 112.915 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -79.14 64.69 8.86 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.115 2.543 . . . . 0.0 112.493 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -48.49 0.47 Allowed 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.12 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -110.65 -5.26 15.07 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.999 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.51 -42.09 7.87 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.397 -179.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.19 131.69 10.66 Favored Glycine 0 C--N 1.34 0.771 0 O-C-N 123.383 0.427 . . . . 0.0 112.467 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.38 -1.234 . . . . 0.0 112.476 179.957 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 120.473 0.178 . . . . 0.0 111.043 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.75 85.15 0.05 OUTLIER Glycine 0 C--N 1.336 0.558 0 CA-C-N 115.867 -0.606 . . . . 0.0 112.502 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -128.84 150.98 50.1 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.631 0.253 . . . . 0.0 110.993 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 78.9 m -89.26 148.99 23.28 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.324 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -114.92 112.03 38.31 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.968 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 56.33 26.53 10.71 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.964 0.906 . . . . 0.0 112.696 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.69 16.42 56.64 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 115.827 -0.624 . . . . 0.0 113.56 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -132.54 124.63 28.84 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.618 0.247 . . . . 0.0 110.746 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.534 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.4 t -134.67 116.43 12.71 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.796 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -80.72 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.709 0 C-N-CA 122.342 2.028 . . . . 0.0 112.859 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.08 -30.51 8.0 Favored Glycine 0 C--N 1.342 0.87 0 O-C-N 123.392 0.433 . . . . 0.0 113.043 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.71 42.7 3.06 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.542 -0.361 . . . . 0.0 112.607 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.742 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -134.38 -171.58 2.8 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.62 0.368 . . . . 0.0 110.796 -179.94 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.3 m -95.84 156.88 16.15 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.745 0.307 . . . . 0.0 111.754 -178.403 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 41.6 t -128.22 125.21 38.51 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.847 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 66.5 m -88.04 144.13 26.69 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.601 179.126 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -54.78 -20.86 9.43 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -77.46 -6.68 54.37 Favored 'General case' 0 CA--C 1.54 0.582 0 O-C-N 123.106 0.254 . . . . 0.0 111.13 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.06 48.53 2.42 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.573 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.431 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 21.4 m-85 -136.45 159.92 40.32 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.742 ' HB3' HD13 ' A' ' 13' ' ' LEU . 13.6 m -122.32 149.89 43.13 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.557 179.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.425 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . 176.86 154.5 11.99 Favored Glycine 0 C--N 1.341 0.836 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.746 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -111.76 145.15 39.86 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 123.665 0.273 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.96 -178.0 30.54 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-O 119.412 -0.66 . . . . 0.0 112.78 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.91 62.91 7.48 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 123.034 2.489 . . . . 0.0 112.467 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.27 -45.93 0.42 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.178 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.425 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.0 m-85 -116.82 -1.76 11.97 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.174 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m -93.98 -42.71 8.9 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.519 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.19 -131.9 1.27 Allowed Glycine 0 C--N 1.34 0.783 0 O-C-N 123.428 0.455 . . . . 0.0 112.481 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.337 -1.257 . . . . 0.0 112.627 179.961 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.344 0 CA-C-O 120.441 0.162 . . . . 0.0 111.053 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 105.02 -56.71 0.53 Allowed Glycine 0 C--N 1.337 0.592 0 O-C-N 123.707 0.629 . . . . 0.0 112.438 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -129.44 150.63 50.71 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 122.333 0.253 . . . . 0.0 111.156 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.563 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 99.5 m -93.17 149.55 21.14 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.236 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.9 108.01 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 56.06 27.27 11.13 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 123.952 0.901 . . . . 0.0 112.658 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.65 16.66 48.09 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.626 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -132.88 124.83 28.64 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.716 0.258 . . . . 0.0 110.796 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.563 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 41.2 t -133.92 119.26 14.65 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.989 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -80.42 -161.63 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 122.405 2.07 . . . . 0.0 112.782 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.42 -30.61 7.56 Favored Glycine 0 C--N 1.342 0.878 0 CA-C-N 116.397 -0.365 . . . . 0.0 113.033 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.67 42.77 2.83 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 121.614 -0.327 . . . . 0.0 112.739 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.738 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -134.84 -168.25 2.13 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.502 0.321 . . . . 0.0 110.804 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 70.2 m -100.9 160.2 14.57 Favored 'General case' 0 C--N 1.343 0.308 0 CA-C-O 120.673 0.273 . . . . 0.0 111.651 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.7 t -128.5 128.76 44.97 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.881 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.5 p -90.84 146.36 24.0 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.761 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -53.58 -20.16 4.75 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -178.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.78 -5.44 48.22 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 122.381 0.273 . . . . 0.0 111.272 179.132 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.35 45.57 4.33 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-N 115.758 -0.655 . . . . 0.0 112.175 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -134.46 161.37 35.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.646 0.26 . . . . 0.0 111.699 -179.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.738 ' HB3' HD13 ' A' ' 13' ' ' LEU . 11.2 m -116.84 152.6 34.11 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.675 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 175.16 160.38 22.95 Favored Glycine 0 C--N 1.343 0.936 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.759 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -115.58 143.4 45.39 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.605 0.238 . . . . 0.0 111.005 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.1 -178.8 32.14 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.888 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.07 64.55 8.85 Favored 'Trans proline' 0 C--N 1.37 1.675 0 C-N-CA 123.052 2.501 . . . . 0.0 112.412 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -47.23 0.46 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.114 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 -5.31 12.68 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.016 178.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -98.73 -42.27 7.3 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.461 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -149.38 -95.49 0.14 Allowed Glycine 0 C--N 1.34 0.805 0 O-C-N 123.381 0.425 . . . . 0.0 112.576 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.444 -1.198 . . . . 0.0 112.534 -179.996 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.334 0 CA-C-O 120.503 0.192 . . . . 0.0 111.017 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 154.9 86.68 0.06 OUTLIER Glycine 0 C--N 1.337 0.616 0 CA-C-N 115.857 -0.61 . . . . 0.0 112.487 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -131.81 151.56 51.59 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 123.679 0.282 . . . . 0.0 110.786 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 73.7 m -95.1 118.18 31.46 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.042 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 8.4 t -129.69 84.59 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.472 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 55.12 29.18 12.08 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.847 0.859 . . . . 0.0 112.428 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.73 -38.95 0.05 OUTLIER Glycine 0 C--N 1.34 0.756 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.984 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 61.47 162.5 0.07 Allowed 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 124.037 0.935 . . . . 0.0 112.67 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 77.2 m -87.0 151.87 52.53 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.352 -179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.52 -155.59 0.03 OUTLIER 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.838 2.358 . . . . 0.0 113.265 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.8 26.87 6.24 Favored Glycine 0 C--N 1.344 1.016 0 C-N-CA 121.76 -0.257 . . . . 0.0 113.393 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.66 -48.98 1.87 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 121.577 -0.344 . . . . 0.0 112.388 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -119.61 -173.4 2.52 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.558 0.343 . . . . 0.0 110.711 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.9 m -115.1 153.16 31.25 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.344 -179.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -122.33 131.7 54.03 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.05 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.9 m -92.56 143.0 26.78 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.497 179.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -57.6 -18.04 17.63 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -78.13 -7.17 56.68 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.33 0.252 . . . . 0.0 111.077 179.246 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 97.64 48.29 1.99 Allowed Glycine 0 C--N 1.341 0.855 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.67 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -138.03 160.47 39.26 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.737 0.303 . . . . 0.0 111.78 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 0.1 OUTLIER -134.65 144.18 47.7 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.96 179.721 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.455 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . -179.32 161.63 27.84 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.982 -0.554 . . . . 0.0 112.538 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.7 t -109.61 148.53 31.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 120.602 0.239 . . . . 0.0 111.141 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.39 179.19 26.04 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-O 119.328 -0.707 . . . . 0.0 112.882 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -77.91 63.45 8.13 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 123.024 2.483 . . . . 0.0 112.412 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.48 -47.83 0.43 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.21 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.455 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 97.1 m-85 -107.67 -3.35 19.29 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.03 178.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.7 m -93.91 -42.45 9.07 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.574 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.69 -56.42 0.52 Allowed Glycine 0 C--N 1.34 0.754 0 O-C-N 123.423 0.452 . . . . 0.0 112.521 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.418 -1.212 . . . . 0.0 112.548 179.996 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.303 0 CA-C-O 120.502 0.192 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.53 86.08 1.89 Allowed Glycine 0 C--N 1.338 0.653 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.578 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -128.67 145.71 51.08 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 123.609 0.241 . . . . 0.0 110.844 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.492 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.5 m -93.58 149.17 21.45 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.285 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.437 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.1 t -119.84 105.58 17.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.747 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . 0.437 HH11 ' CG1' ' A' ' 5' ' ' VAL . 8.3 mpt_? 55.99 27.18 10.84 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.848 0.859 . . . . 0.0 112.603 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.93 26.67 18.68 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.435 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -136.11 117.68 14.88 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-O 120.682 0.277 . . . . 0.0 110.803 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.492 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.1 t -138.98 114.57 8.49 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.719 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -81.35 -161.87 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.36 2.04 . . . . 0.0 112.844 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.57 -30.85 7.34 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.447 0.467 . . . . 0.0 113.013 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.47 43.44 3.43 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 121.697 -0.287 . . . . 0.0 112.707 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.709 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.41 -171.31 2.67 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 122.473 0.309 . . . . 0.0 110.807 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.411 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.9 m -93.82 155.07 17.4 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -125.84 125.2 42.48 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.712 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 75.6 m -90.9 143.57 26.59 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.735 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.83 -21.15 10.38 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -76.25 -6.81 53.09 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.381 0.273 . . . . 0.0 111.371 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.67 47.89 2.63 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.501 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -138.05 164.15 29.82 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.709 ' HB3' HD12 ' A' ' 13' ' ' LEU . 20.0 m -126.93 151.57 48.3 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.634 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 177.11 158.6 20.71 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.843 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.9 m -112.91 144.03 43.17 Favored 'General case' 0 C--O 1.235 0.318 0 O-C-N 123.659 0.27 . . . . 0.0 110.969 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.21 -177.56 31.23 Favored Glycine 0 CA--C 1.529 0.925 0 CA-C-O 119.393 -0.671 . . . . 0.0 112.776 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.76 62.99 7.39 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.996 2.464 . . . . 0.0 112.524 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.48 -46.36 0.46 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.25 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -116.72 -1.54 12.07 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.12 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 83.0 m -93.73 -42.75 8.98 Favored 'General case' 0 C--N 1.344 0.344 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.528 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.98 118.01 4.12 Favored Glycine 0 C--N 1.341 0.831 0 O-C-N 123.43 0.456 . . . . 0.0 112.513 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.333 -1.259 . . . . 0.0 112.584 179.927 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.343 0 CA-C-O 120.481 0.181 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.92 64.29 0.41 Allowed Glycine 0 C--N 1.336 0.568 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.498 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -128.33 151.23 49.57 Favored 'General case' 0 N--CA 1.466 0.366 0 O-C-N 123.618 0.246 . . . . 0.0 110.928 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.816 ' HG ' ' HB2' ' A' ' 21' ' ' CYS . 66.0 m -96.34 137.11 35.9 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.298 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.7 t -101.16 95.11 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 59.63 24.12 12.93 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 123.745 0.818 . . . . 0.0 112.234 -179.366 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.87 52.75 3.04 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.015 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 -135.59 121.75 20.22 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 120.814 0.34 . . . . 0.0 111.507 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.551 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 26.0 m -143.71 152.39 55.91 Favored Pre-proline 0 N--CA 1.469 0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.491 179.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -69.5 -159.39 0.05 OUTLIER 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 122.591 2.194 . . . . 0.0 113.075 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.59 37.46 3.8 Favored Glycine 0 C--N 1.341 0.829 0 O-C-N 123.324 0.39 . . . . 0.0 112.894 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.67 -40.57 0.52 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 121.548 -0.358 . . . . 0.0 112.68 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.591 HD12 ' SG ' ' A' ' 21' ' ' CYS . 1.5 pt? -123.96 178.39 5.31 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 122.4 0.28 . . . . 0.0 110.884 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.442 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 68.9 m -110.57 157.96 19.08 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.678 -0.237 . . . . 0.0 111.569 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.551 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 49.9 t -120.84 129.25 53.46 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.231 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.418 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 38.5 p -94.61 144.56 25.5 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.435 179.226 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -56.0 -17.75 7.59 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -76.4 -7.36 54.87 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.701 0.286 . . . . 0.0 111.282 179.132 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 46.84 2.76 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.629 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.418 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 95.0 m-85 -139.57 156.88 46.62 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.504 0.192 . . . . 0.0 111.489 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.816 ' HB2' ' HG ' ' A' ' 4' ' ' CYS . 0.7 OUTLIER -137.81 133.73 34.35 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.55 179.395 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.414 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . -164.88 166.97 38.39 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.667 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.2 t -105.94 148.32 27.79 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.664 0.268 . . . . 0.0 111.063 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.22 177.81 25.3 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.405 -0.664 . . . . 0.0 112.807 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -79.57 64.51 8.86 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.948 2.432 . . . . 0.0 112.468 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.61 -48.77 0.39 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.053 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.414 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 98.6 m-85 -103.66 -5.63 22.41 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.021 178.654 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 86.0 m -95.16 -41.2 9.21 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.491 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.2 -61.12 0.82 Allowed Glycine 0 C--N 1.341 0.828 0 CA-C-N 116.215 -0.448 . . . . 0.0 112.506 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.367 -1.24 . . . . 0.0 112.613 179.978 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.327 0 CA-C-O 120.543 0.211 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 108.18 -54.8 0.54 Allowed Glycine 0 C--N 1.338 0.641 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.589 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -124.6 149.89 46.57 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 122.307 0.243 . . . . 0.0 110.931 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.516 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 93.0 m -91.52 150.26 21.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.276 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -121.95 112.53 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.922 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 77.1 mtp180 57.62 25.84 12.16 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.859 0.863 . . . . 0.0 112.626 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.55 18.49 54.85 Favored Glycine 0 C--N 1.338 0.662 0 CA-C-N 115.779 -0.646 . . . . 0.0 113.531 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -133.02 124.39 27.59 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.634 0.254 . . . . 0.0 110.822 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.516 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.2 t -135.55 116.57 11.88 Favored Pre-proline 0 CA--C 1.54 0.571 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.844 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -80.82 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 122.36 2.04 . . . . 0.0 112.859 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.05 -30.69 7.75 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.388 0.43 . . . . 0.0 113.013 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.93 42.27 3.11 Favored Glycine 0 C--N 1.338 0.639 0 C-N-CA 121.617 -0.325 . . . . 0.0 112.685 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.71 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -134.71 -171.24 2.73 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 122.578 0.351 . . . . 0.0 110.729 -179.952 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.401 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 99.6 m -96.08 156.76 16.2 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 111.895 0.331 . . . . 0.0 111.895 -178.404 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -126.69 127.4 45.08 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.8 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.476 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 35.5 p -93.61 143.67 26.09 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.61 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -54.24 -20.43 6.97 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 -178.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -76.08 -6.88 53.17 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.356 0.263 . . . . 0.0 111.321 179.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.79 47.15 3.0 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.558 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.476 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 89.5 m-85 -138.25 161.98 35.49 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.483 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.71 ' HB3' HD12 ' A' ' 13' ' ' LEU . 15.1 m -123.54 151.68 42.61 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.685 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.458 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . 176.31 155.32 12.97 Favored Glycine 0 C--N 1.34 0.804 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.84 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -110.67 145.1 38.56 Favored 'General case' 0 C--O 1.235 0.34 0 O-C-N 123.723 0.308 . . . . 0.0 110.822 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 100.58 -178.71 28.92 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-O 119.368 -0.684 . . . . 0.0 112.809 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -76.83 62.75 7.38 Favored 'Trans proline' 0 C--N 1.371 1.721 0 C-N-CA 122.974 2.449 . . . . 0.0 112.508 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.9 -46.22 0.4 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.135 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.458 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.7 m-85 -114.32 -2.62 13.26 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.158 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.6 m -94.05 -41.98 9.26 Favored 'General case' 0 C--N 1.344 0.332 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.544 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -153.86 96.62 0.16 Allowed Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.293 -0.412 . . . . 0.0 112.51 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 118.394 -1.226 . . . . 0.0 112.484 179.966 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.516 0.198 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.52 70.83 0.93 Allowed Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.583 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -128.17 145.63 50.97 Favored 'General case' 0 N--CA 1.465 0.306 0 O-C-N 123.607 0.239 . . . . 0.0 110.849 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.741 ' HG ' ' HB2' ' A' ' 21' ' ' CYS . 58.2 m -98.64 130.89 45.17 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 123.675 0.61 . . . . 0.0 111.115 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.4 t -101.76 95.26 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 58.24 24.69 11.75 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.815 0.846 . . . . 0.0 112.322 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 87.41 47.44 4.62 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-N 115.662 -0.699 . . . . 0.0 112.965 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.72 119.0 18.76 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 120.86 0.362 . . . . 0.0 111.28 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 54.8 m -141.25 151.78 62.53 Favored Pre-proline 0 CA--C 1.536 0.437 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.626 179.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . 0.408 ' HG2' HD22 ' A' ' 13' ' ' LEU . 59.7 Cg_endo -70.36 -159.23 0.06 OUTLIER 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.46 2.107 . . . . 0.0 113.007 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.82 37.7 3.68 Favored Glycine 0 C--N 1.34 0.794 0 O-C-N 123.341 0.401 . . . . 0.0 112.864 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.97 -44.14 0.38 Allowed Glycine 0 C--N 1.338 0.647 0 C-N-CA 121.655 -0.307 . . . . 0.0 112.539 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.606 HD12 ' SG ' ' A' ' 21' ' ' CYS . 1.3 pt? -118.62 178.84 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 122.478 0.311 . . . . 0.0 110.87 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 69.1 m -109.87 152.43 25.79 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 123.103 0.252 . . . . 0.0 111.43 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.561 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 46.4 t -109.82 128.37 55.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.146 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 57.9 m -95.92 138.7 33.18 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.529 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -54.3 -22.1 11.05 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 -178.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -76.27 -6.81 53.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.418 0.287 . . . . 0.0 111.229 179.158 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.96 44.35 3.61 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.51 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -143.03 123.61 14.04 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.629 0.252 . . . . 0.0 111.373 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.741 ' HB2' ' HG ' ' A' ' 4' ' ' CYS . 0.6 OUTLIER -106.05 140.41 39.08 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.66 179.92 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -170.83 167.9 41.04 Favored Glycine 0 C--N 1.338 0.691 0 O-C-N 123.603 0.565 . . . . 0.0 112.668 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 p -105.37 150.75 24.95 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.604 0.24 . . . . 0.0 111.369 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.77 176.35 26.96 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.276 -0.735 . . . . 0.0 112.876 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -78.53 63.79 8.5 Favored 'Trans proline' 0 C--N 1.371 1.754 0 C-N-CA 122.945 2.43 . . . . 0.0 112.375 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.4 -48.27 0.44 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.158 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -105.62 -3.7 21.97 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.026 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.2 m -94.96 -43.71 8.04 Favored 'General case' 0 C--N 1.343 0.298 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.499 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.67 -88.01 0.5 Allowed Glycine 0 C--N 1.341 0.821 0 O-C-N 123.449 0.468 . . . . 0.0 112.486 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.121 0 CA-C-O 118.343 -1.254 . . . . 0.0 112.667 179.999 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.539 0.209 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 161.55 77.53 0.03 OUTLIER Glycine 0 C--N 1.337 0.627 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.44 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -129.25 142.46 50.84 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 122.349 0.26 . . . . 0.0 110.845 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 97.5 m -92.02 150.12 21.16 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.339 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -123.46 110.62 26.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.785 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 57.46 25.76 11.79 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 123.88 0.872 . . . . 0.0 112.68 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.07 21.76 37.83 Favored Glycine 0 C--N 1.339 0.732 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.524 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -134.79 123.55 23.75 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 120.654 0.264 . . . . 0.0 110.787 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.529 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 48.2 t -136.82 116.96 10.77 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.815 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -80.77 -161.84 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.69 0 C-N-CA 122.37 2.047 . . . . 0.0 112.877 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.99 -30.39 7.62 Favored Glycine 0 C--N 1.341 0.815 0 O-C-N 123.344 0.403 . . . . 0.0 113.057 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.43 42.74 3.36 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.582 -0.342 . . . . 0.0 112.675 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.716 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.86 -170.26 2.47 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 122.532 0.333 . . . . 0.0 110.796 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.9 m -95.42 154.55 17.15 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.766 0.317 . . . . 0.0 111.725 -178.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.8 t -123.89 128.95 50.21 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.792 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.469 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 46.9 p -96.78 141.65 29.74 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.46 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -54.94 -19.32 6.45 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -178.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -76.33 -7.25 54.56 Favored 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.141 0.275 . . . . 0.0 111.239 179.116 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.58 46.64 2.92 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.607 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.469 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 93.3 m-85 -139.6 164.25 30.4 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.716 ' HB3' HD13 ' A' ' 13' ' ' LEU . 19.8 m -126.4 152.64 46.07 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.752 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.565 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . 179.51 153.41 11.77 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.641 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 53.1 m -103.62 137.51 41.57 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.271 0.228 . . . . 0.0 111.324 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.59 179.95 22.14 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.36 -0.689 . . . . 0.0 112.953 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -80.13 65.94 8.85 Favored 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 123.101 2.534 . . . . 0.0 112.378 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.06 -49.34 0.42 Allowed 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.124 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.565 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 94.1 m-85 -101.11 -5.88 25.08 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.087 178.628 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.6 -42.54 8.36 Favored 'General case' 0 C--N 1.343 0.305 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.484 -179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.37 -56.38 0.46 Allowed Glycine 0 C--N 1.34 0.799 0 O-C-N 123.445 0.466 . . . . 0.0 112.498 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.357 -1.246 . . . . 0.0 112.504 179.998 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.301 0 CA-C-O 120.52 0.2 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.12 -53.72 0.01 OUTLIER Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.55 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -104.45 152.05 22.8 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 122.369 0.268 . . . . 0.0 110.937 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.512 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 72.4 m -90.38 148.89 22.53 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.239 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -117.68 112.1 37.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.889 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 57.04 25.87 11.27 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 123.912 0.885 . . . . 0.0 112.688 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.98 20.39 46.74 Favored Glycine 0 C--N 1.339 0.705 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.478 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -133.91 123.68 25.1 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.594 0.235 . . . . 0.0 110.813 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.512 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 38.7 t -136.38 116.43 11.05 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.7 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -80.73 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.369 1.634 0 C-N-CA 122.348 2.032 . . . . 0.0 112.883 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.04 -30.65 7.8 Favored Glycine 0 C--N 1.34 0.798 0 O-C-N 123.377 0.423 . . . . 0.0 113.038 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.51 42.97 3.04 Favored Glycine 0 C--N 1.339 0.695 0 C-N-CA 121.588 -0.339 . . . . 0.0 112.588 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.727 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -134.38 -171.68 2.82 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 122.649 0.38 . . . . 0.0 110.778 -179.86 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 74.9 m -97.03 158.36 15.46 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.685 0.279 . . . . 0.0 111.744 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.435 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 43.0 t -128.6 127.2 41.79 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.089 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -89.22 144.85 25.8 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.394 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -53.94 -22.36 10.03 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -178.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -76.2 -5.72 48.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.622 0.248 . . . . 0.0 111.511 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.57 48.48 2.75 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.631 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.435 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.1 m-85 -136.23 160.96 37.1 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -179.503 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.727 ' HB3' HD12 ' A' ' 13' ' ' LEU . 15.4 m -121.9 151.15 41.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.776 179.729 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.58 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . 175.98 150.09 7.87 Favored Glycine 0 C--N 1.341 0.857 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.658 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.5 t -108.85 145.53 35.14 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.628 0.251 . . . . 0.0 110.804 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.71 -177.49 29.33 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.369 -0.684 . . . . 0.0 112.77 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.16 62.76 7.6 Favored 'Trans proline' 0 C--N 1.37 1.707 0 C-N-CA 122.962 2.441 . . . . 0.0 112.596 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.54 -45.81 0.37 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.083 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.58 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.0 m-85 -114.7 -3.43 12.85 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.12 178.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.0 m -94.7 -44.48 7.78 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.568 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -154.37 124.46 1.55 Allowed Glycine 0 C--N 1.341 0.846 0 O-C-N 123.469 0.481 . . . . 0.0 112.403 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.416 -1.214 . . . . 0.0 112.581 179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.478 0.18 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 151.22 -59.19 0.42 Allowed Glycine 0 C--N 1.337 0.607 0 CA-C-N 115.872 -0.603 . . . . 0.0 112.514 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -129.26 143.06 50.71 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 123.649 0.264 . . . . 0.0 110.901 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 62.3 m -98.68 136.42 38.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -116.41 114.6 46.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.284 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 54.97 26.25 7.76 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.953 0.901 . . . . 0.0 112.957 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.64 27.49 29.41 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.974 -0.557 . . . . 0.0 113.515 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -129.59 113.96 15.47 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 120.89 0.376 . . . . 0.0 110.694 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 46.7 t -146.96 115.36 4.35 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.768 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -81.04 -162.86 0.2 Allowed 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.373 2.049 . . . . 0.0 112.626 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.84 -30.17 6.82 Favored Glycine 0 C--N 1.34 0.795 0 O-C-N 123.38 0.425 . . . . 0.0 112.975 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.2 46.1 2.67 Favored Glycine 0 C--N 1.339 0.717 0 C-N-CA 121.674 -0.298 . . . . 0.0 112.873 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.585 HD13 ' SG ' ' A' ' 21' ' ' CYS . 0.6 OUTLIER -134.19 -172.43 3.0 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 122.486 0.315 . . . . 0.0 110.81 179.951 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.664 ' HG ' ' H ' ' A' ' 15' ' ' CYS . 16.5 t -104.86 170.18 8.02 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -178.085 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.664 ' H ' ' HG ' ' A' ' 14' ' ' CYS . 50.3 m -122.08 130.53 53.34 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.613 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 t -91.46 142.51 27.59 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.312 178.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -55.1 -20.97 11.19 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -77.65 -5.31 49.94 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.384 0.274 . . . . 0.0 111.461 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.07 46.64 3.04 Favored Glycine 0 C--N 1.343 0.924 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.462 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -136.92 169.62 17.46 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.6 0.238 . . . . 0.0 111.602 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.585 ' SG ' HD13 ' A' ' 13' ' ' LEU . 0.5 OUTLIER -127.07 141.54 51.75 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.621 179.86 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.469 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . -179.54 150.84 9.6 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 123.514 0.509 . . . . 0.0 112.361 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -100.94 143.38 31.16 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.618 0.246 . . . . 0.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.38 -179.66 32.14 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 119.376 -0.68 . . . . 0.0 112.943 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -79.97 65.41 8.89 Favored 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 123.007 2.471 . . . . 0.0 112.425 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.19 -49.54 0.42 Allowed 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.986 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.469 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 86.1 m-85 -106.52 -6.51 18.05 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.015 178.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.44 -42.58 4.53 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.355 -179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.39 142.57 15.92 Favored Glycine 0 C--N 1.34 0.794 0 O-C-N 123.501 0.501 . . . . 0.0 112.535 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.108 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.46 -179.938 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.249 0 CA-C-O 120.538 0.208 . . . . 0.0 111.04 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 155.58 -67.84 0.3 Allowed Glycine 0 C--N 1.337 0.627 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.455 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -110.33 149.13 30.64 Favored 'General case' 0 C--O 1.235 0.325 0 O-C-N 123.631 0.254 . . . . 0.0 110.962 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.544 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 86.2 m -91.46 150.47 21.22 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.394 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -118.46 112.66 39.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.871 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 56.86 26.03 11.13 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.891 0.876 . . . . 0.0 112.782 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.82 17.13 57.1 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.817 -0.628 . . . . 0.0 113.581 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -133.09 125.7 30.17 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.748 0.274 . . . . 0.0 110.824 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.544 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.7 t -134.94 117.92 12.97 Favored Pre-proline 0 CA--C 1.539 0.555 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.824 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -80.27 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.72 0 C-N-CA 122.43 2.087 . . . . 0.0 112.92 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.75 -30.37 8.01 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.437 0.46 . . . . 0.0 113.015 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.61 41.8 3.07 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 121.559 -0.353 . . . . 0.0 112.637 -179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.743 HD13 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.86 -170.96 2.61 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 122.644 0.377 . . . . 0.0 110.788 -179.938 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -98.36 160.03 14.56 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.648 0.261 . . . . 0.0 111.656 -178.515 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -127.73 128.6 45.67 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.058 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.9 t -90.26 143.66 26.56 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.3 179.151 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.46 -21.55 10.24 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -178.67 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -76.99 -5.72 49.76 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 123.152 0.282 . . . . 0.0 111.47 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.78 48.72 2.65 Favored Glycine 0 C--N 1.341 0.839 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.622 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -136.78 160.99 37.2 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.718 0.294 . . . . 0.0 111.752 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.743 ' HB3' HD13 ' A' ' 13' ' ' LEU . 16.2 m -120.85 148.95 43.33 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.627 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.513 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . 179.51 149.51 8.45 Favored Glycine 0 C--N 1.341 0.849 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.55 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.3 p -103.83 134.13 47.65 Favored 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.635 0.256 . . . . 0.0 111.225 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.55 -178.89 21.9 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.908 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -80.03 65.2 8.91 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 123.101 2.534 . . . . 0.0 112.417 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.75 -48.83 0.43 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.129 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.513 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.6 m-85 -105.74 -5.5 19.87 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.029 178.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.9 -42.07 8.49 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.422 -179.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.98 129.79 6.78 Favored Glycine 0 C--N 1.34 0.783 0 O-C-N 123.351 0.407 . . . . 0.0 112.556 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.501 -1.166 . . . . 0.0 112.52 179.98 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.288 0 CA-C-O 120.482 0.182 . . . . 0.0 111.06 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.23 -110.64 0.62 Allowed Glycine 0 C--N 1.338 0.661 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.482 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -130.86 152.93 49.65 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 123.654 0.267 . . . . 0.0 110.991 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 85.4 m -88.35 148.79 24.09 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.319 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.1 t -113.21 107.2 22.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 56.12 26.71 10.5 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.932 0.893 . . . . 0.0 112.647 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.4 20.89 33.71 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.465 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.1 mtp180 -134.2 121.86 21.98 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 116.72 0.26 . . . . 0.0 110.771 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . 0.54 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.2 t -137.06 115.72 10.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.824 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.93 -161.46 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 122.393 2.062 . . . . 0.0 112.912 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.69 -31.18 7.44 Favored Glycine 0 C--N 1.34 0.771 0 O-C-N 123.317 0.386 . . . . 0.0 113.016 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.15 42.56 2.99 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.544 -179.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.743 HD12 ' HB3' ' A' ' 21' ' ' CYS . 0.7 OUTLIER -133.59 -169.45 2.29 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.588 0.355 . . . . 0.0 110.695 -179.883 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -98.0 155.61 17.02 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.715 0.293 . . . . 0.0 111.58 -178.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 40.4 t -126.38 127.98 46.33 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.934 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.7 m -92.07 141.82 28.19 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.419 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -55.22 -19.78 9.0 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -77.07 -6.16 51.7 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.458 0.303 . . . . 0.0 111.361 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.49 48.28 2.59 Favored Glycine 0 C--N 1.343 0.936 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.702 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -138.83 161.14 38.0 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.743 ' HB3' HD12 ' A' ' 13' ' ' LEU . 14.5 m -123.96 151.15 43.96 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.65 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.526 ' HA3' ' CD2' ' A' ' 27' ' ' TYR . . . 177.47 153.46 11.04 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.694 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 42.0 p -106.36 140.78 38.74 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 122.325 0.25 . . . . 0.0 111.253 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.53 -178.98 24.41 Favored Glycine 0 CA--C 1.529 0.923 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.867 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.46 65.86 8.87 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.086 2.524 . . . . 0.0 112.409 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.97 -49.45 0.43 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.996 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.526 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.4 m-85 -103.57 -7.24 20.95 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.958 178.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.92 -43.72 7.34 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 118.84 117.56 2.72 Favored Glycine 0 C--N 1.341 0.822 0 O-C-N 123.447 0.467 . . . . 0.0 112.536 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.528 -1.151 . . . . 0.0 112.551 -179.989 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.235 0.323 0 CA-C-O 120.536 0.208 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 83.3 m -91.84 146.28 23.88 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.234 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -114.11 110.6 32.71 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.958 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 56.02 27.15 10.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 123.975 0.91 . . . . 0.0 112.382 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.3 21.49 38.0 Favored Glycine 0 C--N 1.338 0.689 0 CA-C-N 115.818 -0.628 . . . . 0.0 113.42 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 76.8 mtp180 -134.3 122.7 23.04 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-O 120.645 0.26 . . . . 0.0 110.796 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.5 t -136.58 115.92 10.72 Favored Pre-proline 0 CA--C 1.54 0.565 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.787 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -80.95 -161.93 0.17 Allowed 'Trans proline' 0 C--N 1.37 1.689 0 C-N-CA 122.362 2.041 . . . . 0.0 112.845 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.22 -30.6 7.48 Favored Glycine 0 C--N 1.34 0.78 0 O-C-N 123.421 0.451 . . . . 0.0 113.04 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.61 43.33 3.42 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 121.599 -0.334 . . . . 0.0 112.728 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.57 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -132.93 -170.33 2.43 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.487 0.315 . . . . 0.0 110.843 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 72.5 m -95.0 154.45 17.16 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 120.759 0.314 . . . . 0.0 111.844 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 42.5 t -129.02 126.56 39.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.837 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.487 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 36.8 p -92.24 144.88 24.96 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.603 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.18 -20.82 7.46 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -76.03 -6.66 52.07 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.337 0.255 . . . . 0.0 111.379 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.77 48.12 2.79 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.609 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.487 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 88.3 m-85 -137.86 160.47 39.2 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -179.496 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 13.2 m -123.34 152.2 41.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.616 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.57 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.16 159.24 22.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.951 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.8 m -116.39 143.74 45.17 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 122.405 0.282 . . . . 0.0 110.925 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.18 -175.39 29.56 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.414 -0.659 . . . . 0.0 112.876 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -77.43 63.01 7.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 123.092 2.528 . . . . 0.0 112.49 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.11 -46.05 0.43 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.107 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -118.45 -2.68 11.02 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.121 178.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.7 m . . . . . 0 C--N 1.344 0.341 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.521 -179.777 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 . . . . . 0 N--CA 1.465 0.314 0 CA-C-O 120.526 0.203 . . . . 0.0 110.981 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.3 m -94.31 151.81 19.14 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.263 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -125.66 113.35 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 36.5 ttt180 55.95 26.23 9.63 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.998 0.919 . . . . 0.0 112.594 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.57 26.28 39.49 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.89 -0.595 . . . . 0.0 113.66 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -131.82 116.14 16.85 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 110.753 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.8 t -142.54 107.92 5.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.851 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.42 -160.61 0.12 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.462 2.108 . . . . 0.0 112.846 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.26 -32.12 7.28 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.285 0.365 . . . . 0.0 113.038 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.02 42.11 2.49 Favored Glycine 0 C--N 1.338 0.662 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.641 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.577 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -131.77 -169.52 2.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 122.683 0.393 . . . . 0.0 110.599 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 26.2 p -108.5 156.03 19.95 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.55 0.214 . . . . 0.0 111.296 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.6 t -126.21 131.7 51.92 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.642 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.4 t -89.58 144.88 25.66 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.253 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -56.04 -19.38 12.57 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -178.706 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -77.66 -5.6 50.98 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 123.095 0.247 . . . . 0.0 111.497 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 48.36 2.45 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.615 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -135.93 161.3 36.01 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.593 0.235 . . . . 0.0 111.571 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.11 145.93 49.79 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.574 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.577 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -175.75 -179.55 46.32 Favored Glycine 0 C--N 1.341 0.838 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.056 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 35.2 p -129.62 136.93 50.36 Favored 'General case' 0 C--O 1.236 0.372 0 O-C-N 123.723 0.307 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.63 -176.71 28.91 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 119.433 -0.649 . . . . 0.0 112.68 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -77.51 64.54 8.04 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 123.006 2.471 . . . . 0.0 112.364 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -137.49 -46.49 0.55 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.098 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -120.41 -6.22 9.81 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.059 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 38.1 m . . . . . 0 C--N 1.345 0.386 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.62 -179.385 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 N--CA 1.466 0.33 0 CA-C-O 120.58 0.229 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.437 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.8 m -94.88 137.51 33.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.163 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 14.6 p -105.28 109.95 29.41 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.724 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 68.4 mtp180 55.1 26.14 7.89 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 123.984 0.914 . . . . 0.0 112.732 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.64 26.56 24.66 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.871 -0.604 . . . . 0.0 113.408 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -134.89 117.4 15.82 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.668 0.27 . . . . 0.0 110.742 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.437 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 42.7 t -140.51 110.38 6.85 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.928 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.93 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.372 2.048 . . . . 0.0 112.723 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.93 -31.87 6.89 Favored Glycine 0 C--N 1.34 0.784 0 O-C-N 123.384 0.428 . . . . 0.0 112.995 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.75 2.68 Favored Glycine 0 C--N 1.338 0.675 0 C-N-CA 121.608 -0.33 . . . . 0.0 112.784 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.579 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -132.0 -171.48 2.64 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 122.578 0.351 . . . . 0.0 110.786 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.412 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 92.7 m -96.46 154.51 17.23 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.747 0.308 . . . . 0.0 111.689 -178.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 51.8 t -130.48 126.08 35.99 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.017 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.7 t -90.29 144.03 26.22 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.469 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.71 -20.11 13.28 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -76.87 -6.09 50.99 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.389 0.275 . . . . 0.0 111.508 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.18 48.19 2.47 Favored Glycine 0 C--N 1.343 0.941 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.644 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.421 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.8 m-85 -136.22 160.55 38.34 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.687 0.28 . . . . 0.0 111.716 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -132.21 147.99 52.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.83 179.927 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.579 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 174.55 163.87 28.51 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.216 -0.516 . . . . 0.0 112.737 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -113.28 149.6 33.65 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.3 -179.35 32.13 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.336 -0.702 . . . . 0.0 112.827 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -77.36 63.12 7.79 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.98 2.454 . . . . 0.0 112.458 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.89 -46.64 0.44 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.198 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -114.82 -2.62 12.9 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.08 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.0 m . . . . . 0 C--N 1.344 0.357 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.508 -179.77 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 N--CA 1.464 0.269 0 CA-C-O 120.589 0.233 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.494 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 82.5 m -94.41 151.81 19.09 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.338 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -125.55 111.3 26.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.942 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 56.56 26.16 10.7 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 123.928 0.891 . . . . 0.0 112.795 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.5 22.7 39.32 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.561 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.33 120.8 21.48 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.692 0.282 . . . . 0.0 110.813 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.494 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.0 t -138.54 114.36 8.79 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.861 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -81.72 -161.53 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.678 0 C-N-CA 122.403 2.069 . . . . 0.0 112.732 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.05 -30.46 7.56 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 123.364 0.415 . . . . 0.0 113.054 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.57 43.22 3.21 Favored Glycine 0 C--N 1.337 0.635 0 C-N-CA 121.616 -0.326 . . . . 0.0 112.785 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.576 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -132.97 -171.84 2.78 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 122.465 0.306 . . . . 0.0 110.799 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 80.2 m -96.66 158.41 15.44 Favored 'General case' 0 C--N 1.344 0.341 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -178.543 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 54.1 t -129.84 125.48 35.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.044 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.1 t -88.2 144.68 26.31 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.426 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -55.12 -21.43 13.01 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -76.29 -6.02 49.61 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 123.13 0.269 . . . . 0.0 111.396 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.28 48.33 2.63 Favored Glycine 0 C--N 1.342 0.896 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.519 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.419 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 88.6 m-85 -136.85 163.05 31.56 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.632 0.253 . . . . 0.0 111.638 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -129.2 148.57 51.15 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.941 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.576 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 174.26 167.05 33.24 Favored Glycine 0 C--N 1.342 0.87 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.561 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.0 t -119.96 148.28 43.72 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-O 120.626 0.25 . . . . 0.0 111.108 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 110.21 178.65 20.84 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-O 119.305 -0.719 . . . . 0.0 112.904 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.59 64.22 8.58 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.952 2.435 . . . . 0.0 112.373 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -148.1 -45.05 0.16 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.776 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -99.77 -10.25 22.06 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.867 178.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.344 0.338 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.347 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.236 0.342 0 CA-C-O 120.595 0.235 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.513 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 5.2 t -97.28 151.45 19.87 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.869 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -117.92 109.49 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.346 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 53.88 27.19 6.92 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.124 0.97 . . . . 0.0 113.008 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.53 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 87.34 28.65 24.38 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-N 115.944 -0.571 . . . . 0.0 113.328 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -137.26 116.36 12.49 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 122.499 0.32 . . . . 0.0 110.479 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.513 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 6.1 t -138.73 119.8 10.02 Favored Pre-proline 0 CA--C 1.539 0.526 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.938 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -80.1 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 122.338 2.026 . . . . 0.0 112.849 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.4 -30.59 8.03 Favored Glycine 0 C--N 1.341 0.832 0 O-C-N 123.361 0.413 . . . . 0.0 113.073 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.74 38.22 2.08 Favored Glycine 0 C--N 1.338 0.671 0 C-N-CA 121.567 -0.349 . . . . 0.0 112.742 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.591 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -134.85 -169.92 2.45 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.637 0.375 . . . . 0.0 110.609 -179.978 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.8 t -106.83 161.65 14.5 Favored 'General case' 0 C--N 1.344 0.332 0 CA-C-O 120.631 0.253 . . . . 0.0 111.653 -178.369 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.53 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 40.4 t -118.75 129.26 55.16 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.982 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 t -88.52 142.23 27.88 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.388 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.43 -21.83 10.89 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -77.26 -5.62 50.08 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.639 0.257 . . . . 0.0 111.45 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.72 47.8 2.87 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.449 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -137.59 166.46 23.86 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.2 m -117.86 152.03 36.2 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.753 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.591 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 166.12 152.26 7.15 Favored Glycine 0 C--N 1.34 0.803 0 C-N-CA 121.266 -0.493 . . . . 0.0 112.532 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -108.07 143.38 36.88 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 122.286 0.234 . . . . 0.0 110.866 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.28 -178.19 31.52 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.854 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -79.2 64.72 8.87 Favored 'Trans proline' 0 C--N 1.371 1.719 0 C-N-CA 123.017 2.478 . . . . 0.0 112.443 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.5 -47.67 0.38 Allowed 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.932 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.404 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 85.1 m-85 -111.99 -5.81 14.27 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.074 178.554 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.235 0.307 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.409 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.7 tt0 . . . . . 0 N--CA 1.486 1.351 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.0 m -93.8 148.01 22.52 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.286 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.37 115.94 43.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.053 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 57.81 24.9 11.31 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 123.972 0.909 . . . . 0.0 112.815 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.76 19.45 57.98 Favored Glycine 0 C--N 1.339 0.731 0 CA-C-N 115.758 -0.655 . . . . 0.0 113.647 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -131.31 121.1 24.13 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.693 0.283 . . . . 0.0 110.804 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.433 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.6 t -138.33 112.26 8.59 Favored Pre-proline 0 CA--C 1.54 0.594 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.819 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -82.25 -161.66 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.365 2.044 . . . . 0.0 112.758 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.35 -31.21 7.28 Favored Glycine 0 C--N 1.34 0.787 0 O-C-N 123.341 0.4 . . . . 0.0 113.041 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.34 2.76 Favored Glycine 0 C--N 1.338 0.688 0 C-N-CA 121.54 -0.362 . . . . 0.0 112.741 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.39 -172.52 2.97 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.609 0.363 . . . . 0.0 110.743 -179.994 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.0 m -97.06 157.73 15.77 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.727 0.298 . . . . 0.0 111.737 -178.556 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 49.0 t -129.59 126.0 37.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.991 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.7 t -90.44 144.46 25.78 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.497 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -55.58 -20.75 14.43 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -76.6 -6.16 50.81 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 123.139 0.274 . . . . 0.0 111.525 179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.93 48.12 2.53 Favored Glycine 0 C--N 1.342 0.874 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.581 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 84.9 m-85 -136.09 161.49 35.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.697 0.284 . . . . 0.0 111.691 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -131.31 145.03 51.69 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.679 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.61 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.81 157.7 19.2 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.664 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 41.2 p -107.98 149.04 28.87 Favored 'General case' 0 C--O 1.235 0.332 0 O-C-N 123.612 0.242 . . . . 0.0 111.165 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.99 -179.86 31.39 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-O 119.361 -0.688 . . . . 0.0 112.834 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.99 63.01 7.58 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 122.976 2.451 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.34 -46.39 0.42 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.242 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.434 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.5 m-85 -114.06 -2.35 13.51 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.079 178.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.5 m . . . . . 0 C--N 1.343 0.32 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.557 -179.77 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 . . . . . 0 N--CA 1.465 0.286 0 CA-C-O 120.492 0.187 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.415 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 8.8 t -109.95 141.64 42.42 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.637 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -104.32 95.23 3.65 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 54.62 26.23 7.19 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.999 0.919 . . . . 0.0 112.777 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.735 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 89.02 46.54 4.44 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.028 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -132.76 116.19 16.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.923 0.392 . . . . 0.0 111.218 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -141.65 156.88 66.15 Favored Pre-proline 0 CA--C 1.539 0.535 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.398 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.84 -159.0 0.04 OUTLIER 'Trans proline' 0 C--N 1.375 1.934 0 C-N-CA 122.472 2.115 . . . . 0.0 113.189 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.92 35.28 4.97 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 123.266 0.354 . . . . 0.0 112.977 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -122.92 -45.77 0.29 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 121.587 -0.34 . . . . 0.0 112.578 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.53 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 1.0 OUTLIER -113.51 -176.59 2.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.452 0.301 . . . . 0.0 110.995 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -124.08 156.03 37.31 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.584 0.23 . . . . 0.0 111.432 -178.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.735 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 52.7 t -117.04 133.36 56.1 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.127 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.503 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 40.0 p -96.69 145.39 25.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.446 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.61 -18.78 8.41 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -76.45 -7.04 54.25 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.674 0.273 . . . . 0.0 111.409 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.01 47.42 2.65 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.606 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.503 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 87.4 m-85 -136.93 155.74 49.36 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -137.52 130.06 29.77 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.598 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.53 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -164.82 173.11 40.69 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.529 0.518 . . . . 0.0 112.974 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.3 m -112.63 152.06 29.39 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 122.368 0.267 . . . . 0.0 111.257 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.09 177.68 26.54 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.895 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -79.31 64.61 8.86 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.943 2.428 . . . . 0.0 112.379 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.25 -47.89 0.35 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.135 -0.939 . . . . 0.0 109.947 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.13 -8.14 18.62 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.94 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.5 m . . . . . 0 C--N 1.343 0.324 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.436 179.905 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.236 0.343 0 CA-C-O 120.466 0.174 . . . . 0.0 110.937 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 96.4 m -91.97 149.56 21.47 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.314 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.407 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.2 t -115.82 106.52 20.59 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.917 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.407 HH11 ' CG1' ' A' ' 5' ' ' VAL . 7.8 mpt_? 55.46 27.52 10.31 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.972 0.909 . . . . 0.0 112.668 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.1 20.38 36.26 Favored Glycine 0 C--N 1.339 0.728 0 CA-C-N 115.903 -0.589 . . . . 0.0 113.457 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.89 121.09 21.23 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.651 0.262 . . . . 0.0 110.743 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.529 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 40.6 t -136.44 116.67 11.05 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.825 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -80.92 -161.57 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.335 2.024 . . . . 0.0 112.859 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.85 -30.71 7.64 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.435 0.459 . . . . 0.0 113.068 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.31 42.29 3.25 Favored Glycine 0 C--N 1.338 0.687 0 C-N-CA 121.545 -0.36 . . . . 0.0 112.66 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.584 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -133.87 -170.31 2.48 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 122.582 0.353 . . . . 0.0 110.784 -179.974 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -97.04 158.17 15.56 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 120.728 0.299 . . . . 0.0 111.735 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 t -125.8 125.97 43.78 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.6 t -88.55 143.15 27.14 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.425 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -54.78 -20.99 9.71 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -77.29 -5.91 51.22 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.355 0.262 . . . . 0.0 111.4 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.04 48.08 2.73 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.587 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -137.34 163.6 30.61 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.426 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 17.9 m -123.79 149.76 45.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.533 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.584 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 178.55 157.13 18.57 Favored Glycine 0 C--N 1.342 0.866 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.837 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.6 m -109.74 135.08 51.23 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 122.356 0.262 . . . . 0.0 111.128 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.8 -177.73 24.6 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.422 -0.654 . . . . 0.0 112.915 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -79.14 64.69 8.86 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.115 2.543 . . . . 0.0 112.493 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -48.49 0.47 Allowed 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.12 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -110.65 -5.26 15.07 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.999 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.236 0.358 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.397 -179.664 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 . . . . . 0 N--CA 1.465 0.32 0 CA-C-O 120.631 0.253 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 78.9 m -89.26 148.99 23.28 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.324 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -114.92 112.03 38.31 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.968 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 56.33 26.53 10.71 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.964 0.906 . . . . 0.0 112.696 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.69 16.42 56.64 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 115.827 -0.624 . . . . 0.0 113.56 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -132.54 124.63 28.84 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.618 0.247 . . . . 0.0 110.746 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.537 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.4 t -134.67 116.43 12.71 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.796 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -80.72 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.709 0 C-N-CA 122.342 2.028 . . . . 0.0 112.859 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.08 -30.51 8.0 Favored Glycine 0 C--N 1.342 0.87 0 O-C-N 123.392 0.433 . . . . 0.0 113.043 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.71 42.7 3.06 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.542 -0.361 . . . . 0.0 112.607 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.38 -171.58 2.8 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.62 0.368 . . . . 0.0 110.796 -179.94 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.3 m -95.84 156.88 16.15 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.745 0.307 . . . . 0.0 111.754 -178.403 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 41.6 t -128.22 125.21 38.51 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.847 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 66.5 m -88.04 144.13 26.69 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.601 179.126 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -54.78 -20.86 9.43 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -77.46 -6.68 54.37 Favored 'General case' 0 CA--C 1.54 0.582 0 O-C-N 123.106 0.254 . . . . 0.0 111.13 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.06 48.53 2.42 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.573 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.431 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 21.4 m-85 -136.45 159.92 40.32 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.44 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 13.6 m -122.32 149.89 43.13 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.557 179.688 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.59 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 176.86 154.5 11.99 Favored Glycine 0 C--N 1.341 0.836 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.746 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -111.76 145.15 39.86 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 123.665 0.273 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.96 -178.0 30.54 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-O 119.412 -0.66 . . . . 0.0 112.78 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.91 62.91 7.48 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 123.034 2.489 . . . . 0.0 112.467 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.27 -45.93 0.42 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.178 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.42 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.0 m-85 -116.82 -1.76 11.97 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.174 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 C--N 1.344 0.366 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.519 -179.795 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 . . . . . 0 N--CA 1.466 0.372 0 CA-C-O 120.546 0.212 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.567 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 99.5 m -93.17 149.55 21.14 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.236 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.9 108.01 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 56.06 27.27 11.13 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 123.952 0.901 . . . . 0.0 112.658 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.65 16.66 48.09 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.626 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -132.88 124.83 28.64 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.716 0.258 . . . . 0.0 110.796 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.567 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 41.2 t -133.92 119.26 14.65 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.989 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -80.42 -161.63 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 122.405 2.07 . . . . 0.0 112.782 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.42 -30.61 7.56 Favored Glycine 0 C--N 1.342 0.878 0 CA-C-N 116.397 -0.365 . . . . 0.0 113.033 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.67 42.77 2.83 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 121.614 -0.327 . . . . 0.0 112.739 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.569 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.84 -168.25 2.13 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.502 0.321 . . . . 0.0 110.804 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 70.2 m -100.9 160.2 14.57 Favored 'General case' 0 C--N 1.343 0.308 0 CA-C-O 120.673 0.273 . . . . 0.0 111.651 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.7 t -128.5 128.76 44.97 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.881 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.5 p -90.84 146.36 24.0 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.761 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -53.58 -20.16 4.75 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -178.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.78 -5.44 48.22 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 122.381 0.273 . . . . 0.0 111.272 179.132 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.35 45.57 4.33 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-N 115.758 -0.655 . . . . 0.0 112.175 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -134.46 161.37 35.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.646 0.26 . . . . 0.0 111.699 -179.087 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.2 m -116.84 152.6 34.11 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.569 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 175.16 160.38 22.95 Favored Glycine 0 C--N 1.343 0.936 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.759 -179.771 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -115.58 143.4 45.39 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.605 0.238 . . . . 0.0 111.005 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.1 -178.8 32.14 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.888 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.07 64.55 8.85 Favored 'Trans proline' 0 C--N 1.37 1.675 0 C-N-CA 123.052 2.501 . . . . 0.0 112.412 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -47.23 0.46 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.114 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 -5.31 12.68 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.016 178.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.235 0.322 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.461 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 . . . . . 0 N--CA 1.466 0.355 0 CA-C-O 120.467 0.175 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 73.7 m -95.1 118.18 31.46 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.042 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 8.4 t -129.69 84.59 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.472 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 55.12 29.18 12.08 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.847 0.859 . . . . 0.0 112.428 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.73 -38.95 0.05 OUTLIER Glycine 0 C--N 1.34 0.756 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.984 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 61.47 162.5 0.07 Allowed 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 124.037 0.935 . . . . 0.0 112.67 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.533 ' SG ' HD11 ' A' ' 13' ' ' LEU . 77.2 m -87.0 151.87 52.53 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.352 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.52 -155.59 0.03 OUTLIER 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.838 2.358 . . . . 0.0 113.265 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.8 26.87 6.24 Favored Glycine 0 C--N 1.344 1.016 0 C-N-CA 121.76 -0.257 . . . . 0.0 113.393 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.66 -48.98 1.87 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 121.577 -0.344 . . . . 0.0 112.388 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.533 HD11 ' SG ' ' A' ' 9' ' ' CYS . 0.7 OUTLIER -119.61 -173.4 2.52 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.558 0.343 . . . . 0.0 110.711 179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.9 m -115.1 153.16 31.25 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.344 -179.259 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -122.33 131.7 54.03 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.05 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.9 m -92.56 143.0 26.78 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.497 179.397 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -57.6 -18.04 17.63 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -78.13 -7.17 56.68 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.33 0.252 . . . . 0.0 111.077 179.246 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 97.64 48.29 1.99 Allowed Glycine 0 C--N 1.341 0.855 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.67 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -138.03 160.47 39.26 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.737 0.303 . . . . 0.0 111.78 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 0.1 OUTLIER -134.65 144.18 47.7 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.96 179.721 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.447 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . -179.32 161.63 27.84 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.982 -0.554 . . . . 0.0 112.538 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.7 t -109.61 148.53 31.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 120.602 0.239 . . . . 0.0 111.141 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.39 179.19 26.04 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-O 119.328 -0.707 . . . . 0.0 112.882 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -77.91 63.45 8.13 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 123.024 2.483 . . . . 0.0 112.412 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.48 -47.83 0.43 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.21 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.447 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 97.1 m-85 -107.67 -3.35 19.29 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.03 178.768 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.7 m . . . . . 0 C--O 1.235 0.338 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.574 -179.869 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 . . . . . 0 C--O 1.235 0.317 0 CA-C-O 120.51 0.195 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.496 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.5 m -93.58 149.17 21.45 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.285 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.445 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.1 t -119.84 105.58 17.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.747 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ARG . . . . . 0.445 HH11 ' CG1' ' A' ' 5' ' ' VAL . 8.3 mpt_? 55.99 27.18 10.84 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.848 0.859 . . . . 0.0 112.603 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.93 26.67 18.68 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.435 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -136.11 117.68 14.88 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-O 120.682 0.277 . . . . 0.0 110.803 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.496 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.1 t -138.98 114.57 8.49 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.719 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -81.35 -161.87 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.36 2.04 . . . . 0.0 112.844 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.57 -30.85 7.34 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.447 0.467 . . . . 0.0 113.013 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.47 43.44 3.43 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 121.697 -0.287 . . . . 0.0 112.707 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.587 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.41 -171.31 2.67 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 122.473 0.309 . . . . 0.0 110.807 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.9 m -93.82 155.07 17.4 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -125.84 125.2 42.48 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.712 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 75.6 m -90.9 143.57 26.59 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.735 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.83 -21.15 10.38 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -76.25 -6.81 53.09 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.381 0.273 . . . . 0.0 111.371 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.67 47.89 2.63 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.501 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -138.05 164.15 29.82 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.455 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 20.0 m -126.93 151.57 48.3 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.634 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.587 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.11 158.6 20.71 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.843 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.9 m -112.91 144.03 43.17 Favored 'General case' 0 C--O 1.235 0.318 0 O-C-N 123.659 0.27 . . . . 0.0 110.969 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.21 -177.56 31.23 Favored Glycine 0 CA--C 1.529 0.925 0 CA-C-O 119.393 -0.671 . . . . 0.0 112.776 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.76 62.99 7.39 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.996 2.464 . . . . 0.0 112.524 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.48 -46.36 0.46 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.25 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -116.72 -1.54 12.07 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.12 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 83.0 m . . . . . 0 C--N 1.344 0.344 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.528 -179.829 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 . . . . . 0 N--CA 1.466 0.366 0 CA-C-O 120.607 0.241 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.456 ' SG ' ' SG ' ' A' ' 9' ' ' CYS . 66.0 m -96.34 137.11 35.9 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.298 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.7 t -101.16 95.11 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.341 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 59.63 24.12 12.93 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 123.745 0.818 . . . . 0.0 112.234 -179.366 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.87 52.75 3.04 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.015 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 -135.59 121.75 20.22 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 120.814 0.34 . . . . 0.0 111.507 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.543 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 26.0 m -143.71 152.39 55.91 Favored Pre-proline 0 N--CA 1.469 0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.491 179.389 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -69.5 -159.39 0.05 OUTLIER 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 122.591 2.194 . . . . 0.0 113.075 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.59 37.46 3.8 Favored Glycine 0 C--N 1.341 0.829 0 O-C-N 123.324 0.39 . . . . 0.0 112.894 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.67 -40.57 0.52 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 121.548 -0.358 . . . . 0.0 112.68 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 22' ' ' GLY . 1.5 pt? -123.96 178.39 5.31 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 122.4 0.28 . . . . 0.0 110.884 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 68.9 m -110.57 157.96 19.08 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.678 -0.237 . . . . 0.0 111.569 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.543 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 49.9 t -120.84 129.25 53.46 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.231 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.415 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 38.5 p -94.61 144.56 25.5 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.435 179.226 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -56.0 -17.75 7.59 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -76.4 -7.36 54.87 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.701 0.286 . . . . 0.0 111.282 179.132 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 46.84 2.76 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.629 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.415 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 95.0 m-85 -139.57 156.88 46.62 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.504 0.192 . . . . 0.0 111.489 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.7 OUTLIER -137.81 133.73 34.35 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.55 179.395 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.495 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -164.88 166.97 38.39 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.667 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.2 t -105.94 148.32 27.79 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.664 0.268 . . . . 0.0 111.063 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.22 177.81 25.3 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.405 -0.664 . . . . 0.0 112.807 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -79.57 64.51 8.86 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.948 2.432 . . . . 0.0 112.468 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.61 -48.77 0.39 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.053 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -103.66 -5.63 22.41 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.021 178.654 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 86.0 m . . . . . 0 C--N 1.345 0.375 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.491 -179.982 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 . . . . . 0 N--CA 1.465 0.317 0 CA-C-O 120.573 0.225 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 93.0 m -91.52 150.26 21.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.276 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -121.95 112.53 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.922 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 77.1 mtp180 57.62 25.84 12.16 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.859 0.863 . . . . 0.0 112.626 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.55 18.49 54.85 Favored Glycine 0 C--N 1.338 0.662 0 CA-C-N 115.779 -0.646 . . . . 0.0 113.531 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -133.02 124.39 27.59 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.634 0.254 . . . . 0.0 110.822 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.2 t -135.55 116.57 11.88 Favored Pre-proline 0 CA--C 1.54 0.571 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.844 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -80.82 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 122.36 2.04 . . . . 0.0 112.859 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.05 -30.69 7.75 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.388 0.43 . . . . 0.0 113.013 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.93 42.27 3.11 Favored Glycine 0 C--N 1.338 0.639 0 C-N-CA 121.617 -0.325 . . . . 0.0 112.685 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.71 -171.24 2.73 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 122.578 0.351 . . . . 0.0 110.729 -179.952 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 99.6 m -96.08 156.76 16.2 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 111.895 0.331 . . . . 0.0 111.895 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -126.69 127.4 45.08 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.8 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.475 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 35.5 p -93.61 143.67 26.09 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.61 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -54.24 -20.43 6.97 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 -178.71 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -76.08 -6.88 53.17 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.356 0.263 . . . . 0.0 111.321 179.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.79 47.15 3.0 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.558 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.475 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 89.5 m-85 -138.25 161.98 35.49 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.483 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.44 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 15.1 m -123.54 151.68 42.61 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.685 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.59 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 176.31 155.32 12.97 Favored Glycine 0 C--N 1.34 0.804 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.84 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -110.67 145.1 38.56 Favored 'General case' 0 C--O 1.235 0.34 0 O-C-N 123.723 0.308 . . . . 0.0 110.822 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 100.58 -178.71 28.92 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-O 119.368 -0.684 . . . . 0.0 112.809 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -76.83 62.75 7.38 Favored 'Trans proline' 0 C--N 1.371 1.721 0 C-N-CA 122.974 2.449 . . . . 0.0 112.508 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.9 -46.22 0.4 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.135 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.453 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.7 m-85 -114.32 -2.62 13.26 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.158 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.6 m . . . . . 0 C--N 1.344 0.332 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.544 -179.827 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 120.452 0.168 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.414 ' SG ' ' SG ' ' A' ' 9' ' ' CYS . 58.2 m -98.64 130.89 45.17 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 123.675 0.61 . . . . 0.0 111.115 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.4 t -101.76 95.26 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 58.24 24.69 11.75 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.815 0.846 . . . . 0.0 112.322 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 87.41 47.44 4.62 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-N 115.662 -0.699 . . . . 0.0 112.965 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.72 119.0 18.76 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 120.86 0.362 . . . . 0.0 111.28 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 54.8 m -141.25 151.78 62.53 Favored Pre-proline 0 CA--C 1.536 0.437 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.626 179.536 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.36 -159.23 0.06 OUTLIER 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.46 2.107 . . . . 0.0 113.007 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.82 37.7 3.68 Favored Glycine 0 C--N 1.34 0.794 0 O-C-N 123.341 0.401 . . . . 0.0 112.864 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.97 -44.14 0.38 Allowed Glycine 0 C--N 1.338 0.647 0 C-N-CA 121.655 -0.307 . . . . 0.0 112.539 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.543 HD12 ' N ' ' A' ' 22' ' ' GLY . 1.3 pt? -118.62 178.84 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 122.478 0.311 . . . . 0.0 110.87 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 69.1 m -109.87 152.43 25.79 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 123.103 0.252 . . . . 0.0 111.43 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.549 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 46.4 t -109.82 128.37 55.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.146 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 57.9 m -95.92 138.7 33.18 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.529 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -54.3 -22.1 11.05 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 -178.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -76.27 -6.81 53.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.418 0.287 . . . . 0.0 111.229 179.158 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.96 44.35 3.61 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.51 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -143.03 123.61 14.04 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.629 0.252 . . . . 0.0 111.373 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -106.05 140.41 39.08 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.66 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.543 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -170.83 167.9 41.04 Favored Glycine 0 C--N 1.338 0.691 0 O-C-N 123.603 0.565 . . . . 0.0 112.668 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 p -105.37 150.75 24.95 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.604 0.24 . . . . 0.0 111.369 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.77 176.35 26.96 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.276 -0.735 . . . . 0.0 112.876 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -78.53 63.79 8.5 Favored 'Trans proline' 0 C--N 1.371 1.754 0 C-N-CA 122.945 2.43 . . . . 0.0 112.375 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.4 -48.27 0.44 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.158 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -105.62 -3.7 21.97 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.026 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.2 m . . . . . 0 C--N 1.343 0.298 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.499 -179.817 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 . . . . . 0 C--O 1.235 0.308 0 CA-C-O 120.507 0.194 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.539 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 97.5 m -92.02 150.12 21.16 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.339 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -123.46 110.62 26.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.785 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 57.46 25.76 11.79 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 123.88 0.872 . . . . 0.0 112.68 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.07 21.76 37.83 Favored Glycine 0 C--N 1.339 0.732 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.524 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -134.79 123.55 23.75 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 120.654 0.264 . . . . 0.0 110.787 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.539 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 48.2 t -136.82 116.96 10.77 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.815 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -80.77 -161.84 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.69 0 C-N-CA 122.37 2.047 . . . . 0.0 112.877 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.99 -30.39 7.62 Favored Glycine 0 C--N 1.341 0.815 0 O-C-N 123.344 0.403 . . . . 0.0 113.057 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.43 42.74 3.36 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.582 -0.342 . . . . 0.0 112.675 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.583 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.86 -170.26 2.47 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 122.532 0.333 . . . . 0.0 110.796 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.9 m -95.42 154.55 17.15 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.766 0.317 . . . . 0.0 111.725 -178.399 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.8 t -123.89 128.95 50.21 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.792 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.468 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 46.9 p -96.78 141.65 29.74 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.46 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -54.94 -19.32 6.45 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -178.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -76.33 -7.25 54.56 Favored 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.141 0.275 . . . . 0.0 111.239 179.116 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.58 46.64 2.92 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.607 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.468 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 93.3 m-85 -139.6 164.25 30.4 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.435 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 19.8 m -126.4 152.64 46.07 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.752 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.583 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 179.51 153.41 11.77 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.641 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 53.1 m -103.62 137.51 41.57 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.271 0.228 . . . . 0.0 111.324 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.59 179.95 22.14 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.36 -0.689 . . . . 0.0 112.953 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -80.13 65.94 8.85 Favored 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 123.101 2.534 . . . . 0.0 112.378 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.06 -49.34 0.42 Allowed 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.124 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.561 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 94.1 m-85 -101.11 -5.88 25.08 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.087 178.628 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.343 0.305 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.484 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 . . . . . 0 C--O 1.234 0.271 0 CA-C-O 120.608 0.242 . . . . 0.0 110.937 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.52 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 72.4 m -90.38 148.89 22.53 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.239 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -117.68 112.1 37.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.889 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 57.04 25.87 11.27 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 123.912 0.885 . . . . 0.0 112.688 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.98 20.39 46.74 Favored Glycine 0 C--N 1.339 0.705 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.478 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -133.91 123.68 25.1 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.594 0.235 . . . . 0.0 110.813 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.52 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 38.7 t -136.38 116.43 11.05 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.7 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -80.73 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.369 1.634 0 C-N-CA 122.348 2.032 . . . . 0.0 112.883 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.04 -30.65 7.8 Favored Glycine 0 C--N 1.34 0.798 0 O-C-N 123.377 0.423 . . . . 0.0 113.038 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.51 42.97 3.04 Favored Glycine 0 C--N 1.339 0.695 0 C-N-CA 121.588 -0.339 . . . . 0.0 112.588 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.605 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.38 -171.68 2.82 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 122.649 0.38 . . . . 0.0 110.778 -179.86 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 74.9 m -97.03 158.36 15.46 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.685 0.279 . . . . 0.0 111.744 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 43.0 t -128.6 127.2 41.79 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.089 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -89.22 144.85 25.8 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.394 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -53.94 -22.36 10.03 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -178.753 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -76.2 -5.72 48.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.622 0.248 . . . . 0.0 111.511 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.57 48.48 2.75 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.631 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.434 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.1 m-85 -136.23 160.96 37.1 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -179.503 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.441 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 15.4 m -121.9 151.15 41.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.776 179.729 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.605 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 175.98 150.09 7.87 Favored Glycine 0 C--N 1.341 0.857 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.658 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.5 t -108.85 145.53 35.14 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.628 0.251 . . . . 0.0 110.804 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.71 -177.49 29.33 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.369 -0.684 . . . . 0.0 112.77 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.16 62.76 7.6 Favored 'Trans proline' 0 C--N 1.37 1.707 0 C-N-CA 122.962 2.441 . . . . 0.0 112.596 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.54 -45.81 0.37 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.083 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.577 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.0 m-85 -114.7 -3.43 12.85 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.12 178.825 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.0 m . . . . . 0 C--N 1.343 0.322 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.568 -179.779 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 . . . . . 0 C--O 1.235 0.321 0 CA-C-O 120.499 0.19 . . . . 0.0 110.901 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 62.3 m -98.68 136.42 38.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -116.41 114.6 46.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.284 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 54.97 26.25 7.76 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.953 0.901 . . . . 0.0 112.957 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.64 27.49 29.41 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.974 -0.557 . . . . 0.0 113.515 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -129.59 113.96 15.47 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 120.89 0.376 . . . . 0.0 110.694 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 46.7 t -146.96 115.36 4.35 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.768 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -81.04 -162.86 0.2 Allowed 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.373 2.049 . . . . 0.0 112.626 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.84 -30.17 6.82 Favored Glycine 0 C--N 1.34 0.795 0 O-C-N 123.38 0.425 . . . . 0.0 112.975 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.2 46.1 2.67 Favored Glycine 0 C--N 1.339 0.717 0 C-N-CA 121.674 -0.298 . . . . 0.0 112.873 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.621 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -134.19 -172.43 3.0 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 122.486 0.315 . . . . 0.0 110.81 179.951 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -104.86 170.18 8.02 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -178.085 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.3 m -122.08 130.53 53.34 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.613 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 t -91.46 142.51 27.59 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.312 178.835 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -55.1 -20.97 11.19 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -77.65 -5.31 49.94 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.384 0.274 . . . . 0.0 111.461 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.07 46.64 3.04 Favored Glycine 0 C--N 1.343 0.924 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.462 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -136.92 169.62 17.46 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.6 0.238 . . . . 0.0 111.602 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.07 141.54 51.75 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.621 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.621 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -179.54 150.84 9.6 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 123.514 0.509 . . . . 0.0 112.361 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -100.94 143.38 31.16 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.618 0.246 . . . . 0.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.38 -179.66 32.14 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 119.376 -0.68 . . . . 0.0 112.943 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -79.97 65.41 8.89 Favored 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 123.007 2.471 . . . . 0.0 112.425 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.19 -49.54 0.42 Allowed 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.986 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.466 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 86.1 m-85 -106.52 -6.51 18.05 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.015 178.475 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.235 0.296 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.355 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 . . . . . 0 C--O 1.235 0.325 0 CA-C-O 120.538 0.209 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.559 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 86.2 m -91.46 150.47 21.22 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.394 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -118.46 112.66 39.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.871 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 56.86 26.03 11.13 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.891 0.876 . . . . 0.0 112.782 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.82 17.13 57.1 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.817 -0.628 . . . . 0.0 113.581 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -133.09 125.7 30.17 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.748 0.274 . . . . 0.0 110.824 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.559 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.7 t -134.94 117.92 12.97 Favored Pre-proline 0 CA--C 1.539 0.555 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.824 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -80.27 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.72 0 C-N-CA 122.43 2.087 . . . . 0.0 112.92 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.75 -30.37 8.01 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.437 0.46 . . . . 0.0 113.015 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.61 41.8 3.07 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 121.559 -0.353 . . . . 0.0 112.637 -179.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.593 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.86 -170.96 2.61 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 122.644 0.377 . . . . 0.0 110.788 -179.938 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -98.36 160.03 14.56 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.648 0.261 . . . . 0.0 111.656 -178.515 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -127.73 128.6 45.67 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.058 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.9 t -90.26 143.66 26.56 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.3 179.151 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.46 -21.55 10.24 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -178.67 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -76.99 -5.72 49.76 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 123.152 0.282 . . . . 0.0 111.47 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.78 48.72 2.65 Favored Glycine 0 C--N 1.341 0.839 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.622 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -136.78 160.99 37.2 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.718 0.294 . . . . 0.0 111.752 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 16.2 m -120.85 148.95 43.33 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.627 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.593 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 179.51 149.51 8.45 Favored Glycine 0 C--N 1.341 0.849 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.55 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.3 p -103.83 134.13 47.65 Favored 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.635 0.256 . . . . 0.0 111.225 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.55 -178.89 21.9 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.908 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -80.03 65.2 8.91 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 123.101 2.534 . . . . 0.0 112.417 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.75 -48.83 0.43 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.129 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.512 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.6 m-85 -105.74 -5.5 19.87 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.029 178.684 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.236 0.365 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.422 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 . . . . . 0 C--O 1.236 0.348 0 CA-C-O 120.498 0.19 . . . . 0.0 110.991 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.543 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 85.4 m -88.35 148.79 24.09 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.319 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.1 t -113.21 107.2 22.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 56.12 26.71 10.5 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.932 0.893 . . . . 0.0 112.647 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.4 20.89 33.71 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.465 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.1 mtp180 -134.2 121.86 21.98 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 116.72 0.26 . . . . 0.0 110.771 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.543 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.2 t -137.06 115.72 10.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.824 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.93 -161.46 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 122.393 2.062 . . . . 0.0 112.912 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.69 -31.18 7.44 Favored Glycine 0 C--N 1.34 0.771 0 O-C-N 123.317 0.386 . . . . 0.0 113.016 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.15 42.56 2.99 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.544 -179.736 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.582 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.59 -169.45 2.29 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.588 0.355 . . . . 0.0 110.695 -179.883 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -98.0 155.61 17.02 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.715 0.293 . . . . 0.0 111.58 -178.568 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 40.4 t -126.38 127.98 46.33 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.934 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.7 m -92.07 141.82 28.19 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.419 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -55.22 -19.78 9.0 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -77.07 -6.16 51.7 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.458 0.303 . . . . 0.0 111.361 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.49 48.28 2.59 Favored Glycine 0 C--N 1.343 0.936 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.702 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -138.83 161.14 38.0 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.435 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 14.5 m -123.96 151.15 43.96 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.65 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.582 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.47 153.46 11.04 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.694 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 42.0 p -106.36 140.78 38.74 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 122.325 0.25 . . . . 0.0 111.253 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.53 -178.98 24.41 Favored Glycine 0 CA--C 1.529 0.923 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.867 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.46 65.86 8.87 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.086 2.524 . . . . 0.0 112.409 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.97 -49.45 0.43 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.996 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' TYR . . . . . 0.521 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.4 m-85 -103.57 -7.24 20.95 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.958 178.648 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.343 0.314 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.314 0 CA-C-O 120.485 0.184 . . . . 0.0 111.047 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.09 93.55 2.17 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.447 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -128.75 147.79 50.8 Favored 'General case' 0 C--O 1.235 0.323 0 O-C-N 123.668 0.275 . . . . 0.0 110.88 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 83.3 m -91.84 146.28 23.88 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.234 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -114.11 110.6 32.71 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.958 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 56.02 27.15 10.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 123.975 0.91 . . . . 0.0 112.382 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.3 21.49 38.0 Favored Glycine 0 C--N 1.338 0.689 0 CA-C-N 115.818 -0.628 . . . . 0.0 113.42 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 76.8 mtp180 -134.3 122.7 23.04 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-O 120.645 0.26 . . . . 0.0 110.796 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.5 t -136.58 115.92 10.72 Favored Pre-proline 0 CA--C 1.54 0.565 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.787 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -80.95 -161.93 0.17 Allowed 'Trans proline' 0 C--N 1.37 1.689 0 C-N-CA 122.362 2.041 . . . . 0.0 112.845 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.22 -30.6 7.48 Favored Glycine 0 C--N 1.34 0.78 0 O-C-N 123.421 0.451 . . . . 0.0 113.04 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.61 43.33 3.42 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 121.599 -0.334 . . . . 0.0 112.728 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.57 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -132.93 -170.33 2.43 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.487 0.315 . . . . 0.0 110.843 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 72.5 m -95.0 154.45 17.16 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 120.759 0.314 . . . . 0.0 111.844 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 42.5 t -129.02 126.56 39.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.837 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.487 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 36.8 p -92.24 144.88 24.96 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.603 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.18 -20.82 7.46 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -76.03 -6.66 52.07 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.337 0.255 . . . . 0.0 111.379 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.77 48.12 2.79 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.609 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.487 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 88.3 m-85 -137.86 160.47 39.2 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -179.496 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 13.2 m -123.34 152.2 41.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.616 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.57 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.16 159.24 22.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.951 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.8 m -116.39 143.74 45.17 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 122.405 0.282 . . . . 0.0 110.925 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.18 -175.39 29.56 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.414 -0.659 . . . . 0.0 112.876 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -77.43 63.01 7.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 123.092 2.528 . . . . 0.0 112.49 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.11 -46.05 0.43 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.107 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -118.45 -2.68 11.02 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.121 178.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.7 m -95.98 -43.25 7.89 Favored 'General case' 0 C--N 1.344 0.341 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.521 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.73 -76.76 0.29 Allowed Glycine 0 C--N 1.34 0.795 0 O-C-N 123.396 0.435 . . . . 0.0 112.473 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.34 -1.255 . . . . 0.0 112.49 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.323 0 CA-C-O 120.524 0.202 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 129.53 55.07 0.1 Allowed Glycine 0 C--N 1.337 0.625 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.477 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -108.72 151.71 25.82 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 122.364 0.266 . . . . 0.0 110.981 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.3 m -94.31 151.81 19.14 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.263 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -125.66 113.35 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 36.5 ttt180 55.95 26.23 9.63 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.998 0.919 . . . . 0.0 112.594 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.57 26.28 39.49 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.89 -0.595 . . . . 0.0 113.66 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -131.82 116.14 16.85 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 110.753 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.8 t -142.54 107.92 5.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.851 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.42 -160.61 0.12 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.462 2.108 . . . . 0.0 112.846 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.26 -32.12 7.28 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.285 0.365 . . . . 0.0 113.038 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.02 42.11 2.49 Favored Glycine 0 C--N 1.338 0.662 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.641 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.577 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -131.77 -169.52 2.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 122.683 0.393 . . . . 0.0 110.599 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 26.2 p -108.5 156.03 19.95 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.55 0.214 . . . . 0.0 111.296 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.6 t -126.21 131.7 51.92 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.642 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.4 t -89.58 144.88 25.66 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.253 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -56.04 -19.38 12.57 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -178.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -77.66 -5.6 50.98 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 123.095 0.247 . . . . 0.0 111.497 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 48.36 2.45 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.615 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -135.93 161.3 36.01 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.593 0.235 . . . . 0.0 111.571 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.11 145.93 49.79 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.574 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.577 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -175.75 -179.55 46.32 Favored Glycine 0 C--N 1.341 0.838 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.056 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 35.2 p -129.62 136.93 50.36 Favored 'General case' 0 C--O 1.236 0.372 0 O-C-N 123.723 0.307 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.63 -176.71 28.91 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 119.433 -0.649 . . . . 0.0 112.68 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -77.51 64.54 8.04 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 123.006 2.471 . . . . 0.0 112.364 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -137.49 -46.49 0.55 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.098 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -120.41 -6.22 9.81 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.059 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 38.1 m -92.14 -44.24 8.91 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.62 -179.385 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -143.43 -107.14 0.58 Allowed Glycine 0 C--N 1.34 0.783 0 O-C-N 123.385 0.428 . . . . 0.0 112.51 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.394 -1.226 . . . . 0.0 112.674 -179.975 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.325 0 CA-C-O 120.465 0.174 . . . . 0.0 111.038 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 115.06 -54.53 0.57 Allowed Glycine 0 C--N 1.336 0.567 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.539 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -117.75 149.97 39.89 Favored 'General case' 0 N--CA 1.466 0.33 0 O-C-N 123.631 0.253 . . . . 0.0 110.85 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.437 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.8 m -94.88 137.51 33.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.163 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 14.6 p -105.28 109.95 29.41 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.724 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 68.4 mtp180 55.1 26.14 7.89 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 123.984 0.914 . . . . 0.0 112.732 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.64 26.56 24.66 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.871 -0.604 . . . . 0.0 113.408 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -134.89 117.4 15.82 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.668 0.27 . . . . 0.0 110.742 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.437 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 42.7 t -140.51 110.38 6.85 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.928 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.93 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.372 2.048 . . . . 0.0 112.723 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.93 -31.87 6.89 Favored Glycine 0 C--N 1.34 0.784 0 O-C-N 123.384 0.428 . . . . 0.0 112.995 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.75 2.68 Favored Glycine 0 C--N 1.338 0.675 0 C-N-CA 121.608 -0.33 . . . . 0.0 112.784 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.579 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -132.0 -171.48 2.64 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 122.578 0.351 . . . . 0.0 110.786 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.412 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 92.7 m -96.46 154.51 17.23 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.747 0.308 . . . . 0.0 111.689 -178.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 51.8 t -130.48 126.08 35.99 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.017 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.7 t -90.29 144.03 26.22 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.469 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.71 -20.11 13.28 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -76.87 -6.09 50.99 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.389 0.275 . . . . 0.0 111.508 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.18 48.19 2.47 Favored Glycine 0 C--N 1.343 0.941 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.644 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.421 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.8 m-85 -136.22 160.55 38.34 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.687 0.28 . . . . 0.0 111.716 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -132.21 147.99 52.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.83 179.927 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.579 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 174.55 163.87 28.51 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.216 -0.516 . . . . 0.0 112.737 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -113.28 149.6 33.65 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.3 -179.35 32.13 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.336 -0.702 . . . . 0.0 112.827 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -77.36 63.12 7.79 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.98 2.454 . . . . 0.0 112.458 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.89 -46.64 0.44 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.198 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -114.82 -2.62 12.9 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.08 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.0 m -93.85 -42.11 9.27 Favored 'General case' 0 C--N 1.344 0.357 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.508 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -133.17 -140.46 4.4 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.5 0.5 . . . . 0.0 112.542 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.352 -1.249 . . . . 0.0 112.421 179.995 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.465 0.174 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 139.2 -58.96 0.6 Allowed Glycine 0 C--N 1.338 0.663 0 O-C-N 123.685 0.616 . . . . 0.0 112.531 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -113.65 148.17 36.78 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 123.634 0.255 . . . . 0.0 110.928 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.494 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 82.5 m -94.41 151.81 19.09 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.338 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -125.55 111.3 26.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.942 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 56.56 26.16 10.7 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 123.928 0.891 . . . . 0.0 112.795 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.5 22.7 39.32 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.561 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.33 120.8 21.48 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.692 0.282 . . . . 0.0 110.813 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.494 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.0 t -138.54 114.36 8.79 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.861 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -81.72 -161.53 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.678 0 C-N-CA 122.403 2.069 . . . . 0.0 112.732 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.05 -30.46 7.56 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 123.364 0.415 . . . . 0.0 113.054 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.57 43.22 3.21 Favored Glycine 0 C--N 1.337 0.635 0 C-N-CA 121.616 -0.326 . . . . 0.0 112.785 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.576 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -132.97 -171.84 2.78 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 122.465 0.306 . . . . 0.0 110.799 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 80.2 m -96.66 158.41 15.44 Favored 'General case' 0 C--N 1.344 0.341 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -178.543 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 54.1 t -129.84 125.48 35.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.044 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.1 t -88.2 144.68 26.31 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.426 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -55.12 -21.43 13.01 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -76.29 -6.02 49.61 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 123.13 0.269 . . . . 0.0 111.396 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.28 48.33 2.63 Favored Glycine 0 C--N 1.342 0.896 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.519 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.419 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 88.6 m-85 -136.85 163.05 31.56 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.632 0.253 . . . . 0.0 111.638 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -129.2 148.57 51.15 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.941 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.576 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 174.26 167.05 33.24 Favored Glycine 0 C--N 1.342 0.87 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.561 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.0 t -119.96 148.28 43.72 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-O 120.626 0.25 . . . . 0.0 111.108 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 110.21 178.65 20.84 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-O 119.305 -0.719 . . . . 0.0 112.904 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.59 64.22 8.58 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.952 2.435 . . . . 0.0 112.373 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -148.1 -45.05 0.16 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.776 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -99.77 -10.25 22.06 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.867 178.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -126.51 -41.86 1.84 Allowed 'General case' 0 C--N 1.344 0.338 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.347 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -98.35 93.01 1.3 Allowed Glycine 0 C--N 1.339 0.737 0 O-C-N 123.483 0.489 . . . . 0.0 112.486 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.507 -1.163 . . . . 0.0 112.543 179.952 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.524 0.202 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 148.55 -55.54 0.5 Allowed Glycine 0 C--N 1.338 0.648 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.482 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -100.53 151.2 21.86 Favored 'General case' 0 C--O 1.236 0.342 0 O-C-N 123.648 0.264 . . . . 0.0 110.95 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.513 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 5.2 t -97.28 151.45 19.87 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.869 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -117.92 109.49 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.346 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 53.88 27.19 6.92 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.124 0.97 . . . . 0.0 113.008 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.53 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 87.34 28.65 24.38 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-N 115.944 -0.571 . . . . 0.0 113.328 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -137.26 116.36 12.49 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 122.499 0.32 . . . . 0.0 110.479 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.513 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 6.1 t -138.73 119.8 10.02 Favored Pre-proline 0 CA--C 1.539 0.526 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.938 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -80.1 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 122.338 2.026 . . . . 0.0 112.849 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.4 -30.59 8.03 Favored Glycine 0 C--N 1.341 0.832 0 O-C-N 123.361 0.413 . . . . 0.0 113.073 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.74 38.22 2.08 Favored Glycine 0 C--N 1.338 0.671 0 C-N-CA 121.567 -0.349 . . . . 0.0 112.742 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.591 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -134.85 -169.92 2.45 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.637 0.375 . . . . 0.0 110.609 -179.978 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.8 t -106.83 161.65 14.5 Favored 'General case' 0 C--N 1.344 0.332 0 CA-C-O 120.631 0.253 . . . . 0.0 111.653 -178.369 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.53 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 40.4 t -118.75 129.26 55.16 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.982 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 t -88.52 142.23 27.88 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.388 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.43 -21.83 10.89 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -77.26 -5.62 50.08 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.639 0.257 . . . . 0.0 111.45 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.72 47.8 2.87 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.449 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -137.59 166.46 23.86 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.2 m -117.86 152.03 36.2 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.753 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.591 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 166.12 152.26 7.15 Favored Glycine 0 C--N 1.34 0.803 0 C-N-CA 121.266 -0.493 . . . . 0.0 112.532 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -108.07 143.38 36.88 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 122.286 0.234 . . . . 0.0 110.866 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.28 -178.19 31.52 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.854 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -79.2 64.72 8.87 Favored 'Trans proline' 0 C--N 1.371 1.719 0 C-N-CA 123.017 2.478 . . . . 0.0 112.443 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.5 -47.67 0.38 Allowed 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.932 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.404 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 85.1 m-85 -111.99 -5.81 14.27 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.074 178.554 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.58 -42.68 4.48 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.409 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -115.52 132.3 10.21 Favored Glycine 0 C--N 1.34 0.792 0 O-C-N 123.424 0.452 . . . . 0.0 112.489 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.374 -1.237 . . . . 0.0 112.585 179.978 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.328 0 CA-C-O 120.503 0.192 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.82 105.79 2.7 Favored Glycine 0 C--N 1.337 0.595 0 CA-C-N 115.826 -0.625 . . . . 0.0 112.459 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.7 tt0 63.97 145.21 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 124.009 0.923 . . . . 0.0 111.934 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.0 m -93.8 148.01 22.52 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.286 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.37 115.94 43.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.053 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 57.81 24.9 11.31 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 123.972 0.909 . . . . 0.0 112.815 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.76 19.45 57.98 Favored Glycine 0 C--N 1.339 0.731 0 CA-C-N 115.758 -0.655 . . . . 0.0 113.647 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -131.31 121.1 24.13 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.693 0.283 . . . . 0.0 110.804 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.433 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.6 t -138.33 112.26 8.59 Favored Pre-proline 0 CA--C 1.54 0.594 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.819 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -82.25 -161.66 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.365 2.044 . . . . 0.0 112.758 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.35 -31.21 7.28 Favored Glycine 0 C--N 1.34 0.787 0 O-C-N 123.341 0.4 . . . . 0.0 113.041 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.34 2.76 Favored Glycine 0 C--N 1.338 0.688 0 C-N-CA 121.54 -0.362 . . . . 0.0 112.741 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.39 -172.52 2.97 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.609 0.363 . . . . 0.0 110.743 -179.994 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.0 m -97.06 157.73 15.77 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.727 0.298 . . . . 0.0 111.737 -178.556 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 49.0 t -129.59 126.0 37.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.991 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.7 t -90.44 144.46 25.78 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.497 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -55.58 -20.75 14.43 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -76.6 -6.16 50.81 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 123.139 0.274 . . . . 0.0 111.525 179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.93 48.12 2.53 Favored Glycine 0 C--N 1.342 0.874 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.581 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 84.9 m-85 -136.09 161.49 35.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.697 0.284 . . . . 0.0 111.691 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -131.31 145.03 51.69 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.679 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.61 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.81 157.7 19.2 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.664 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 41.2 p -107.98 149.04 28.87 Favored 'General case' 0 C--O 1.235 0.332 0 O-C-N 123.612 0.242 . . . . 0.0 111.165 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.99 -179.86 31.39 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-O 119.361 -0.688 . . . . 0.0 112.834 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.99 63.01 7.58 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 122.976 2.451 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.34 -46.39 0.42 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.242 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.434 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.5 m-85 -114.06 -2.35 13.51 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.079 178.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.5 m -93.64 -42.41 9.2 Favored 'General case' 0 C--N 1.343 0.32 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.557 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -137.84 -149.81 5.59 Favored Glycine 0 C--N 1.341 0.824 0 O-C-N 123.423 0.452 . . . . 0.0 112.527 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.433 -1.204 . . . . 0.0 112.527 179.984 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.275 0 CA-C-O 120.456 0.169 . . . . 0.0 111.109 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.2 65.91 0.15 Allowed Glycine 0 C--N 1.337 0.626 0 O-C-N 123.656 0.598 . . . . 0.0 112.48 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -119.73 139.45 52.25 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 122.323 0.249 . . . . 0.0 110.873 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.415 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 8.8 t -109.95 141.64 42.42 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.637 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -104.32 95.23 3.65 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 54.62 26.23 7.19 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.999 0.919 . . . . 0.0 112.777 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.735 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 89.02 46.54 4.44 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.028 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -132.76 116.19 16.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.923 0.392 . . . . 0.0 111.218 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -141.65 156.88 66.15 Favored Pre-proline 0 CA--C 1.539 0.535 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.398 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.84 -159.0 0.04 OUTLIER 'Trans proline' 0 C--N 1.375 1.934 0 C-N-CA 122.472 2.115 . . . . 0.0 113.189 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.92 35.28 4.97 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 123.266 0.354 . . . . 0.0 112.977 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -122.92 -45.77 0.29 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 121.587 -0.34 . . . . 0.0 112.578 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.53 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 1.0 OUTLIER -113.51 -176.59 2.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.452 0.301 . . . . 0.0 110.995 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -124.08 156.03 37.31 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.584 0.23 . . . . 0.0 111.432 -178.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.735 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 52.7 t -117.04 133.36 56.1 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.127 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.503 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 40.0 p -96.69 145.39 25.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.446 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.61 -18.78 8.41 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -76.45 -7.04 54.25 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.674 0.273 . . . . 0.0 111.409 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.01 47.42 2.65 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.606 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.503 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 87.4 m-85 -136.93 155.74 49.36 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -137.52 130.06 29.77 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.598 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.53 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -164.82 173.11 40.69 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.529 0.518 . . . . 0.0 112.974 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.3 m -112.63 152.06 29.39 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 122.368 0.267 . . . . 0.0 111.257 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.09 177.68 26.54 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.895 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -79.31 64.61 8.86 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.943 2.428 . . . . 0.0 112.379 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.25 -47.89 0.35 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.135 -0.939 . . . . 0.0 109.947 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.13 -8.14 18.62 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.94 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.5 m -98.64 -42.96 7.02 Favored 'General case' 0 C--N 1.343 0.324 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.436 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.1 121.55 7.27 Favored Glycine 0 C--N 1.34 0.804 0 O-C-N 123.465 0.478 . . . . 0.0 112.569 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.09 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.598 179.994 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.51 0.195 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.26 73.64 0.22 Allowed Glycine 0 C--N 1.336 0.567 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.537 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -128.86 148.37 50.89 Favored 'General case' 0 C--O 1.236 0.343 0 O-C-N 123.66 0.271 . . . . 0.0 110.937 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 96.4 m -91.97 149.56 21.47 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.314 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.407 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.2 t -115.82 106.52 20.59 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.917 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.407 HH11 ' CG1' ' A' ' 5' ' ' VAL . 7.8 mpt_? 55.46 27.52 10.31 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.972 0.909 . . . . 0.0 112.668 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.1 20.38 36.26 Favored Glycine 0 C--N 1.339 0.728 0 CA-C-N 115.903 -0.589 . . . . 0.0 113.457 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.89 121.09 21.23 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.651 0.262 . . . . 0.0 110.743 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.529 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 40.6 t -136.44 116.67 11.05 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.825 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -80.92 -161.57 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.335 2.024 . . . . 0.0 112.859 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.85 -30.71 7.64 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.435 0.459 . . . . 0.0 113.068 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.31 42.29 3.25 Favored Glycine 0 C--N 1.338 0.687 0 C-N-CA 121.545 -0.36 . . . . 0.0 112.66 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.584 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -133.87 -170.31 2.48 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 122.582 0.353 . . . . 0.0 110.784 -179.974 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -97.04 158.17 15.56 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 120.728 0.299 . . . . 0.0 111.735 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 t -125.8 125.97 43.78 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.6 t -88.55 143.15 27.14 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.425 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -54.78 -20.99 9.71 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -77.29 -5.91 51.22 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.355 0.262 . . . . 0.0 111.4 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.04 48.08 2.73 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.587 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -137.34 163.6 30.61 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.426 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 17.9 m -123.79 149.76 45.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.533 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.584 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 178.55 157.13 18.57 Favored Glycine 0 C--N 1.342 0.866 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.837 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.6 m -109.74 135.08 51.23 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 122.356 0.262 . . . . 0.0 111.128 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.8 -177.73 24.6 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.422 -0.654 . . . . 0.0 112.915 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -79.14 64.69 8.86 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.115 2.543 . . . . 0.0 112.493 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -48.49 0.47 Allowed 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.12 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -110.65 -5.26 15.07 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.999 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.51 -42.09 7.87 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.397 -179.664 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.19 131.69 10.66 Favored Glycine 0 C--N 1.34 0.771 0 O-C-N 123.383 0.427 . . . . 0.0 112.467 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.38 -1.234 . . . . 0.0 112.476 179.957 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 120.473 0.178 . . . . 0.0 111.043 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.75 85.15 0.05 OUTLIER Glycine 0 C--N 1.336 0.558 0 CA-C-N 115.867 -0.606 . . . . 0.0 112.502 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -128.84 150.98 50.1 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.631 0.253 . . . . 0.0 110.993 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 78.9 m -89.26 148.99 23.28 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.324 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -114.92 112.03 38.31 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.968 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 56.33 26.53 10.71 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.964 0.906 . . . . 0.0 112.696 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.69 16.42 56.64 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 115.827 -0.624 . . . . 0.0 113.56 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -132.54 124.63 28.84 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.618 0.247 . . . . 0.0 110.746 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.537 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.4 t -134.67 116.43 12.71 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.796 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -80.72 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.709 0 C-N-CA 122.342 2.028 . . . . 0.0 112.859 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.08 -30.51 8.0 Favored Glycine 0 C--N 1.342 0.87 0 O-C-N 123.392 0.433 . . . . 0.0 113.043 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.71 42.7 3.06 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.542 -0.361 . . . . 0.0 112.607 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.38 -171.58 2.8 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.62 0.368 . . . . 0.0 110.796 -179.94 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.3 m -95.84 156.88 16.15 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.745 0.307 . . . . 0.0 111.754 -178.403 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 41.6 t -128.22 125.21 38.51 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.847 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 66.5 m -88.04 144.13 26.69 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.601 179.126 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -54.78 -20.86 9.43 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -77.46 -6.68 54.37 Favored 'General case' 0 CA--C 1.54 0.582 0 O-C-N 123.106 0.254 . . . . 0.0 111.13 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.06 48.53 2.42 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.573 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.431 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 21.4 m-85 -136.45 159.92 40.32 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.44 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 13.6 m -122.32 149.89 43.13 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.557 179.688 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.59 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 176.86 154.5 11.99 Favored Glycine 0 C--N 1.341 0.836 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.746 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -111.76 145.15 39.86 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 123.665 0.273 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.96 -178.0 30.54 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-O 119.412 -0.66 . . . . 0.0 112.78 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.91 62.91 7.48 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 123.034 2.489 . . . . 0.0 112.467 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.27 -45.93 0.42 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.178 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.42 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.0 m-85 -116.82 -1.76 11.97 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.174 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m -93.98 -42.71 8.9 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.519 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.19 -131.9 1.27 Allowed Glycine 0 C--N 1.34 0.783 0 O-C-N 123.428 0.455 . . . . 0.0 112.481 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.337 -1.257 . . . . 0.0 112.627 179.961 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.344 0 CA-C-O 120.441 0.162 . . . . 0.0 111.053 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 105.02 -56.71 0.53 Allowed Glycine 0 C--N 1.337 0.592 0 O-C-N 123.707 0.629 . . . . 0.0 112.438 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -129.44 150.63 50.71 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 122.333 0.253 . . . . 0.0 111.156 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.567 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 99.5 m -93.17 149.55 21.14 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.236 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.9 108.01 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 56.06 27.27 11.13 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 123.952 0.901 . . . . 0.0 112.658 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.65 16.66 48.09 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.626 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -132.88 124.83 28.64 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.716 0.258 . . . . 0.0 110.796 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.567 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 41.2 t -133.92 119.26 14.65 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.989 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -80.42 -161.63 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 122.405 2.07 . . . . 0.0 112.782 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.42 -30.61 7.56 Favored Glycine 0 C--N 1.342 0.878 0 CA-C-N 116.397 -0.365 . . . . 0.0 113.033 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.67 42.77 2.83 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 121.614 -0.327 . . . . 0.0 112.739 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.569 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.84 -168.25 2.13 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.502 0.321 . . . . 0.0 110.804 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 70.2 m -100.9 160.2 14.57 Favored 'General case' 0 C--N 1.343 0.308 0 CA-C-O 120.673 0.273 . . . . 0.0 111.651 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.7 t -128.5 128.76 44.97 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.881 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.5 p -90.84 146.36 24.0 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.761 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -53.58 -20.16 4.75 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -178.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.78 -5.44 48.22 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 122.381 0.273 . . . . 0.0 111.272 179.132 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.35 45.57 4.33 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-N 115.758 -0.655 . . . . 0.0 112.175 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -134.46 161.37 35.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.646 0.26 . . . . 0.0 111.699 -179.087 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.2 m -116.84 152.6 34.11 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.569 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 175.16 160.38 22.95 Favored Glycine 0 C--N 1.343 0.936 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.759 -179.771 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -115.58 143.4 45.39 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.605 0.238 . . . . 0.0 111.005 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.1 -178.8 32.14 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.888 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.07 64.55 8.85 Favored 'Trans proline' 0 C--N 1.37 1.675 0 C-N-CA 123.052 2.501 . . . . 0.0 112.412 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -47.23 0.46 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.114 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 -5.31 12.68 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.016 178.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -98.73 -42.27 7.3 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.461 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -149.38 -95.49 0.14 Allowed Glycine 0 C--N 1.34 0.805 0 O-C-N 123.381 0.425 . . . . 0.0 112.576 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.444 -1.198 . . . . 0.0 112.534 -179.996 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.334 0 CA-C-O 120.503 0.192 . . . . 0.0 111.017 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 154.9 86.68 0.06 OUTLIER Glycine 0 C--N 1.337 0.616 0 CA-C-N 115.857 -0.61 . . . . 0.0 112.487 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -131.81 151.56 51.59 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 123.679 0.282 . . . . 0.0 110.786 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 73.7 m -95.1 118.18 31.46 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.042 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 8.4 t -129.69 84.59 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.472 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 55.12 29.18 12.08 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.847 0.859 . . . . 0.0 112.428 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.73 -38.95 0.05 OUTLIER Glycine 0 C--N 1.34 0.756 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.984 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 61.47 162.5 0.07 Allowed 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 124.037 0.935 . . . . 0.0 112.67 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.533 ' SG ' HD11 ' A' ' 13' ' ' LEU . 77.2 m -87.0 151.87 52.53 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.352 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.52 -155.59 0.03 OUTLIER 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.838 2.358 . . . . 0.0 113.265 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.8 26.87 6.24 Favored Glycine 0 C--N 1.344 1.016 0 C-N-CA 121.76 -0.257 . . . . 0.0 113.393 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.66 -48.98 1.87 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 121.577 -0.344 . . . . 0.0 112.388 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.533 HD11 ' SG ' ' A' ' 9' ' ' CYS . 0.7 OUTLIER -119.61 -173.4 2.52 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.558 0.343 . . . . 0.0 110.711 179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.9 m -115.1 153.16 31.25 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.344 -179.259 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -122.33 131.7 54.03 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.05 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.9 m -92.56 143.0 26.78 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.497 179.397 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -57.6 -18.04 17.63 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -78.13 -7.17 56.68 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.33 0.252 . . . . 0.0 111.077 179.246 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 97.64 48.29 1.99 Allowed Glycine 0 C--N 1.341 0.855 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.67 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -138.03 160.47 39.26 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.737 0.303 . . . . 0.0 111.78 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 0.1 OUTLIER -134.65 144.18 47.7 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.96 179.721 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.447 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . -179.32 161.63 27.84 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.982 -0.554 . . . . 0.0 112.538 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.7 t -109.61 148.53 31.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 120.602 0.239 . . . . 0.0 111.141 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.39 179.19 26.04 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-O 119.328 -0.707 . . . . 0.0 112.882 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -77.91 63.45 8.13 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 123.024 2.483 . . . . 0.0 112.412 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.48 -47.83 0.43 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.21 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.447 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 97.1 m-85 -107.67 -3.35 19.29 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.03 178.768 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.7 m -93.91 -42.45 9.07 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.574 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.69 -56.42 0.52 Allowed Glycine 0 C--N 1.34 0.754 0 O-C-N 123.423 0.452 . . . . 0.0 112.521 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.418 -1.212 . . . . 0.0 112.548 179.996 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.303 0 CA-C-O 120.502 0.192 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.53 86.08 1.89 Allowed Glycine 0 C--N 1.338 0.653 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.578 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -128.67 145.71 51.08 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 123.609 0.241 . . . . 0.0 110.844 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.496 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.5 m -93.58 149.17 21.45 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.285 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.445 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.1 t -119.84 105.58 17.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.747 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ARG . . . . . 0.445 HH11 ' CG1' ' A' ' 5' ' ' VAL . 8.3 mpt_? 55.99 27.18 10.84 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.848 0.859 . . . . 0.0 112.603 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.93 26.67 18.68 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.435 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -136.11 117.68 14.88 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-O 120.682 0.277 . . . . 0.0 110.803 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.496 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.1 t -138.98 114.57 8.49 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.719 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -81.35 -161.87 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.36 2.04 . . . . 0.0 112.844 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.57 -30.85 7.34 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.447 0.467 . . . . 0.0 113.013 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.47 43.44 3.43 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 121.697 -0.287 . . . . 0.0 112.707 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.587 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.41 -171.31 2.67 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 122.473 0.309 . . . . 0.0 110.807 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.9 m -93.82 155.07 17.4 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -125.84 125.2 42.48 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.712 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 75.6 m -90.9 143.57 26.59 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.735 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.83 -21.15 10.38 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -76.25 -6.81 53.09 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.381 0.273 . . . . 0.0 111.371 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.67 47.89 2.63 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.501 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -138.05 164.15 29.82 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.455 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 20.0 m -126.93 151.57 48.3 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.634 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.587 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.11 158.6 20.71 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.843 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.9 m -112.91 144.03 43.17 Favored 'General case' 0 C--O 1.235 0.318 0 O-C-N 123.659 0.27 . . . . 0.0 110.969 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.21 -177.56 31.23 Favored Glycine 0 CA--C 1.529 0.925 0 CA-C-O 119.393 -0.671 . . . . 0.0 112.776 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.76 62.99 7.39 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.996 2.464 . . . . 0.0 112.524 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.48 -46.36 0.46 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.25 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -116.72 -1.54 12.07 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.12 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 83.0 m -93.73 -42.75 8.98 Favored 'General case' 0 C--N 1.344 0.344 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.528 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.98 118.01 4.12 Favored Glycine 0 C--N 1.341 0.831 0 O-C-N 123.43 0.456 . . . . 0.0 112.513 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.333 -1.259 . . . . 0.0 112.584 179.927 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.343 0 CA-C-O 120.481 0.181 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.92 64.29 0.41 Allowed Glycine 0 C--N 1.336 0.568 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.498 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -128.33 151.23 49.57 Favored 'General case' 0 N--CA 1.466 0.366 0 O-C-N 123.618 0.246 . . . . 0.0 110.928 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.456 ' SG ' ' SG ' ' A' ' 9' ' ' CYS . 66.0 m -96.34 137.11 35.9 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.298 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.7 t -101.16 95.11 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.341 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 59.63 24.12 12.93 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 123.745 0.818 . . . . 0.0 112.234 -179.366 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.87 52.75 3.04 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.015 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 -135.59 121.75 20.22 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 120.814 0.34 . . . . 0.0 111.507 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.543 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 26.0 m -143.71 152.39 55.91 Favored Pre-proline 0 N--CA 1.469 0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.491 179.389 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -69.5 -159.39 0.05 OUTLIER 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 122.591 2.194 . . . . 0.0 113.075 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.59 37.46 3.8 Favored Glycine 0 C--N 1.341 0.829 0 O-C-N 123.324 0.39 . . . . 0.0 112.894 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.67 -40.57 0.52 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 121.548 -0.358 . . . . 0.0 112.68 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 22' ' ' GLY . 1.5 pt? -123.96 178.39 5.31 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 122.4 0.28 . . . . 0.0 110.884 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 68.9 m -110.57 157.96 19.08 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.678 -0.237 . . . . 0.0 111.569 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.543 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 49.9 t -120.84 129.25 53.46 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.231 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.415 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 38.5 p -94.61 144.56 25.5 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.435 179.226 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -56.0 -17.75 7.59 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -76.4 -7.36 54.87 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.701 0.286 . . . . 0.0 111.282 179.132 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 46.84 2.76 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.629 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.415 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 95.0 m-85 -139.57 156.88 46.62 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.504 0.192 . . . . 0.0 111.489 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.7 OUTLIER -137.81 133.73 34.35 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.55 179.395 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.495 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -164.88 166.97 38.39 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.667 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.2 t -105.94 148.32 27.79 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.664 0.268 . . . . 0.0 111.063 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.22 177.81 25.3 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.405 -0.664 . . . . 0.0 112.807 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -79.57 64.51 8.86 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.948 2.432 . . . . 0.0 112.468 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.61 -48.77 0.39 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.053 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -103.66 -5.63 22.41 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.021 178.654 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 86.0 m -95.16 -41.2 9.21 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.491 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.2 -61.12 0.82 Allowed Glycine 0 C--N 1.341 0.828 0 CA-C-N 116.215 -0.448 . . . . 0.0 112.506 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.367 -1.24 . . . . 0.0 112.613 179.978 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.327 0 CA-C-O 120.543 0.211 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 108.18 -54.8 0.54 Allowed Glycine 0 C--N 1.338 0.641 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.589 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -124.6 149.89 46.57 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 122.307 0.243 . . . . 0.0 110.931 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 93.0 m -91.52 150.26 21.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.276 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -121.95 112.53 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.922 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 77.1 mtp180 57.62 25.84 12.16 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.859 0.863 . . . . 0.0 112.626 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.55 18.49 54.85 Favored Glycine 0 C--N 1.338 0.662 0 CA-C-N 115.779 -0.646 . . . . 0.0 113.531 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -133.02 124.39 27.59 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.634 0.254 . . . . 0.0 110.822 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.2 t -135.55 116.57 11.88 Favored Pre-proline 0 CA--C 1.54 0.571 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.844 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -80.82 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 122.36 2.04 . . . . 0.0 112.859 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.05 -30.69 7.75 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.388 0.43 . . . . 0.0 113.013 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.93 42.27 3.11 Favored Glycine 0 C--N 1.338 0.639 0 C-N-CA 121.617 -0.325 . . . . 0.0 112.685 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.71 -171.24 2.73 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 122.578 0.351 . . . . 0.0 110.729 -179.952 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 99.6 m -96.08 156.76 16.2 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 111.895 0.331 . . . . 0.0 111.895 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -126.69 127.4 45.08 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.8 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.475 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 35.5 p -93.61 143.67 26.09 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.61 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -54.24 -20.43 6.97 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 -178.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -76.08 -6.88 53.17 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.356 0.263 . . . . 0.0 111.321 179.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.79 47.15 3.0 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.558 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.475 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 89.5 m-85 -138.25 161.98 35.49 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.483 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.44 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 15.1 m -123.54 151.68 42.61 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.685 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.59 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 176.31 155.32 12.97 Favored Glycine 0 C--N 1.34 0.804 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.84 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -110.67 145.1 38.56 Favored 'General case' 0 C--O 1.235 0.34 0 O-C-N 123.723 0.308 . . . . 0.0 110.822 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 100.58 -178.71 28.92 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-O 119.368 -0.684 . . . . 0.0 112.809 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -76.83 62.75 7.38 Favored 'Trans proline' 0 C--N 1.371 1.721 0 C-N-CA 122.974 2.449 . . . . 0.0 112.508 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.9 -46.22 0.4 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.135 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.453 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.7 m-85 -114.32 -2.62 13.26 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.158 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.6 m -94.05 -41.98 9.26 Favored 'General case' 0 C--N 1.344 0.332 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.544 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -153.86 96.62 0.16 Allowed Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.293 -0.412 . . . . 0.0 112.51 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 118.394 -1.226 . . . . 0.0 112.484 179.966 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.516 0.198 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.52 70.83 0.93 Allowed Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.583 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -128.17 145.63 50.97 Favored 'General case' 0 N--CA 1.465 0.306 0 O-C-N 123.607 0.239 . . . . 0.0 110.849 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.414 ' SG ' ' SG ' ' A' ' 9' ' ' CYS . 58.2 m -98.64 130.89 45.17 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 123.675 0.61 . . . . 0.0 111.115 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.4 t -101.76 95.26 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 58.24 24.69 11.75 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.815 0.846 . . . . 0.0 112.322 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 87.41 47.44 4.62 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-N 115.662 -0.699 . . . . 0.0 112.965 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.72 119.0 18.76 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 120.86 0.362 . . . . 0.0 111.28 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 54.8 m -141.25 151.78 62.53 Favored Pre-proline 0 CA--C 1.536 0.437 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.626 179.536 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.36 -159.23 0.06 OUTLIER 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.46 2.107 . . . . 0.0 113.007 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.82 37.7 3.68 Favored Glycine 0 C--N 1.34 0.794 0 O-C-N 123.341 0.401 . . . . 0.0 112.864 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.97 -44.14 0.38 Allowed Glycine 0 C--N 1.338 0.647 0 C-N-CA 121.655 -0.307 . . . . 0.0 112.539 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.543 HD12 ' N ' ' A' ' 22' ' ' GLY . 1.3 pt? -118.62 178.84 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 122.478 0.311 . . . . 0.0 110.87 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 69.1 m -109.87 152.43 25.79 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 123.103 0.252 . . . . 0.0 111.43 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.549 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 46.4 t -109.82 128.37 55.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.146 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 57.9 m -95.92 138.7 33.18 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.529 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -54.3 -22.1 11.05 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 -178.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -76.27 -6.81 53.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.418 0.287 . . . . 0.0 111.229 179.158 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.96 44.35 3.61 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.51 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -143.03 123.61 14.04 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.629 0.252 . . . . 0.0 111.373 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -106.05 140.41 39.08 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.66 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.543 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -170.83 167.9 41.04 Favored Glycine 0 C--N 1.338 0.691 0 O-C-N 123.603 0.565 . . . . 0.0 112.668 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 p -105.37 150.75 24.95 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.604 0.24 . . . . 0.0 111.369 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.77 176.35 26.96 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.276 -0.735 . . . . 0.0 112.876 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -78.53 63.79 8.5 Favored 'Trans proline' 0 C--N 1.371 1.754 0 C-N-CA 122.945 2.43 . . . . 0.0 112.375 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.4 -48.27 0.44 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.158 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -105.62 -3.7 21.97 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.026 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.2 m -94.96 -43.71 8.04 Favored 'General case' 0 C--N 1.343 0.298 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.499 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.67 -88.01 0.5 Allowed Glycine 0 C--N 1.341 0.821 0 O-C-N 123.449 0.468 . . . . 0.0 112.486 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.121 0 CA-C-O 118.343 -1.254 . . . . 0.0 112.667 179.999 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.539 0.209 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 161.55 77.53 0.03 OUTLIER Glycine 0 C--N 1.337 0.627 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.44 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -129.25 142.46 50.84 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 122.349 0.26 . . . . 0.0 110.845 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.539 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 97.5 m -92.02 150.12 21.16 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.339 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -123.46 110.62 26.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.785 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 57.46 25.76 11.79 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 123.88 0.872 . . . . 0.0 112.68 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.07 21.76 37.83 Favored Glycine 0 C--N 1.339 0.732 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.524 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -134.79 123.55 23.75 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 120.654 0.264 . . . . 0.0 110.787 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.539 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 48.2 t -136.82 116.96 10.77 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.815 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -80.77 -161.84 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.69 0 C-N-CA 122.37 2.047 . . . . 0.0 112.877 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.99 -30.39 7.62 Favored Glycine 0 C--N 1.341 0.815 0 O-C-N 123.344 0.403 . . . . 0.0 113.057 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.43 42.74 3.36 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.582 -0.342 . . . . 0.0 112.675 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.583 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.86 -170.26 2.47 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 122.532 0.333 . . . . 0.0 110.796 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.9 m -95.42 154.55 17.15 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.766 0.317 . . . . 0.0 111.725 -178.399 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.8 t -123.89 128.95 50.21 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.792 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.468 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 46.9 p -96.78 141.65 29.74 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.46 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -54.94 -19.32 6.45 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -178.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -76.33 -7.25 54.56 Favored 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.141 0.275 . . . . 0.0 111.239 179.116 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.58 46.64 2.92 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.607 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.468 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 93.3 m-85 -139.6 164.25 30.4 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.435 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 19.8 m -126.4 152.64 46.07 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.752 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.583 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 179.51 153.41 11.77 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.641 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 53.1 m -103.62 137.51 41.57 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.271 0.228 . . . . 0.0 111.324 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.59 179.95 22.14 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.36 -0.689 . . . . 0.0 112.953 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -80.13 65.94 8.85 Favored 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 123.101 2.534 . . . . 0.0 112.378 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.06 -49.34 0.42 Allowed 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.124 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.561 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 94.1 m-85 -101.11 -5.88 25.08 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.087 178.628 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.6 -42.54 8.36 Favored 'General case' 0 C--N 1.343 0.305 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.484 -179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.37 -56.38 0.46 Allowed Glycine 0 C--N 1.34 0.799 0 O-C-N 123.445 0.466 . . . . 0.0 112.498 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.357 -1.246 . . . . 0.0 112.504 179.998 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.301 0 CA-C-O 120.52 0.2 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.12 -53.72 0.01 OUTLIER Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.55 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -104.45 152.05 22.8 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 122.369 0.268 . . . . 0.0 110.937 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.52 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 72.4 m -90.38 148.89 22.53 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.239 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -117.68 112.1 37.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.889 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 57.04 25.87 11.27 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 123.912 0.885 . . . . 0.0 112.688 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.98 20.39 46.74 Favored Glycine 0 C--N 1.339 0.705 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.478 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -133.91 123.68 25.1 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.594 0.235 . . . . 0.0 110.813 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.52 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 38.7 t -136.38 116.43 11.05 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.7 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -80.73 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.369 1.634 0 C-N-CA 122.348 2.032 . . . . 0.0 112.883 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.04 -30.65 7.8 Favored Glycine 0 C--N 1.34 0.798 0 O-C-N 123.377 0.423 . . . . 0.0 113.038 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.51 42.97 3.04 Favored Glycine 0 C--N 1.339 0.695 0 C-N-CA 121.588 -0.339 . . . . 0.0 112.588 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.605 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.38 -171.68 2.82 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 122.649 0.38 . . . . 0.0 110.778 -179.86 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 74.9 m -97.03 158.36 15.46 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.685 0.279 . . . . 0.0 111.744 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 43.0 t -128.6 127.2 41.79 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.089 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -89.22 144.85 25.8 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.394 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -53.94 -22.36 10.03 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -178.753 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -76.2 -5.72 48.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.622 0.248 . . . . 0.0 111.511 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.57 48.48 2.75 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.631 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.434 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.1 m-85 -136.23 160.96 37.1 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -179.503 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.441 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 15.4 m -121.9 151.15 41.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.776 179.729 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.605 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 175.98 150.09 7.87 Favored Glycine 0 C--N 1.341 0.857 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.658 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.5 t -108.85 145.53 35.14 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.628 0.251 . . . . 0.0 110.804 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.71 -177.49 29.33 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.369 -0.684 . . . . 0.0 112.77 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.16 62.76 7.6 Favored 'Trans proline' 0 C--N 1.37 1.707 0 C-N-CA 122.962 2.441 . . . . 0.0 112.596 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.54 -45.81 0.37 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.083 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.577 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.0 m-85 -114.7 -3.43 12.85 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.12 178.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.0 m -94.7 -44.48 7.78 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.568 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -154.37 124.46 1.55 Allowed Glycine 0 C--N 1.341 0.846 0 O-C-N 123.469 0.481 . . . . 0.0 112.403 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.416 -1.214 . . . . 0.0 112.581 179.993 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.478 0.18 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 151.22 -59.19 0.42 Allowed Glycine 0 C--N 1.337 0.607 0 CA-C-N 115.872 -0.603 . . . . 0.0 112.514 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -129.26 143.06 50.71 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 123.649 0.264 . . . . 0.0 110.901 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 62.3 m -98.68 136.42 38.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -116.41 114.6 46.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.284 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 54.97 26.25 7.76 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.953 0.901 . . . . 0.0 112.957 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.64 27.49 29.41 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.974 -0.557 . . . . 0.0 113.515 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -129.59 113.96 15.47 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 120.89 0.376 . . . . 0.0 110.694 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 46.7 t -146.96 115.36 4.35 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.768 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -81.04 -162.86 0.2 Allowed 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.373 2.049 . . . . 0.0 112.626 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.84 -30.17 6.82 Favored Glycine 0 C--N 1.34 0.795 0 O-C-N 123.38 0.425 . . . . 0.0 112.975 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.2 46.1 2.67 Favored Glycine 0 C--N 1.339 0.717 0 C-N-CA 121.674 -0.298 . . . . 0.0 112.873 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.621 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -134.19 -172.43 3.0 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 122.486 0.315 . . . . 0.0 110.81 179.951 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -104.86 170.18 8.02 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -178.085 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.3 m -122.08 130.53 53.34 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.613 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 t -91.46 142.51 27.59 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.312 178.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -55.1 -20.97 11.19 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -77.65 -5.31 49.94 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.384 0.274 . . . . 0.0 111.461 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.07 46.64 3.04 Favored Glycine 0 C--N 1.343 0.924 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.462 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -136.92 169.62 17.46 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.6 0.238 . . . . 0.0 111.602 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.07 141.54 51.75 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.621 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.621 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -179.54 150.84 9.6 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 123.514 0.509 . . . . 0.0 112.361 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -100.94 143.38 31.16 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.618 0.246 . . . . 0.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.38 -179.66 32.14 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 119.376 -0.68 . . . . 0.0 112.943 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -79.97 65.41 8.89 Favored 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 123.007 2.471 . . . . 0.0 112.425 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.19 -49.54 0.42 Allowed 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.986 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.466 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 86.1 m-85 -106.52 -6.51 18.05 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.015 178.475 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.44 -42.58 4.53 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.355 -179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.39 142.57 15.92 Favored Glycine 0 C--N 1.34 0.794 0 O-C-N 123.501 0.501 . . . . 0.0 112.535 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.108 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.46 -179.938 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.249 0 CA-C-O 120.538 0.208 . . . . 0.0 111.04 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 155.58 -67.84 0.3 Allowed Glycine 0 C--N 1.337 0.627 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.455 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -110.33 149.13 30.64 Favored 'General case' 0 C--O 1.235 0.325 0 O-C-N 123.631 0.254 . . . . 0.0 110.962 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.559 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 86.2 m -91.46 150.47 21.22 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.394 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -118.46 112.66 39.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.871 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 56.86 26.03 11.13 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.891 0.876 . . . . 0.0 112.782 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.82 17.13 57.1 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.817 -0.628 . . . . 0.0 113.581 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -133.09 125.7 30.17 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.748 0.274 . . . . 0.0 110.824 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.559 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.7 t -134.94 117.92 12.97 Favored Pre-proline 0 CA--C 1.539 0.555 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.824 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -80.27 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.72 0 C-N-CA 122.43 2.087 . . . . 0.0 112.92 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.75 -30.37 8.01 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.437 0.46 . . . . 0.0 113.015 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.61 41.8 3.07 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 121.559 -0.353 . . . . 0.0 112.637 -179.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.593 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.86 -170.96 2.61 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 122.644 0.377 . . . . 0.0 110.788 -179.938 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -98.36 160.03 14.56 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.648 0.261 . . . . 0.0 111.656 -178.515 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -127.73 128.6 45.67 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.058 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.9 t -90.26 143.66 26.56 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.3 179.151 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.46 -21.55 10.24 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -178.67 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -76.99 -5.72 49.76 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 123.152 0.282 . . . . 0.0 111.47 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.78 48.72 2.65 Favored Glycine 0 C--N 1.341 0.839 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.622 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -136.78 160.99 37.2 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.718 0.294 . . . . 0.0 111.752 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 16.2 m -120.85 148.95 43.33 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.627 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.593 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 179.51 149.51 8.45 Favored Glycine 0 C--N 1.341 0.849 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.55 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.3 p -103.83 134.13 47.65 Favored 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.635 0.256 . . . . 0.0 111.225 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.55 -178.89 21.9 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.908 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -80.03 65.2 8.91 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 123.101 2.534 . . . . 0.0 112.417 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.75 -48.83 0.43 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.129 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.512 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.6 m-85 -105.74 -5.5 19.87 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.029 178.684 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.9 -42.07 8.49 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.422 -179.743 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.98 129.79 6.78 Favored Glycine 0 C--N 1.34 0.783 0 O-C-N 123.351 0.407 . . . . 0.0 112.556 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.501 -1.166 . . . . 0.0 112.52 179.98 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.288 0 CA-C-O 120.482 0.182 . . . . 0.0 111.06 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.23 -110.64 0.62 Allowed Glycine 0 C--N 1.338 0.661 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.482 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -130.86 152.93 49.65 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 123.654 0.267 . . . . 0.0 110.991 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.543 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 85.4 m -88.35 148.79 24.09 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.319 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.1 t -113.21 107.2 22.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 56.12 26.71 10.5 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.932 0.893 . . . . 0.0 112.647 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.4 20.89 33.71 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.465 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.1 mtp180 -134.2 121.86 21.98 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 116.72 0.26 . . . . 0.0 110.771 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.543 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.2 t -137.06 115.72 10.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.824 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.93 -161.46 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 122.393 2.062 . . . . 0.0 112.912 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.69 -31.18 7.44 Favored Glycine 0 C--N 1.34 0.771 0 O-C-N 123.317 0.386 . . . . 0.0 113.016 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.15 42.56 2.99 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.544 -179.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.582 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.59 -169.45 2.29 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.588 0.355 . . . . 0.0 110.695 -179.883 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -98.0 155.61 17.02 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.715 0.293 . . . . 0.0 111.58 -178.568 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 40.4 t -126.38 127.98 46.33 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.934 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.7 m -92.07 141.82 28.19 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.419 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -55.22 -19.78 9.0 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -77.07 -6.16 51.7 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.458 0.303 . . . . 0.0 111.361 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.49 48.28 2.59 Favored Glycine 0 C--N 1.343 0.936 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.702 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -138.83 161.14 38.0 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.435 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 14.5 m -123.96 151.15 43.96 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.65 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.582 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.47 153.46 11.04 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.694 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 42.0 p -106.36 140.78 38.74 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 122.325 0.25 . . . . 0.0 111.253 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.53 -178.98 24.41 Favored Glycine 0 CA--C 1.529 0.923 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.867 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.46 65.86 8.87 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.086 2.524 . . . . 0.0 112.409 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.97 -49.45 0.43 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.996 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.521 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.4 m-85 -103.57 -7.24 20.95 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.958 178.648 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.92 -43.72 7.34 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 118.84 117.56 2.72 Favored Glycine 0 C--N 1.341 0.822 0 O-C-N 123.447 0.467 . . . . 0.0 112.536 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.528 -1.151 . . . . 0.0 112.551 -179.989 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.235 0.323 0 CA-C-O 120.536 0.208 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 83.3 m -91.84 146.28 23.88 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.234 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -114.11 110.6 32.71 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.958 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 56.02 27.15 10.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 123.975 0.91 . . . . 0.0 112.382 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.3 21.49 38.0 Favored Glycine 0 C--N 1.338 0.689 0 CA-C-N 115.818 -0.628 . . . . 0.0 113.42 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 76.8 mtp180 -134.3 122.7 23.04 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-O 120.645 0.26 . . . . 0.0 110.796 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.5 t -136.58 115.92 10.72 Favored Pre-proline 0 CA--C 1.54 0.565 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.787 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -80.95 -161.93 0.17 Allowed 'Trans proline' 0 C--N 1.37 1.689 0 C-N-CA 122.362 2.041 . . . . 0.0 112.845 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.22 -30.6 7.48 Favored Glycine 0 C--N 1.34 0.78 0 O-C-N 123.421 0.451 . . . . 0.0 113.04 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.61 43.33 3.42 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 121.599 -0.334 . . . . 0.0 112.728 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.57 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -132.93 -170.33 2.43 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.487 0.315 . . . . 0.0 110.843 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 72.5 m -95.0 154.45 17.16 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 120.759 0.314 . . . . 0.0 111.844 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 42.5 t -129.02 126.56 39.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.837 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.487 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 36.8 p -92.24 144.88 24.96 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.603 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.18 -20.82 7.46 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -76.03 -6.66 52.07 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.337 0.255 . . . . 0.0 111.379 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.77 48.12 2.79 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.609 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.487 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 88.3 m-85 -137.86 160.47 39.2 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -179.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 13.2 m -123.34 152.2 41.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.616 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.57 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.16 159.24 22.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.951 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.8 m -116.39 143.74 45.17 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 122.405 0.282 . . . . 0.0 110.925 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.18 -175.39 29.56 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.414 -0.659 . . . . 0.0 112.876 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -77.43 63.01 7.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 123.092 2.528 . . . . 0.0 112.49 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.11 -46.05 0.43 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.107 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -118.45 -2.68 11.02 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.121 178.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.7 m . . . . . 0 C--N 1.344 0.341 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.521 -179.777 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 . . . . . 0 N--CA 1.465 0.314 0 CA-C-O 120.526 0.203 . . . . 0.0 110.981 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.3 m -94.31 151.81 19.14 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.263 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -125.66 113.35 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 36.5 ttt180 55.95 26.23 9.63 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.998 0.919 . . . . 0.0 112.594 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.57 26.28 39.49 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.89 -0.595 . . . . 0.0 113.66 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -131.82 116.14 16.85 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 110.753 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.8 t -142.54 107.92 5.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.851 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.42 -160.61 0.12 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.462 2.108 . . . . 0.0 112.846 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.26 -32.12 7.28 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.285 0.365 . . . . 0.0 113.038 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.02 42.11 2.49 Favored Glycine 0 C--N 1.338 0.662 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.641 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.577 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -131.77 -169.52 2.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 122.683 0.393 . . . . 0.0 110.599 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 26.2 p -108.5 156.03 19.95 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.55 0.214 . . . . 0.0 111.296 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.6 t -126.21 131.7 51.92 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.642 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.4 t -89.58 144.88 25.66 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.253 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -56.04 -19.38 12.57 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -178.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -77.66 -5.6 50.98 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 123.095 0.247 . . . . 0.0 111.497 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 48.36 2.45 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.615 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -135.93 161.3 36.01 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.593 0.235 . . . . 0.0 111.571 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.11 145.93 49.79 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.574 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.577 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -175.75 -179.55 46.32 Favored Glycine 0 C--N 1.341 0.838 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.056 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 35.2 p -129.62 136.93 50.36 Favored 'General case' 0 C--O 1.236 0.372 0 O-C-N 123.723 0.307 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.63 -176.71 28.91 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 119.433 -0.649 . . . . 0.0 112.68 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -77.51 64.54 8.04 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 123.006 2.471 . . . . 0.0 112.364 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -137.49 -46.49 0.55 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.098 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -120.41 -6.22 9.81 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.059 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 38.1 m . . . . . 0 C--N 1.345 0.386 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.62 -179.385 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 . . . . . 0 N--CA 1.466 0.33 0 CA-C-O 120.58 0.229 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.437 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.8 m -94.88 137.51 33.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.163 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 14.6 p -105.28 109.95 29.41 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.724 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 68.4 mtp180 55.1 26.14 7.89 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 123.984 0.914 . . . . 0.0 112.732 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.64 26.56 24.66 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.871 -0.604 . . . . 0.0 113.408 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -134.89 117.4 15.82 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.668 0.27 . . . . 0.0 110.742 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.437 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 42.7 t -140.51 110.38 6.85 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.928 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.93 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.372 2.048 . . . . 0.0 112.723 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.93 -31.87 6.89 Favored Glycine 0 C--N 1.34 0.784 0 O-C-N 123.384 0.428 . . . . 0.0 112.995 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.75 2.68 Favored Glycine 0 C--N 1.338 0.675 0 C-N-CA 121.608 -0.33 . . . . 0.0 112.784 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.579 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -132.0 -171.48 2.64 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 122.578 0.351 . . . . 0.0 110.786 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.412 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 92.7 m -96.46 154.51 17.23 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.747 0.308 . . . . 0.0 111.689 -178.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 51.8 t -130.48 126.08 35.99 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.017 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.7 t -90.29 144.03 26.22 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.469 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.71 -20.11 13.28 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -76.87 -6.09 50.99 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.389 0.275 . . . . 0.0 111.508 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.18 48.19 2.47 Favored Glycine 0 C--N 1.343 0.941 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.644 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.421 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.8 m-85 -136.22 160.55 38.34 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.687 0.28 . . . . 0.0 111.716 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -132.21 147.99 52.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.83 179.927 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.579 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 174.55 163.87 28.51 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.216 -0.516 . . . . 0.0 112.737 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -113.28 149.6 33.65 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.3 -179.35 32.13 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.336 -0.702 . . . . 0.0 112.827 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -77.36 63.12 7.79 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.98 2.454 . . . . 0.0 112.458 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.89 -46.64 0.44 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.198 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -114.82 -2.62 12.9 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.08 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.0 m . . . . . 0 C--N 1.344 0.357 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.508 -179.77 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 N--CA 1.464 0.269 0 CA-C-O 120.589 0.233 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.494 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 82.5 m -94.41 151.81 19.09 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.338 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -125.55 111.3 26.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.942 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 56.56 26.16 10.7 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 123.928 0.891 . . . . 0.0 112.795 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.5 22.7 39.32 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.561 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.33 120.8 21.48 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.692 0.282 . . . . 0.0 110.813 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.494 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.0 t -138.54 114.36 8.79 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.861 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -81.72 -161.53 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.678 0 C-N-CA 122.403 2.069 . . . . 0.0 112.732 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.05 -30.46 7.56 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 123.364 0.415 . . . . 0.0 113.054 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.57 43.22 3.21 Favored Glycine 0 C--N 1.337 0.635 0 C-N-CA 121.616 -0.326 . . . . 0.0 112.785 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.576 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -132.97 -171.84 2.78 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 122.465 0.306 . . . . 0.0 110.799 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 80.2 m -96.66 158.41 15.44 Favored 'General case' 0 C--N 1.344 0.341 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -178.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 54.1 t -129.84 125.48 35.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.044 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.1 t -88.2 144.68 26.31 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.426 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -55.12 -21.43 13.01 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -76.29 -6.02 49.61 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 123.13 0.269 . . . . 0.0 111.396 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.28 48.33 2.63 Favored Glycine 0 C--N 1.342 0.896 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.519 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.419 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 88.6 m-85 -136.85 163.05 31.56 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.632 0.253 . . . . 0.0 111.638 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -129.2 148.57 51.15 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.941 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.576 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 174.26 167.05 33.24 Favored Glycine 0 C--N 1.342 0.87 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.561 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.0 t -119.96 148.28 43.72 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-O 120.626 0.25 . . . . 0.0 111.108 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 110.21 178.65 20.84 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-O 119.305 -0.719 . . . . 0.0 112.904 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.59 64.22 8.58 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.952 2.435 . . . . 0.0 112.373 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -148.1 -45.05 0.16 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.776 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -99.77 -10.25 22.06 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.867 178.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.344 0.338 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.347 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.236 0.342 0 CA-C-O 120.595 0.235 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.513 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 5.2 t -97.28 151.45 19.87 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.869 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -117.92 109.49 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.346 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 53.88 27.19 6.92 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.124 0.97 . . . . 0.0 113.008 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.53 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 87.34 28.65 24.38 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-N 115.944 -0.571 . . . . 0.0 113.328 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -137.26 116.36 12.49 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 122.499 0.32 . . . . 0.0 110.479 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.513 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 6.1 t -138.73 119.8 10.02 Favored Pre-proline 0 CA--C 1.539 0.526 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.938 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -80.1 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 122.338 2.026 . . . . 0.0 112.849 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.4 -30.59 8.03 Favored Glycine 0 C--N 1.341 0.832 0 O-C-N 123.361 0.413 . . . . 0.0 113.073 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.74 38.22 2.08 Favored Glycine 0 C--N 1.338 0.671 0 C-N-CA 121.567 -0.349 . . . . 0.0 112.742 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.591 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -134.85 -169.92 2.45 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.637 0.375 . . . . 0.0 110.609 -179.978 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.8 t -106.83 161.65 14.5 Favored 'General case' 0 C--N 1.344 0.332 0 CA-C-O 120.631 0.253 . . . . 0.0 111.653 -178.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.53 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 40.4 t -118.75 129.26 55.16 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.982 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 t -88.52 142.23 27.88 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.388 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.43 -21.83 10.89 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -77.26 -5.62 50.08 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.639 0.257 . . . . 0.0 111.45 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.72 47.8 2.87 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.449 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -137.59 166.46 23.86 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.2 m -117.86 152.03 36.2 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.753 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.591 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 166.12 152.26 7.15 Favored Glycine 0 C--N 1.34 0.803 0 C-N-CA 121.266 -0.493 . . . . 0.0 112.532 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -108.07 143.38 36.88 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 122.286 0.234 . . . . 0.0 110.866 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.28 -178.19 31.52 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.854 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -79.2 64.72 8.87 Favored 'Trans proline' 0 C--N 1.371 1.719 0 C-N-CA 123.017 2.478 . . . . 0.0 112.443 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.5 -47.67 0.38 Allowed 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.932 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.404 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 85.1 m-85 -111.99 -5.81 14.27 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.074 178.554 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.235 0.307 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.409 -179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.7 tt0 . . . . . 0 N--CA 1.486 1.351 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.0 m -93.8 148.01 22.52 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.286 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.37 115.94 43.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.053 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 57.81 24.9 11.31 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 123.972 0.909 . . . . 0.0 112.815 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.76 19.45 57.98 Favored Glycine 0 C--N 1.339 0.731 0 CA-C-N 115.758 -0.655 . . . . 0.0 113.647 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -131.31 121.1 24.13 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.693 0.283 . . . . 0.0 110.804 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.433 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.6 t -138.33 112.26 8.59 Favored Pre-proline 0 CA--C 1.54 0.594 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.819 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -82.25 -161.66 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.365 2.044 . . . . 0.0 112.758 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.35 -31.21 7.28 Favored Glycine 0 C--N 1.34 0.787 0 O-C-N 123.341 0.4 . . . . 0.0 113.041 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.34 2.76 Favored Glycine 0 C--N 1.338 0.688 0 C-N-CA 121.54 -0.362 . . . . 0.0 112.741 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.39 -172.52 2.97 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.609 0.363 . . . . 0.0 110.743 -179.994 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.0 m -97.06 157.73 15.77 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.727 0.298 . . . . 0.0 111.737 -178.556 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 49.0 t -129.59 126.0 37.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.991 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.7 t -90.44 144.46 25.78 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.497 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -55.58 -20.75 14.43 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -76.6 -6.16 50.81 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 123.139 0.274 . . . . 0.0 111.525 179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.93 48.12 2.53 Favored Glycine 0 C--N 1.342 0.874 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.581 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 84.9 m-85 -136.09 161.49 35.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.697 0.284 . . . . 0.0 111.691 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -131.31 145.03 51.69 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.679 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.61 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.81 157.7 19.2 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.664 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 41.2 p -107.98 149.04 28.87 Favored 'General case' 0 C--O 1.235 0.332 0 O-C-N 123.612 0.242 . . . . 0.0 111.165 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.99 -179.86 31.39 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-O 119.361 -0.688 . . . . 0.0 112.834 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.99 63.01 7.58 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 122.976 2.451 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.34 -46.39 0.42 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.242 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.434 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.5 m-85 -114.06 -2.35 13.51 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.079 178.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.5 m . . . . . 0 C--N 1.343 0.32 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.557 -179.77 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 . . . . . 0 N--CA 1.465 0.286 0 CA-C-O 120.492 0.187 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.415 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 8.8 t -109.95 141.64 42.42 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.637 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -104.32 95.23 3.65 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 54.62 26.23 7.19 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.999 0.919 . . . . 0.0 112.777 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.735 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 89.02 46.54 4.44 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.028 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -132.76 116.19 16.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.923 0.392 . . . . 0.0 111.218 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -141.65 156.88 66.15 Favored Pre-proline 0 CA--C 1.539 0.535 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.398 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.84 -159.0 0.04 OUTLIER 'Trans proline' 0 C--N 1.375 1.934 0 C-N-CA 122.472 2.115 . . . . 0.0 113.189 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.92 35.28 4.97 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 123.266 0.354 . . . . 0.0 112.977 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -122.92 -45.77 0.29 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 121.587 -0.34 . . . . 0.0 112.578 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.53 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 1.0 OUTLIER -113.51 -176.59 2.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.452 0.301 . . . . 0.0 110.995 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -124.08 156.03 37.31 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.584 0.23 . . . . 0.0 111.432 -178.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.735 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 52.7 t -117.04 133.36 56.1 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.127 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.503 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 40.0 p -96.69 145.39 25.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.446 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.61 -18.78 8.41 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -76.45 -7.04 54.25 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.674 0.273 . . . . 0.0 111.409 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.01 47.42 2.65 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.606 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.503 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 87.4 m-85 -136.93 155.74 49.36 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -137.52 130.06 29.77 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.598 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.53 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -164.82 173.11 40.69 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.529 0.518 . . . . 0.0 112.974 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.3 m -112.63 152.06 29.39 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 122.368 0.267 . . . . 0.0 111.257 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.09 177.68 26.54 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.895 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -79.31 64.61 8.86 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.943 2.428 . . . . 0.0 112.379 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.25 -47.89 0.35 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.135 -0.939 . . . . 0.0 109.947 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.13 -8.14 18.62 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.94 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.5 m . . . . . 0 C--N 1.343 0.324 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.436 179.905 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 . . . . . 0 C--O 1.236 0.343 0 CA-C-O 120.466 0.174 . . . . 0.0 110.937 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 96.4 m -91.97 149.56 21.47 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.314 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.407 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.2 t -115.82 106.52 20.59 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.917 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.407 HH11 ' CG1' ' A' ' 5' ' ' VAL . 7.8 mpt_? 55.46 27.52 10.31 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.972 0.909 . . . . 0.0 112.668 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.1 20.38 36.26 Favored Glycine 0 C--N 1.339 0.728 0 CA-C-N 115.903 -0.589 . . . . 0.0 113.457 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.89 121.09 21.23 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.651 0.262 . . . . 0.0 110.743 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.529 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 40.6 t -136.44 116.67 11.05 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.825 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -80.92 -161.57 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.335 2.024 . . . . 0.0 112.859 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.85 -30.71 7.64 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.435 0.459 . . . . 0.0 113.068 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.31 42.29 3.25 Favored Glycine 0 C--N 1.338 0.687 0 C-N-CA 121.545 -0.36 . . . . 0.0 112.66 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.584 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -133.87 -170.31 2.48 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 122.582 0.353 . . . . 0.0 110.784 -179.974 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -97.04 158.17 15.56 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 120.728 0.299 . . . . 0.0 111.735 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 t -125.8 125.97 43.78 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.6 t -88.55 143.15 27.14 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.425 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -54.78 -20.99 9.71 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -77.29 -5.91 51.22 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.355 0.262 . . . . 0.0 111.4 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.04 48.08 2.73 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.587 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -137.34 163.6 30.61 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.426 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 17.9 m -123.79 149.76 45.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.533 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.584 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 178.55 157.13 18.57 Favored Glycine 0 C--N 1.342 0.866 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.837 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.6 m -109.74 135.08 51.23 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 122.356 0.262 . . . . 0.0 111.128 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.8 -177.73 24.6 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.422 -0.654 . . . . 0.0 112.915 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -79.14 64.69 8.86 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.115 2.543 . . . . 0.0 112.493 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -48.49 0.47 Allowed 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.12 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -110.65 -5.26 15.07 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.999 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.236 0.358 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.397 -179.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 . . . . . 0 N--CA 1.465 0.32 0 CA-C-O 120.631 0.253 . . . . 0.0 110.993 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 78.9 m -89.26 148.99 23.28 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.324 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -114.92 112.03 38.31 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.968 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 56.33 26.53 10.71 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.964 0.906 . . . . 0.0 112.696 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.69 16.42 56.64 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 115.827 -0.624 . . . . 0.0 113.56 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -132.54 124.63 28.84 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.618 0.247 . . . . 0.0 110.746 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.537 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.4 t -134.67 116.43 12.71 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.796 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -80.72 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.709 0 C-N-CA 122.342 2.028 . . . . 0.0 112.859 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.08 -30.51 8.0 Favored Glycine 0 C--N 1.342 0.87 0 O-C-N 123.392 0.433 . . . . 0.0 113.043 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.71 42.7 3.06 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.542 -0.361 . . . . 0.0 112.607 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.38 -171.58 2.8 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.62 0.368 . . . . 0.0 110.796 -179.94 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.3 m -95.84 156.88 16.15 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.745 0.307 . . . . 0.0 111.754 -178.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 41.6 t -128.22 125.21 38.51 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.847 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 66.5 m -88.04 144.13 26.69 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.601 179.126 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -54.78 -20.86 9.43 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -77.46 -6.68 54.37 Favored 'General case' 0 CA--C 1.54 0.582 0 O-C-N 123.106 0.254 . . . . 0.0 111.13 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.06 48.53 2.42 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.573 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.431 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 21.4 m-85 -136.45 159.92 40.32 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.44 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 13.6 m -122.32 149.89 43.13 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.557 179.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.59 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 176.86 154.5 11.99 Favored Glycine 0 C--N 1.341 0.836 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.746 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -111.76 145.15 39.86 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 123.665 0.273 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.96 -178.0 30.54 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-O 119.412 -0.66 . . . . 0.0 112.78 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.91 62.91 7.48 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 123.034 2.489 . . . . 0.0 112.467 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.27 -45.93 0.42 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.178 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.42 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.0 m-85 -116.82 -1.76 11.97 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.174 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 C--N 1.344 0.366 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.519 -179.795 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 . . . . . 0 N--CA 1.466 0.372 0 CA-C-O 120.546 0.212 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.567 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 99.5 m -93.17 149.55 21.14 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.236 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.9 108.01 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 56.06 27.27 11.13 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 123.952 0.901 . . . . 0.0 112.658 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.65 16.66 48.09 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.626 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -132.88 124.83 28.64 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.716 0.258 . . . . 0.0 110.796 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.567 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 41.2 t -133.92 119.26 14.65 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.989 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -80.42 -161.63 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 122.405 2.07 . . . . 0.0 112.782 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.42 -30.61 7.56 Favored Glycine 0 C--N 1.342 0.878 0 CA-C-N 116.397 -0.365 . . . . 0.0 113.033 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.67 42.77 2.83 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 121.614 -0.327 . . . . 0.0 112.739 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.569 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.84 -168.25 2.13 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.502 0.321 . . . . 0.0 110.804 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 70.2 m -100.9 160.2 14.57 Favored 'General case' 0 C--N 1.343 0.308 0 CA-C-O 120.673 0.273 . . . . 0.0 111.651 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.7 t -128.5 128.76 44.97 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.881 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.5 p -90.84 146.36 24.0 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.761 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -53.58 -20.16 4.75 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -178.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.78 -5.44 48.22 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 122.381 0.273 . . . . 0.0 111.272 179.132 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.35 45.57 4.33 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-N 115.758 -0.655 . . . . 0.0 112.175 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -134.46 161.37 35.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.646 0.26 . . . . 0.0 111.699 -179.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.2 m -116.84 152.6 34.11 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.569 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 175.16 160.38 22.95 Favored Glycine 0 C--N 1.343 0.936 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.759 -179.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -115.58 143.4 45.39 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.605 0.238 . . . . 0.0 111.005 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.1 -178.8 32.14 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.888 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.07 64.55 8.85 Favored 'Trans proline' 0 C--N 1.37 1.675 0 C-N-CA 123.052 2.501 . . . . 0.0 112.412 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -47.23 0.46 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.114 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 -5.31 12.68 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.016 178.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.235 0.322 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.461 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 . . . . . 0 N--CA 1.466 0.355 0 CA-C-O 120.467 0.175 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 73.7 m -95.1 118.18 31.46 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.042 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 8.4 t -129.69 84.59 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.472 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 55.12 29.18 12.08 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.847 0.859 . . . . 0.0 112.428 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.73 -38.95 0.05 OUTLIER Glycine 0 C--N 1.34 0.756 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.984 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 61.47 162.5 0.07 Allowed 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 124.037 0.935 . . . . 0.0 112.67 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.533 ' SG ' HD11 ' A' ' 13' ' ' LEU . 77.2 m -87.0 151.87 52.53 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.352 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.52 -155.59 0.03 OUTLIER 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.838 2.358 . . . . 0.0 113.265 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.8 26.87 6.24 Favored Glycine 0 C--N 1.344 1.016 0 C-N-CA 121.76 -0.257 . . . . 0.0 113.393 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.66 -48.98 1.87 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 121.577 -0.344 . . . . 0.0 112.388 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.533 HD11 ' SG ' ' A' ' 9' ' ' CYS . 0.7 OUTLIER -119.61 -173.4 2.52 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.558 0.343 . . . . 0.0 110.711 179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.9 m -115.1 153.16 31.25 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.344 -179.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -122.33 131.7 54.03 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.05 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.9 m -92.56 143.0 26.78 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.497 179.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -57.6 -18.04 17.63 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -78.13 -7.17 56.68 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.33 0.252 . . . . 0.0 111.077 179.246 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 97.64 48.29 1.99 Allowed Glycine 0 C--N 1.341 0.855 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.67 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -138.03 160.47 39.26 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.737 0.303 . . . . 0.0 111.78 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 0.1 OUTLIER -134.65 144.18 47.7 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.96 179.721 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.447 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . -179.32 161.63 27.84 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.982 -0.554 . . . . 0.0 112.538 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.7 t -109.61 148.53 31.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 120.602 0.239 . . . . 0.0 111.141 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.39 179.19 26.04 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-O 119.328 -0.707 . . . . 0.0 112.882 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -77.91 63.45 8.13 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 123.024 2.483 . . . . 0.0 112.412 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.48 -47.83 0.43 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.21 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.447 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 97.1 m-85 -107.67 -3.35 19.29 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.03 178.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.7 m . . . . . 0 C--O 1.235 0.338 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.574 -179.869 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 . . . . . 0 C--O 1.235 0.317 0 CA-C-O 120.51 0.195 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.496 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.5 m -93.58 149.17 21.45 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.285 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.445 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.1 t -119.84 105.58 17.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.747 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . 0.445 HH11 ' CG1' ' A' ' 5' ' ' VAL . 8.3 mpt_? 55.99 27.18 10.84 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.848 0.859 . . . . 0.0 112.603 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.93 26.67 18.68 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.435 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -136.11 117.68 14.88 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-O 120.682 0.277 . . . . 0.0 110.803 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.496 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.1 t -138.98 114.57 8.49 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.719 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -81.35 -161.87 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.36 2.04 . . . . 0.0 112.844 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.57 -30.85 7.34 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.447 0.467 . . . . 0.0 113.013 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.47 43.44 3.43 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 121.697 -0.287 . . . . 0.0 112.707 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.587 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.41 -171.31 2.67 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 122.473 0.309 . . . . 0.0 110.807 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.9 m -93.82 155.07 17.4 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -125.84 125.2 42.48 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.712 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 75.6 m -90.9 143.57 26.59 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.735 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.83 -21.15 10.38 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -76.25 -6.81 53.09 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.381 0.273 . . . . 0.0 111.371 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.67 47.89 2.63 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.501 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -138.05 164.15 29.82 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.455 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 20.0 m -126.93 151.57 48.3 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.634 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.587 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.11 158.6 20.71 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.843 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.9 m -112.91 144.03 43.17 Favored 'General case' 0 C--O 1.235 0.318 0 O-C-N 123.659 0.27 . . . . 0.0 110.969 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.21 -177.56 31.23 Favored Glycine 0 CA--C 1.529 0.925 0 CA-C-O 119.393 -0.671 . . . . 0.0 112.776 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.76 62.99 7.39 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.996 2.464 . . . . 0.0 112.524 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.48 -46.36 0.46 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.25 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -116.72 -1.54 12.07 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.12 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 83.0 m . . . . . 0 C--N 1.344 0.344 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.528 -179.829 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 . . . . . 0 N--CA 1.466 0.366 0 CA-C-O 120.607 0.241 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.456 ' SG ' ' SG ' ' A' ' 9' ' ' CYS . 66.0 m -96.34 137.11 35.9 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.298 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.7 t -101.16 95.11 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 59.63 24.12 12.93 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 123.745 0.818 . . . . 0.0 112.234 -179.366 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.87 52.75 3.04 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.015 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 -135.59 121.75 20.22 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 120.814 0.34 . . . . 0.0 111.507 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.543 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 26.0 m -143.71 152.39 55.91 Favored Pre-proline 0 N--CA 1.469 0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.491 179.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -69.5 -159.39 0.05 OUTLIER 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 122.591 2.194 . . . . 0.0 113.075 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.59 37.46 3.8 Favored Glycine 0 C--N 1.341 0.829 0 O-C-N 123.324 0.39 . . . . 0.0 112.894 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.67 -40.57 0.52 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 121.548 -0.358 . . . . 0.0 112.68 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 22' ' ' GLY . 1.5 pt? -123.96 178.39 5.31 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 122.4 0.28 . . . . 0.0 110.884 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 68.9 m -110.57 157.96 19.08 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.678 -0.237 . . . . 0.0 111.569 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.543 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 49.9 t -120.84 129.25 53.46 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.231 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.415 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 38.5 p -94.61 144.56 25.5 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.435 179.226 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -56.0 -17.75 7.59 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -76.4 -7.36 54.87 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.701 0.286 . . . . 0.0 111.282 179.132 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 46.84 2.76 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.629 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.415 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 95.0 m-85 -139.57 156.88 46.62 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.504 0.192 . . . . 0.0 111.489 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.7 OUTLIER -137.81 133.73 34.35 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.55 179.395 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.495 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -164.88 166.97 38.39 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.667 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.2 t -105.94 148.32 27.79 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.664 0.268 . . . . 0.0 111.063 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.22 177.81 25.3 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.405 -0.664 . . . . 0.0 112.807 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -79.57 64.51 8.86 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.948 2.432 . . . . 0.0 112.468 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.61 -48.77 0.39 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.053 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -103.66 -5.63 22.41 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.021 178.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 86.0 m . . . . . 0 C--N 1.345 0.375 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.491 -179.982 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 . . . . . 0 N--CA 1.465 0.317 0 CA-C-O 120.573 0.225 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 93.0 m -91.52 150.26 21.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.276 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -121.95 112.53 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.922 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 77.1 mtp180 57.62 25.84 12.16 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.859 0.863 . . . . 0.0 112.626 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.55 18.49 54.85 Favored Glycine 0 C--N 1.338 0.662 0 CA-C-N 115.779 -0.646 . . . . 0.0 113.531 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -133.02 124.39 27.59 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.634 0.254 . . . . 0.0 110.822 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.2 t -135.55 116.57 11.88 Favored Pre-proline 0 CA--C 1.54 0.571 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.844 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -80.82 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 122.36 2.04 . . . . 0.0 112.859 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.05 -30.69 7.75 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.388 0.43 . . . . 0.0 113.013 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.93 42.27 3.11 Favored Glycine 0 C--N 1.338 0.639 0 C-N-CA 121.617 -0.325 . . . . 0.0 112.685 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.71 -171.24 2.73 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 122.578 0.351 . . . . 0.0 110.729 -179.952 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 99.6 m -96.08 156.76 16.2 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 111.895 0.331 . . . . 0.0 111.895 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -126.69 127.4 45.08 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.8 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.475 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 35.5 p -93.61 143.67 26.09 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.61 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -54.24 -20.43 6.97 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 -178.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -76.08 -6.88 53.17 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.356 0.263 . . . . 0.0 111.321 179.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.79 47.15 3.0 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.558 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.475 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 89.5 m-85 -138.25 161.98 35.49 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.483 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.44 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 15.1 m -123.54 151.68 42.61 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.685 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.59 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 176.31 155.32 12.97 Favored Glycine 0 C--N 1.34 0.804 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.84 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -110.67 145.1 38.56 Favored 'General case' 0 C--O 1.235 0.34 0 O-C-N 123.723 0.308 . . . . 0.0 110.822 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 100.58 -178.71 28.92 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-O 119.368 -0.684 . . . . 0.0 112.809 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -76.83 62.75 7.38 Favored 'Trans proline' 0 C--N 1.371 1.721 0 C-N-CA 122.974 2.449 . . . . 0.0 112.508 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.9 -46.22 0.4 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.135 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.453 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.7 m-85 -114.32 -2.62 13.26 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.158 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.6 m . . . . . 0 C--N 1.344 0.332 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.544 -179.827 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 120.452 0.168 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.414 ' SG ' ' SG ' ' A' ' 9' ' ' CYS . 58.2 m -98.64 130.89 45.17 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 123.675 0.61 . . . . 0.0 111.115 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.4 t -101.76 95.26 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 58.24 24.69 11.75 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.815 0.846 . . . . 0.0 112.322 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 87.41 47.44 4.62 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-N 115.662 -0.699 . . . . 0.0 112.965 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.72 119.0 18.76 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 120.86 0.362 . . . . 0.0 111.28 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 54.8 m -141.25 151.78 62.53 Favored Pre-proline 0 CA--C 1.536 0.437 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.626 179.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.36 -159.23 0.06 OUTLIER 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.46 2.107 . . . . 0.0 113.007 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.82 37.7 3.68 Favored Glycine 0 C--N 1.34 0.794 0 O-C-N 123.341 0.401 . . . . 0.0 112.864 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.97 -44.14 0.38 Allowed Glycine 0 C--N 1.338 0.647 0 C-N-CA 121.655 -0.307 . . . . 0.0 112.539 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.543 HD12 ' N ' ' A' ' 22' ' ' GLY . 1.3 pt? -118.62 178.84 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 122.478 0.311 . . . . 0.0 110.87 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 69.1 m -109.87 152.43 25.79 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 123.103 0.252 . . . . 0.0 111.43 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.549 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 46.4 t -109.82 128.37 55.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.146 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 57.9 m -95.92 138.7 33.18 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.529 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -54.3 -22.1 11.05 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 -178.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -76.27 -6.81 53.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.418 0.287 . . . . 0.0 111.229 179.158 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.96 44.35 3.61 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.51 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -143.03 123.61 14.04 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.629 0.252 . . . . 0.0 111.373 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -106.05 140.41 39.08 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.66 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.543 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -170.83 167.9 41.04 Favored Glycine 0 C--N 1.338 0.691 0 O-C-N 123.603 0.565 . . . . 0.0 112.668 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 p -105.37 150.75 24.95 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.604 0.24 . . . . 0.0 111.369 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.77 176.35 26.96 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.276 -0.735 . . . . 0.0 112.876 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -78.53 63.79 8.5 Favored 'Trans proline' 0 C--N 1.371 1.754 0 C-N-CA 122.945 2.43 . . . . 0.0 112.375 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.4 -48.27 0.44 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.158 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -105.62 -3.7 21.97 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.026 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.2 m . . . . . 0 C--N 1.343 0.298 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.499 -179.817 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 . . . . . 0 C--O 1.235 0.308 0 CA-C-O 120.507 0.194 . . . . 0.0 110.845 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.539 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 97.5 m -92.02 150.12 21.16 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.339 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -123.46 110.62 26.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.785 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 57.46 25.76 11.79 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 123.88 0.872 . . . . 0.0 112.68 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.07 21.76 37.83 Favored Glycine 0 C--N 1.339 0.732 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.524 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -134.79 123.55 23.75 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 120.654 0.264 . . . . 0.0 110.787 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.539 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 48.2 t -136.82 116.96 10.77 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.815 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -80.77 -161.84 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.69 0 C-N-CA 122.37 2.047 . . . . 0.0 112.877 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.99 -30.39 7.62 Favored Glycine 0 C--N 1.341 0.815 0 O-C-N 123.344 0.403 . . . . 0.0 113.057 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.43 42.74 3.36 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.582 -0.342 . . . . 0.0 112.675 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.583 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.86 -170.26 2.47 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 122.532 0.333 . . . . 0.0 110.796 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.9 m -95.42 154.55 17.15 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.766 0.317 . . . . 0.0 111.725 -178.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.8 t -123.89 128.95 50.21 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.792 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.468 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 46.9 p -96.78 141.65 29.74 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.46 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -54.94 -19.32 6.45 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -178.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -76.33 -7.25 54.56 Favored 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.141 0.275 . . . . 0.0 111.239 179.116 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.58 46.64 2.92 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.607 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.468 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 93.3 m-85 -139.6 164.25 30.4 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.435 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 19.8 m -126.4 152.64 46.07 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.752 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.583 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 179.51 153.41 11.77 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.641 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 53.1 m -103.62 137.51 41.57 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.271 0.228 . . . . 0.0 111.324 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.59 179.95 22.14 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.36 -0.689 . . . . 0.0 112.953 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -80.13 65.94 8.85 Favored 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 123.101 2.534 . . . . 0.0 112.378 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.06 -49.34 0.42 Allowed 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.124 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.561 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 94.1 m-85 -101.11 -5.88 25.08 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.087 178.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.343 0.305 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.484 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 . . . . . 0 C--O 1.234 0.271 0 CA-C-O 120.608 0.242 . . . . 0.0 110.937 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.52 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 72.4 m -90.38 148.89 22.53 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.239 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -117.68 112.1 37.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.889 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 57.04 25.87 11.27 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 123.912 0.885 . . . . 0.0 112.688 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.98 20.39 46.74 Favored Glycine 0 C--N 1.339 0.705 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.478 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -133.91 123.68 25.1 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.594 0.235 . . . . 0.0 110.813 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.52 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 38.7 t -136.38 116.43 11.05 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.7 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -80.73 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.369 1.634 0 C-N-CA 122.348 2.032 . . . . 0.0 112.883 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.04 -30.65 7.8 Favored Glycine 0 C--N 1.34 0.798 0 O-C-N 123.377 0.423 . . . . 0.0 113.038 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.51 42.97 3.04 Favored Glycine 0 C--N 1.339 0.695 0 C-N-CA 121.588 -0.339 . . . . 0.0 112.588 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.605 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.38 -171.68 2.82 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 122.649 0.38 . . . . 0.0 110.778 -179.86 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 74.9 m -97.03 158.36 15.46 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.685 0.279 . . . . 0.0 111.744 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 43.0 t -128.6 127.2 41.79 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.089 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -89.22 144.85 25.8 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.394 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -53.94 -22.36 10.03 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -178.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -76.2 -5.72 48.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.622 0.248 . . . . 0.0 111.511 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.57 48.48 2.75 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.631 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.434 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.1 m-85 -136.23 160.96 37.1 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -179.503 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.441 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 15.4 m -121.9 151.15 41.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.776 179.729 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.605 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 175.98 150.09 7.87 Favored Glycine 0 C--N 1.341 0.857 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.658 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.5 t -108.85 145.53 35.14 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.628 0.251 . . . . 0.0 110.804 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.71 -177.49 29.33 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.369 -0.684 . . . . 0.0 112.77 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.16 62.76 7.6 Favored 'Trans proline' 0 C--N 1.37 1.707 0 C-N-CA 122.962 2.441 . . . . 0.0 112.596 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.54 -45.81 0.37 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.083 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.577 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.0 m-85 -114.7 -3.43 12.85 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.12 178.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.0 m . . . . . 0 C--N 1.343 0.322 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.568 -179.779 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 . . . . . 0 C--O 1.235 0.321 0 CA-C-O 120.499 0.19 . . . . 0.0 110.901 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 62.3 m -98.68 136.42 38.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -116.41 114.6 46.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.284 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 54.97 26.25 7.76 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.953 0.901 . . . . 0.0 112.957 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.64 27.49 29.41 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.974 -0.557 . . . . 0.0 113.515 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -129.59 113.96 15.47 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 120.89 0.376 . . . . 0.0 110.694 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 46.7 t -146.96 115.36 4.35 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.768 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -81.04 -162.86 0.2 Allowed 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.373 2.049 . . . . 0.0 112.626 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.84 -30.17 6.82 Favored Glycine 0 C--N 1.34 0.795 0 O-C-N 123.38 0.425 . . . . 0.0 112.975 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.2 46.1 2.67 Favored Glycine 0 C--N 1.339 0.717 0 C-N-CA 121.674 -0.298 . . . . 0.0 112.873 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.621 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -134.19 -172.43 3.0 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 122.486 0.315 . . . . 0.0 110.81 179.951 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -104.86 170.18 8.02 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -178.085 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.3 m -122.08 130.53 53.34 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.613 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 t -91.46 142.51 27.59 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.312 178.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -55.1 -20.97 11.19 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -77.65 -5.31 49.94 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.384 0.274 . . . . 0.0 111.461 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.07 46.64 3.04 Favored Glycine 0 C--N 1.343 0.924 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.462 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -136.92 169.62 17.46 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.6 0.238 . . . . 0.0 111.602 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.07 141.54 51.75 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.621 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.621 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -179.54 150.84 9.6 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 123.514 0.509 . . . . 0.0 112.361 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -100.94 143.38 31.16 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.618 0.246 . . . . 0.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.38 -179.66 32.14 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 119.376 -0.68 . . . . 0.0 112.943 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -79.97 65.41 8.89 Favored 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 123.007 2.471 . . . . 0.0 112.425 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.19 -49.54 0.42 Allowed 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.986 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.466 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 86.1 m-85 -106.52 -6.51 18.05 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.015 178.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.235 0.296 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.355 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 . . . . . 0 C--O 1.235 0.325 0 CA-C-O 120.538 0.209 . . . . 0.0 110.962 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.559 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 86.2 m -91.46 150.47 21.22 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.394 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -118.46 112.66 39.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.871 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 56.86 26.03 11.13 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.891 0.876 . . . . 0.0 112.782 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.82 17.13 57.1 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.817 -0.628 . . . . 0.0 113.581 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -133.09 125.7 30.17 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.748 0.274 . . . . 0.0 110.824 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.559 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.7 t -134.94 117.92 12.97 Favored Pre-proline 0 CA--C 1.539 0.555 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.824 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -80.27 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.72 0 C-N-CA 122.43 2.087 . . . . 0.0 112.92 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.75 -30.37 8.01 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.437 0.46 . . . . 0.0 113.015 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.61 41.8 3.07 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 121.559 -0.353 . . . . 0.0 112.637 -179.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.593 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.86 -170.96 2.61 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 122.644 0.377 . . . . 0.0 110.788 -179.938 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -98.36 160.03 14.56 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.648 0.261 . . . . 0.0 111.656 -178.515 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -127.73 128.6 45.67 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.058 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.9 t -90.26 143.66 26.56 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.3 179.151 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.46 -21.55 10.24 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -178.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -76.99 -5.72 49.76 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 123.152 0.282 . . . . 0.0 111.47 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.78 48.72 2.65 Favored Glycine 0 C--N 1.341 0.839 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.622 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -136.78 160.99 37.2 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.718 0.294 . . . . 0.0 111.752 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 16.2 m -120.85 148.95 43.33 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.627 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.593 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 179.51 149.51 8.45 Favored Glycine 0 C--N 1.341 0.849 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.55 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.3 p -103.83 134.13 47.65 Favored 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.635 0.256 . . . . 0.0 111.225 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.55 -178.89 21.9 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.908 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -80.03 65.2 8.91 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 123.101 2.534 . . . . 0.0 112.417 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.75 -48.83 0.43 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.129 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.512 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.6 m-85 -105.74 -5.5 19.87 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.029 178.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.236 0.365 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.422 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 . . . . . 0 C--O 1.236 0.348 0 CA-C-O 120.498 0.19 . . . . 0.0 110.991 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.543 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 85.4 m -88.35 148.79 24.09 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.319 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.1 t -113.21 107.2 22.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 56.12 26.71 10.5 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.932 0.893 . . . . 0.0 112.647 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.4 20.89 33.71 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.465 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.1 mtp180 -134.2 121.86 21.98 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 116.72 0.26 . . . . 0.0 110.771 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.543 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.2 t -137.06 115.72 10.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.824 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.93 -161.46 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 122.393 2.062 . . . . 0.0 112.912 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.69 -31.18 7.44 Favored Glycine 0 C--N 1.34 0.771 0 O-C-N 123.317 0.386 . . . . 0.0 113.016 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.15 42.56 2.99 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.544 -179.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.582 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.59 -169.45 2.29 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.588 0.355 . . . . 0.0 110.695 -179.883 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -98.0 155.61 17.02 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.715 0.293 . . . . 0.0 111.58 -178.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 40.4 t -126.38 127.98 46.33 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.934 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.7 m -92.07 141.82 28.19 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.419 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -55.22 -19.78 9.0 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -77.07 -6.16 51.7 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.458 0.303 . . . . 0.0 111.361 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.49 48.28 2.59 Favored Glycine 0 C--N 1.343 0.936 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.702 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -138.83 161.14 38.0 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.435 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 14.5 m -123.96 151.15 43.96 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.65 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.582 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.47 153.46 11.04 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.694 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 42.0 p -106.36 140.78 38.74 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 122.325 0.25 . . . . 0.0 111.253 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.53 -178.98 24.41 Favored Glycine 0 CA--C 1.529 0.923 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.867 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.46 65.86 8.87 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.086 2.524 . . . . 0.0 112.409 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.97 -49.45 0.43 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.996 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' TYR . . . . . 0.521 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.4 m-85 -103.57 -7.24 20.95 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.958 178.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.343 0.314 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.314 0 CA-C-O 120.485 0.184 . . . . 0.0 111.047 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 101.09 93.55 2.17 Favored Glycine 0 C--N 1.337 0.59 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.447 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -128.75 147.79 50.8 Favored 'General case' 0 C--O 1.235 0.323 0 O-C-N 123.668 0.275 . . . . 0.0 110.88 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 83.3 m -91.84 146.28 23.88 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.234 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -114.11 110.6 32.71 Favored 'Isoleucine or valine' 0 C--O 1.235 0.341 0 CA-C-N 115.917 -0.583 . . . . 0.0 109.958 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 22.2 ttp180 56.02 27.15 10.86 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 123.975 0.91 . . . . 0.0 112.382 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.3 21.49 38.0 Favored Glycine 0 C--N 1.338 0.689 0 CA-C-N 115.818 -0.628 . . . . 0.0 113.42 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 76.8 mtp180 -134.3 122.7 23.04 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-O 120.645 0.26 . . . . 0.0 110.796 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.5 t -136.58 115.92 10.72 Favored Pre-proline 0 CA--C 1.54 0.565 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.787 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.2 Cg_endo -80.95 -161.93 0.17 Allowed 'Trans proline' 0 C--N 1.37 1.689 0 C-N-CA 122.362 2.041 . . . . 0.0 112.845 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.22 -30.6 7.48 Favored Glycine 0 C--N 1.34 0.78 0 O-C-N 123.421 0.451 . . . . 0.0 113.04 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.61 43.33 3.42 Favored Glycine 0 C--N 1.339 0.737 0 C-N-CA 121.599 -0.334 . . . . 0.0 112.728 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.57 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -132.93 -170.33 2.43 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.487 0.315 . . . . 0.0 110.843 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 72.5 m -95.0 154.45 17.16 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 120.759 0.314 . . . . 0.0 111.844 -178.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.416 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 42.5 t -129.02 126.56 39.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.837 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.487 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 36.8 p -92.24 144.88 24.96 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.603 179.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.18 -20.82 7.46 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -178.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -76.03 -6.66 52.07 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.337 0.255 . . . . 0.0 111.379 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.77 48.12 2.79 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.909 -0.587 . . . . 0.0 112.609 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.487 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 88.3 m-85 -137.86 160.47 39.2 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.949 0.351 . . . . 0.0 111.949 -179.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 13.2 m -123.34 152.2 41.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.616 179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.57 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.16 159.24 22.02 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.951 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.8 m -116.39 143.74 45.17 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 122.405 0.282 . . . . 0.0 110.925 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.18 -175.39 29.56 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-O 119.414 -0.659 . . . . 0.0 112.876 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_exo -77.43 63.01 7.82 Favored 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 123.092 2.528 . . . . 0.0 112.49 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.11 -46.05 0.43 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.107 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -118.45 -2.68 11.02 Favored 'General case' 0 C--O 1.237 0.406 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.121 178.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 72.7 m -95.98 -43.25 7.89 Favored 'General case' 0 C--N 1.344 0.341 0 CA-C-N 115.771 -0.65 . . . . 0.0 111.521 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.73 -76.76 0.29 Allowed Glycine 0 C--N 1.34 0.795 0 O-C-N 123.396 0.435 . . . . 0.0 112.473 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.079 0 CA-C-O 118.34 -1.255 . . . . 0.0 112.49 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.323 0 CA-C-O 120.524 0.202 . . . . 0.0 111.042 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 129.53 55.07 0.1 Allowed Glycine 0 C--N 1.337 0.625 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.477 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -108.72 151.71 25.82 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 122.364 0.266 . . . . 0.0 110.981 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 74.3 m -94.31 151.81 19.14 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.263 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -125.66 113.35 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.062 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 36.5 ttt180 55.95 26.23 9.63 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.998 0.919 . . . . 0.0 112.594 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 84.57 26.28 39.49 Favored Glycine 0 C--N 1.339 0.747 0 CA-C-N 115.89 -0.595 . . . . 0.0 113.66 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -131.82 116.14 16.85 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 110.753 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.8 t -142.54 107.92 5.58 Favored Pre-proline 0 CA--C 1.542 0.665 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.851 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -83.42 -160.61 0.12 Allowed 'Trans proline' 0 C--N 1.369 1.616 0 C-N-CA 122.462 2.108 . . . . 0.0 112.846 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 98.26 -32.12 7.28 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.285 0.365 . . . . 0.0 113.038 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.02 42.11 2.49 Favored Glycine 0 C--N 1.338 0.662 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.641 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.577 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -131.77 -169.52 2.22 Favored 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 122.683 0.393 . . . . 0.0 110.599 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 26.2 p -108.5 156.03 19.95 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 120.55 0.214 . . . . 0.0 111.296 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.6 t -126.21 131.7 51.92 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.642 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.4 t -89.58 144.88 25.66 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.253 178.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -56.04 -19.38 12.57 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 113.739 1.014 . . . . 0.0 113.739 -178.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -77.66 -5.6 50.98 Favored 'General case' 0 N--CA 1.47 0.568 0 O-C-N 123.095 0.247 . . . . 0.0 111.497 179.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 48.36 2.45 Favored Glycine 0 C--N 1.341 0.82 0 CA-C-N 115.907 -0.588 . . . . 0.0 112.615 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -135.93 161.3 36.01 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.593 0.235 . . . . 0.0 111.571 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -134.11 145.93 49.79 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.574 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.577 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -175.75 -179.55 46.32 Favored Glycine 0 C--N 1.341 0.838 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.056 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 35.2 p -129.62 136.93 50.36 Favored 'General case' 0 C--O 1.236 0.372 0 O-C-N 123.723 0.307 . . . . 0.0 110.919 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.63 -176.71 28.91 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-O 119.433 -0.649 . . . . 0.0 112.68 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -77.51 64.54 8.04 Favored 'Trans proline' 0 C--N 1.369 1.65 0 C-N-CA 123.006 2.471 . . . . 0.0 112.364 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -137.49 -46.49 0.55 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.098 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -120.41 -6.22 9.81 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.059 178.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 38.1 m -92.14 -44.24 8.91 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-N 115.891 -0.595 . . . . 0.0 111.62 -179.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -143.43 -107.14 0.58 Allowed Glycine 0 C--N 1.34 0.783 0 O-C-N 123.385 0.428 . . . . 0.0 112.51 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.394 -1.226 . . . . 0.0 112.674 -179.975 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.325 0 CA-C-O 120.465 0.174 . . . . 0.0 111.038 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 115.06 -54.53 0.57 Allowed Glycine 0 C--N 1.336 0.567 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.539 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -117.75 149.97 39.89 Favored 'General case' 0 N--CA 1.466 0.33 0 O-C-N 123.631 0.253 . . . . 0.0 110.85 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.437 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.8 m -94.88 137.51 33.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.163 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 14.6 p -105.28 109.95 29.41 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.724 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 68.4 mtp180 55.1 26.14 7.89 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 123.984 0.914 . . . . 0.0 112.732 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.64 26.56 24.66 Favored Glycine 0 C--N 1.339 0.716 0 CA-C-N 115.871 -0.604 . . . . 0.0 113.408 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 86.5 mtm180 -134.89 117.4 15.82 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.668 0.27 . . . . 0.0 110.742 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.437 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 42.7 t -140.51 110.38 6.85 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.928 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -82.93 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.674 0 C-N-CA 122.372 2.048 . . . . 0.0 112.723 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.93 -31.87 6.89 Favored Glycine 0 C--N 1.34 0.784 0 O-C-N 123.384 0.428 . . . . 0.0 112.995 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.75 2.68 Favored Glycine 0 C--N 1.338 0.675 0 C-N-CA 121.608 -0.33 . . . . 0.0 112.784 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.579 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -132.0 -171.48 2.64 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 122.578 0.351 . . . . 0.0 110.786 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.412 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 92.7 m -96.46 154.51 17.23 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.747 0.308 . . . . 0.0 111.689 -178.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 51.8 t -130.48 126.08 35.99 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.017 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.7 t -90.29 144.03 26.22 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.469 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.71 -20.11 13.28 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -76.87 -6.09 50.99 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.389 0.275 . . . . 0.0 111.508 179.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.18 48.19 2.47 Favored Glycine 0 C--N 1.343 0.941 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.644 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.421 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.8 m-85 -136.22 160.55 38.34 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.687 0.28 . . . . 0.0 111.716 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.412 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -132.21 147.99 52.44 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.83 179.927 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.579 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 174.55 163.87 28.51 Favored Glycine 0 C--N 1.34 0.75 0 C-N-CA 121.216 -0.516 . . . . 0.0 112.737 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -113.28 149.6 33.65 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.3 -179.35 32.13 Favored Glycine 0 CA--C 1.528 0.858 0 CA-C-O 119.336 -0.702 . . . . 0.0 112.827 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -77.36 63.12 7.79 Favored 'Trans proline' 0 C--N 1.371 1.724 0 C-N-CA 122.98 2.454 . . . . 0.0 112.458 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.89 -46.64 0.44 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.198 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -114.82 -2.62 12.9 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.08 178.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.0 m -93.85 -42.11 9.27 Favored 'General case' 0 C--N 1.344 0.357 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.508 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -133.17 -140.46 4.4 Favored Glycine 0 C--N 1.34 0.778 0 O-C-N 123.5 0.5 . . . . 0.0 112.542 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.352 -1.249 . . . . 0.0 112.421 179.995 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.465 0.174 . . . . 0.0 111.074 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 139.2 -58.96 0.6 Allowed Glycine 0 C--N 1.338 0.663 0 O-C-N 123.685 0.616 . . . . 0.0 112.531 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -113.65 148.17 36.78 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 123.634 0.255 . . . . 0.0 110.928 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.494 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 82.5 m -94.41 151.81 19.09 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.338 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -125.55 111.3 26.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.942 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.4 mtt180 56.56 26.16 10.7 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 123.928 0.891 . . . . 0.0 112.795 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.5 22.7 39.32 Favored Glycine 0 C--N 1.338 0.68 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.561 179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -133.33 120.8 21.48 Favored 'General case' 0 C--O 1.236 0.388 0 CA-C-O 120.692 0.282 . . . . 0.0 110.813 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.494 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 47.0 t -138.54 114.36 8.79 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.861 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -81.72 -161.53 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.678 0 C-N-CA 122.403 2.069 . . . . 0.0 112.732 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.05 -30.46 7.56 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 123.364 0.415 . . . . 0.0 113.054 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.57 43.22 3.21 Favored Glycine 0 C--N 1.337 0.635 0 C-N-CA 121.616 -0.326 . . . . 0.0 112.785 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.576 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -132.97 -171.84 2.78 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 122.465 0.306 . . . . 0.0 110.799 -179.964 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 80.2 m -96.66 158.41 15.44 Favored 'General case' 0 C--N 1.344 0.341 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -178.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 54.1 t -129.84 125.48 35.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.044 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 23.1 t -88.2 144.68 26.31 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.426 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -55.12 -21.43 13.01 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 113.644 0.979 . . . . 0.0 113.644 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -76.29 -6.02 49.61 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 123.13 0.269 . . . . 0.0 111.396 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.28 48.33 2.63 Favored Glycine 0 C--N 1.342 0.896 0 CA-C-N 115.918 -0.583 . . . . 0.0 112.519 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.419 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 88.6 m-85 -136.85 163.05 31.56 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.632 0.253 . . . . 0.0 111.638 -179.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -129.2 148.57 51.15 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.941 -179.954 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.576 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 174.26 167.05 33.24 Favored Glycine 0 C--N 1.342 0.87 0 C-N-CA 121.224 -0.513 . . . . 0.0 112.561 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.0 t -119.96 148.28 43.72 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-O 120.626 0.25 . . . . 0.0 111.108 -179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 110.21 178.65 20.84 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-O 119.305 -0.719 . . . . 0.0 112.904 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -78.59 64.22 8.58 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.952 2.435 . . . . 0.0 112.373 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -148.1 -45.05 0.16 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.041 -0.981 . . . . 0.0 109.776 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -99.77 -10.25 22.06 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.867 178.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -126.51 -41.86 1.84 Allowed 'General case' 0 C--N 1.344 0.338 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.347 179.705 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -98.35 93.01 1.3 Allowed Glycine 0 C--N 1.339 0.737 0 O-C-N 123.483 0.489 . . . . 0.0 112.486 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.507 -1.163 . . . . 0.0 112.543 179.952 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.524 0.202 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 148.55 -55.54 0.5 Allowed Glycine 0 C--N 1.338 0.648 0 CA-C-N 115.89 -0.595 . . . . 0.0 112.482 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -100.53 151.2 21.86 Favored 'General case' 0 C--O 1.236 0.342 0 O-C-N 123.648 0.264 . . . . 0.0 110.95 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.513 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 5.2 t -97.28 151.45 19.87 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.869 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -117.92 109.49 27.53 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.346 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 53.88 27.19 6.92 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 124.124 0.97 . . . . 0.0 113.008 179.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.53 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 87.34 28.65 24.38 Favored Glycine 0 C--N 1.339 0.73 0 CA-C-N 115.944 -0.571 . . . . 0.0 113.328 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -137.26 116.36 12.49 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 122.499 0.32 . . . . 0.0 110.479 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.513 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 6.1 t -138.73 119.8 10.02 Favored Pre-proline 0 CA--C 1.539 0.526 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.938 -179.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -80.1 -161.42 0.15 Allowed 'Trans proline' 0 C--N 1.372 1.77 0 C-N-CA 122.338 2.026 . . . . 0.0 112.849 179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.4 -30.59 8.03 Favored Glycine 0 C--N 1.341 0.832 0 O-C-N 123.361 0.413 . . . . 0.0 113.073 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.74 38.22 2.08 Favored Glycine 0 C--N 1.338 0.671 0 C-N-CA 121.567 -0.349 . . . . 0.0 112.742 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.591 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -134.85 -169.92 2.45 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.637 0.375 . . . . 0.0 110.609 -179.978 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.8 t -106.83 161.65 14.5 Favored 'General case' 0 C--N 1.344 0.332 0 CA-C-O 120.631 0.253 . . . . 0.0 111.653 -178.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.53 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 40.4 t -118.75 129.26 55.16 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.982 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 t -88.52 142.23 27.88 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.388 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.43 -21.83 10.89 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -77.26 -5.62 50.08 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.639 0.257 . . . . 0.0 111.45 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.72 47.8 2.87 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.449 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -137.59 166.46 23.86 Favored 'General case' 0 N--CA 1.471 0.622 0 N-CA-C 111.741 0.274 . . . . 0.0 111.741 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 12.2 m -117.86 152.03 36.2 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.753 179.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.591 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 166.12 152.26 7.15 Favored Glycine 0 C--N 1.34 0.803 0 C-N-CA 121.266 -0.493 . . . . 0.0 112.532 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -108.07 143.38 36.88 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 122.286 0.234 . . . . 0.0 110.866 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.28 -178.19 31.52 Favored Glycine 0 CA--C 1.528 0.862 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.854 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -79.2 64.72 8.87 Favored 'Trans proline' 0 C--N 1.371 1.719 0 C-N-CA 123.017 2.478 . . . . 0.0 112.443 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.5 -47.67 0.38 Allowed 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.159 -0.928 . . . . 0.0 109.932 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.404 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 85.1 m-85 -111.99 -5.81 14.27 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.074 178.554 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.58 -42.68 4.48 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.409 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -115.52 132.3 10.21 Favored Glycine 0 C--N 1.34 0.792 0 O-C-N 123.424 0.452 . . . . 0.0 112.489 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.049 0 CA-C-O 118.374 -1.237 . . . . 0.0 112.585 179.978 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.328 0 CA-C-O 120.503 0.192 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 99.82 105.79 2.7 Favored Glycine 0 C--N 1.337 0.595 0 CA-C-N 115.826 -0.625 . . . . 0.0 112.459 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.7 tt0 63.97 145.21 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 124.009 0.923 . . . . 0.0 111.934 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 73.0 m -93.8 148.01 22.52 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.286 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.37 115.94 43.81 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 CA-C-N 115.802 -0.636 . . . . 0.0 110.053 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 57.81 24.9 11.31 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 123.972 0.909 . . . . 0.0 112.815 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 85.76 19.45 57.98 Favored Glycine 0 C--N 1.339 0.731 0 CA-C-N 115.758 -0.655 . . . . 0.0 113.647 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 97.7 mtt180 -131.31 121.1 24.13 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.693 0.283 . . . . 0.0 110.804 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.433 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.6 t -138.33 112.26 8.59 Favored Pre-proline 0 CA--C 1.54 0.594 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.819 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -82.25 -161.66 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.697 0 C-N-CA 122.365 2.044 . . . . 0.0 112.758 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.35 -31.21 7.28 Favored Glycine 0 C--N 1.34 0.787 0 O-C-N 123.341 0.4 . . . . 0.0 113.041 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.42 44.34 2.76 Favored Glycine 0 C--N 1.338 0.688 0 C-N-CA 121.54 -0.362 . . . . 0.0 112.741 -179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.39 -172.52 2.97 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.609 0.363 . . . . 0.0 110.743 -179.994 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.405 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.0 m -97.06 157.73 15.77 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.727 0.298 . . . . 0.0 111.737 -178.556 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 49.0 t -129.59 126.0 37.47 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.991 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.7 t -90.44 144.46 25.78 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.497 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -55.58 -20.75 14.43 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 83.6 m-85 -76.6 -6.16 50.81 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 123.139 0.274 . . . . 0.0 111.525 179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.93 48.12 2.53 Favored Glycine 0 C--N 1.342 0.874 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.581 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.405 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 84.9 m-85 -136.09 161.49 35.57 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 120.697 0.284 . . . . 0.0 111.691 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.1 OUTLIER -131.31 145.03 51.69 Favored 'General case' 0 C--O 1.235 0.334 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.679 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.61 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.81 157.7 19.2 Favored Glycine 0 C--N 1.341 0.811 0 C-N-CA 121.309 -0.472 . . . . 0.0 112.664 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 41.2 p -107.98 149.04 28.87 Favored 'General case' 0 C--O 1.235 0.332 0 O-C-N 123.612 0.242 . . . . 0.0 111.165 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.99 -179.86 31.39 Favored Glycine 0 CA--C 1.528 0.855 0 CA-C-O 119.361 -0.688 . . . . 0.0 112.834 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.99 63.01 7.58 Favored 'Trans proline' 0 C--N 1.371 1.738 0 C-N-CA 122.976 2.451 . . . . 0.0 112.478 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.34 -46.39 0.42 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.242 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.434 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.5 m-85 -114.06 -2.35 13.51 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.079 178.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 85.5 m -93.64 -42.41 9.2 Favored 'General case' 0 C--N 1.343 0.32 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.557 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -137.84 -149.81 5.59 Favored Glycine 0 C--N 1.341 0.824 0 O-C-N 123.423 0.452 . . . . 0.0 112.527 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.433 -1.204 . . . . 0.0 112.527 179.984 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.275 0 CA-C-O 120.456 0.169 . . . . 0.0 111.109 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.2 65.91 0.15 Allowed Glycine 0 C--N 1.337 0.626 0 O-C-N 123.656 0.598 . . . . 0.0 112.48 -179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -119.73 139.45 52.25 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 122.323 0.249 . . . . 0.0 110.873 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.415 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 8.8 t -109.95 141.64 42.42 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.637 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.8 t -104.32 95.23 3.65 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.939 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 54.62 26.23 7.19 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.999 0.919 . . . . 0.0 112.777 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.735 ' HA2' ' SG ' ' A' ' 15' ' ' CYS . . . 89.02 46.54 4.44 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.761 -0.654 . . . . 0.0 113.028 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 63.3 mtp180 -132.76 116.19 16.26 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 120.923 0.392 . . . . 0.0 111.218 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -141.65 156.88 66.15 Favored Pre-proline 0 CA--C 1.539 0.535 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.398 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.84 -159.0 0.04 OUTLIER 'Trans proline' 0 C--N 1.375 1.934 0 C-N-CA 122.472 2.115 . . . . 0.0 113.189 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -100.92 35.28 4.97 Favored Glycine 0 C--N 1.34 0.764 0 O-C-N 123.266 0.354 . . . . 0.0 112.977 -179.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -122.92 -45.77 0.29 Allowed Glycine 0 C--N 1.337 0.591 0 C-N-CA 121.587 -0.34 . . . . 0.0 112.578 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.53 ' HB2' ' O ' ' A' ' 22' ' ' GLY . 1.0 OUTLIER -113.51 -176.59 2.93 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 122.452 0.301 . . . . 0.0 110.995 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -124.08 156.03 37.31 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.584 0.23 . . . . 0.0 111.432 -178.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.735 ' SG ' ' HA2' ' A' ' 7' ' ' GLY . 52.7 t -117.04 133.36 56.1 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.127 179.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.503 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 40.0 p -96.69 145.39 25.82 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.446 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -55.61 -18.78 8.41 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -178.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -76.45 -7.04 54.25 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.674 0.273 . . . . 0.0 111.409 179.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.01 47.42 2.65 Favored Glycine 0 C--N 1.343 0.939 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.606 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.503 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 87.4 m-85 -136.93 155.74 49.36 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.49 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 0.8 OUTLIER -137.52 130.06 29.77 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.598 179.655 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.53 ' O ' ' HB2' ' A' ' 13' ' ' LEU . . . -164.82 173.11 40.69 Favored Glycine 0 C--N 1.34 0.785 0 O-C-N 123.529 0.518 . . . . 0.0 112.974 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 50.3 m -112.63 152.06 29.39 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 122.368 0.267 . . . . 0.0 111.257 -179.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.09 177.68 26.54 Favored Glycine 0 CA--C 1.53 0.983 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.895 179.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -79.31 64.61 8.86 Favored 'Trans proline' 0 C--N 1.371 1.745 0 C-N-CA 122.943 2.428 . . . . 0.0 112.379 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -142.25 -47.89 0.35 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.135 -0.939 . . . . 0.0 109.947 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.13 -8.14 18.62 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.94 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.5 m -98.64 -42.96 7.02 Favored 'General case' 0 C--N 1.343 0.324 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.436 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.1 121.55 7.27 Favored Glycine 0 C--N 1.34 0.804 0 O-C-N 123.465 0.478 . . . . 0.0 112.569 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.09 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.598 179.994 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.51 0.195 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.26 73.64 0.22 Allowed Glycine 0 C--N 1.336 0.567 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.537 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -128.86 148.37 50.89 Favored 'General case' 0 C--O 1.236 0.343 0 O-C-N 123.66 0.271 . . . . 0.0 110.937 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.529 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 96.4 m -91.97 149.56 21.47 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.314 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.407 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.2 t -115.82 106.52 20.59 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.917 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.407 HH11 ' CG1' ' A' ' 5' ' ' VAL . 7.8 mpt_? 55.46 27.52 10.31 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.972 0.909 . . . . 0.0 112.668 -179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.1 20.38 36.26 Favored Glycine 0 C--N 1.339 0.728 0 CA-C-N 115.903 -0.589 . . . . 0.0 113.457 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.89 121.09 21.23 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.651 0.262 . . . . 0.0 110.743 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.529 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 40.6 t -136.44 116.67 11.05 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.825 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -80.92 -161.57 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.756 0 C-N-CA 122.335 2.024 . . . . 0.0 112.859 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.85 -30.71 7.64 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.435 0.459 . . . . 0.0 113.068 -179.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.31 42.29 3.25 Favored Glycine 0 C--N 1.338 0.687 0 C-N-CA 121.545 -0.36 . . . . 0.0 112.66 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.584 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -133.87 -170.31 2.48 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 122.582 0.353 . . . . 0.0 110.784 -179.974 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -97.04 158.17 15.56 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-O 120.728 0.299 . . . . 0.0 111.735 -178.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 49.3 t -125.8 125.97 43.78 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.862 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.6 t -88.55 143.15 27.14 Favored 'General case' 0 C--O 1.24 0.576 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.425 179.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -54.78 -20.99 9.71 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -178.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -77.29 -5.91 51.22 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 122.355 0.262 . . . . 0.0 111.4 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.04 48.08 2.73 Favored Glycine 0 C--N 1.342 0.903 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.587 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -137.34 163.6 30.61 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.816 0.302 . . . . 0.0 111.816 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.426 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 17.9 m -123.79 149.76 45.28 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.533 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.584 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 178.55 157.13 18.57 Favored Glycine 0 C--N 1.342 0.866 0 C-N-CA 121.023 -0.608 . . . . 0.0 112.837 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.6 m -109.74 135.08 51.23 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 122.356 0.262 . . . . 0.0 111.128 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.8 -177.73 24.6 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.422 -0.654 . . . . 0.0 112.915 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -79.14 64.69 8.86 Favored 'Trans proline' 0 C--N 1.371 1.752 0 C-N-CA 123.115 2.543 . . . . 0.0 112.493 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -48.49 0.47 Allowed 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.12 179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -110.65 -5.26 15.07 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.999 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.51 -42.09 7.87 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.397 -179.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.19 131.69 10.66 Favored Glycine 0 C--N 1.34 0.771 0 O-C-N 123.383 0.427 . . . . 0.0 112.467 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.38 -1.234 . . . . 0.0 112.476 179.957 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.367 0 CA-C-O 120.473 0.178 . . . . 0.0 111.043 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.75 85.15 0.05 OUTLIER Glycine 0 C--N 1.336 0.558 0 CA-C-N 115.867 -0.606 . . . . 0.0 112.502 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -128.84 150.98 50.1 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.631 0.253 . . . . 0.0 110.993 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 78.9 m -89.26 148.99 23.28 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.324 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -114.92 112.03 38.31 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.968 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 32.0 mmt180 56.33 26.53 10.71 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 123.964 0.906 . . . . 0.0 112.696 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 89.69 16.42 56.64 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 115.827 -0.624 . . . . 0.0 113.56 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -132.54 124.63 28.84 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.618 0.247 . . . . 0.0 110.746 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.537 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 34.4 t -134.67 116.43 12.71 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.796 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -80.72 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.709 0 C-N-CA 122.342 2.028 . . . . 0.0 112.859 179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.08 -30.51 8.0 Favored Glycine 0 C--N 1.342 0.87 0 O-C-N 123.392 0.433 . . . . 0.0 113.043 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.71 42.7 3.06 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.542 -0.361 . . . . 0.0 112.607 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.38 -171.58 2.8 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 122.62 0.368 . . . . 0.0 110.796 -179.94 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 78.3 m -95.84 156.88 16.15 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.745 0.307 . . . . 0.0 111.754 -178.403 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.431 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 41.6 t -128.22 125.21 38.51 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.847 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 66.5 m -88.04 144.13 26.69 Favored 'General case' 0 C--O 1.239 0.55 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.601 179.126 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 66.0 mttm -54.78 -20.86 9.43 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 113.701 1.0 . . . . 0.0 113.701 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -77.46 -6.68 54.37 Favored 'General case' 0 CA--C 1.54 0.582 0 O-C-N 123.106 0.254 . . . . 0.0 111.13 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.06 48.53 2.42 Favored Glycine 0 C--N 1.343 0.917 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.573 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.431 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 21.4 m-85 -136.45 159.92 40.32 Favored 'General case' 0 N--CA 1.469 0.491 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 -179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.44 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 13.6 m -122.32 149.89 43.13 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.557 179.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.59 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 176.86 154.5 11.99 Favored Glycine 0 C--N 1.341 0.836 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.746 -179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.8 t -111.76 145.15 39.86 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 123.665 0.273 . . . . 0.0 110.859 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.96 -178.0 30.54 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-O 119.412 -0.66 . . . . 0.0 112.78 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -76.91 62.91 7.48 Favored 'Trans proline' 0 C--N 1.371 1.734 0 C-N-CA 123.034 2.489 . . . . 0.0 112.467 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.27 -45.93 0.42 Allowed 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.178 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.42 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 96.0 m-85 -116.82 -1.76 11.97 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.174 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 81.0 m -93.98 -42.71 8.9 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.519 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.19 -131.9 1.27 Allowed Glycine 0 C--N 1.34 0.783 0 O-C-N 123.428 0.455 . . . . 0.0 112.481 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.047 0 CA-C-O 118.337 -1.257 . . . . 0.0 112.627 179.961 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.344 0 CA-C-O 120.441 0.162 . . . . 0.0 111.053 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 105.02 -56.71 0.53 Allowed Glycine 0 C--N 1.337 0.592 0 O-C-N 123.707 0.629 . . . . 0.0 112.438 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -129.44 150.63 50.71 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 122.333 0.253 . . . . 0.0 111.156 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.567 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 99.5 m -93.17 149.55 21.14 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.236 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -112.9 108.01 24.46 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 65.7 mtp180 56.06 27.27 11.13 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 123.952 0.901 . . . . 0.0 112.658 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.65 16.66 48.09 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.915 -0.584 . . . . 0.0 113.626 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -132.88 124.83 28.64 Favored 'General case' 0 C--O 1.235 0.319 0 CA-C-N 116.716 0.258 . . . . 0.0 110.796 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.567 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 41.2 t -133.92 119.26 14.65 Favored Pre-proline 0 CA--C 1.539 0.551 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.989 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -80.42 -161.63 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.748 0 C-N-CA 122.405 2.07 . . . . 0.0 112.782 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.42 -30.61 7.56 Favored Glycine 0 C--N 1.342 0.878 0 CA-C-N 116.397 -0.365 . . . . 0.0 113.033 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.67 42.77 2.83 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 121.614 -0.327 . . . . 0.0 112.739 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.569 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.84 -168.25 2.13 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.502 0.321 . . . . 0.0 110.804 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 70.2 m -100.9 160.2 14.57 Favored 'General case' 0 C--N 1.343 0.308 0 CA-C-O 120.673 0.273 . . . . 0.0 111.651 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.7 t -128.5 128.76 44.97 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.881 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.5 p -90.84 146.36 24.0 Favored 'General case' 0 C--O 1.241 0.643 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.761 179.28 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 59.1 mttp -53.58 -20.16 4.75 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -178.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 86.4 m-85 -76.78 -5.44 48.22 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 122.381 0.273 . . . . 0.0 111.272 179.132 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 90.35 45.57 4.33 Favored Glycine 0 C--N 1.343 0.944 0 CA-C-N 115.758 -0.655 . . . . 0.0 112.175 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -134.46 161.37 35.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 120.646 0.26 . . . . 0.0 111.699 -179.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 11.2 m -116.84 152.6 34.11 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.675 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.569 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 175.16 160.38 22.95 Favored Glycine 0 C--N 1.343 0.936 0 C-N-CA 121.082 -0.58 . . . . 0.0 112.759 -179.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -115.58 143.4 45.39 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.605 0.238 . . . . 0.0 111.005 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.1 -178.8 32.14 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.888 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.07 64.55 8.85 Favored 'Trans proline' 0 C--N 1.37 1.675 0 C-N-CA 123.052 2.501 . . . . 0.0 112.412 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.63 -47.23 0.46 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.114 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 -5.31 12.68 Favored 'General case' 0 C--O 1.237 0.432 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.016 178.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -98.73 -42.27 7.3 Favored 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.461 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -149.38 -95.49 0.14 Allowed Glycine 0 C--N 1.34 0.805 0 O-C-N 123.381 0.425 . . . . 0.0 112.576 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.124 0 CA-C-O 118.444 -1.198 . . . . 0.0 112.534 -179.996 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.334 0 CA-C-O 120.503 0.192 . . . . 0.0 111.017 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 154.9 86.68 0.06 OUTLIER Glycine 0 C--N 1.337 0.616 0 CA-C-N 115.857 -0.61 . . . . 0.0 112.487 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -131.81 151.56 51.59 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 123.679 0.282 . . . . 0.0 110.786 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 21' ' ' CYS . 73.7 m -95.1 118.18 31.46 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.042 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 8.4 t -129.69 84.59 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.472 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 55.12 29.18 12.08 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 123.847 0.859 . . . . 0.0 112.428 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -145.73 -38.95 0.05 OUTLIER Glycine 0 C--N 1.34 0.756 0 CA-C-N 115.858 -0.61 . . . . 0.0 112.984 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 61.47 162.5 0.07 Allowed 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 124.037 0.935 . . . . 0.0 112.67 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.533 ' SG ' HD11 ' A' ' 13' ' ' LEU . 77.2 m -87.0 151.87 52.53 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.352 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.52 -155.59 0.03 OUTLIER 'Trans proline' 0 C--N 1.374 1.874 0 C-N-CA 122.838 2.358 . . . . 0.0 113.265 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.8 26.87 6.24 Favored Glycine 0 C--N 1.344 1.016 0 C-N-CA 121.76 -0.257 . . . . 0.0 113.393 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -97.66 -48.98 1.87 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 121.577 -0.344 . . . . 0.0 112.388 179.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.533 HD11 ' SG ' ' A' ' 9' ' ' CYS . 0.7 OUTLIER -119.61 -173.4 2.52 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.558 0.343 . . . . 0.0 110.711 179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.9 m -115.1 153.16 31.25 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-O 120.607 0.241 . . . . 0.0 111.344 -179.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -122.33 131.7 54.03 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.05 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.9 m -92.56 143.0 26.78 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.497 179.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -57.6 -18.04 17.63 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -78.13 -7.17 56.68 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 122.33 0.252 . . . . 0.0 111.077 179.246 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 97.64 48.29 1.99 Allowed Glycine 0 C--N 1.341 0.855 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.67 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -138.03 160.47 39.26 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.737 0.303 . . . . 0.0 111.78 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.449 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 0.1 OUTLIER -134.65 144.18 47.7 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.96 179.721 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.447 ' HA3' ' CD1' ' A' ' 27' ' ' TYR . . . -179.32 161.63 27.84 Favored Glycine 0 C--N 1.339 0.709 0 CA-C-N 115.982 -0.554 . . . . 0.0 112.538 -179.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.7 t -109.61 148.53 31.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 120.602 0.239 . . . . 0.0 111.141 -179.607 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.39 179.19 26.04 Favored Glycine 0 CA--C 1.528 0.896 0 CA-C-O 119.328 -0.707 . . . . 0.0 112.882 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -77.91 63.45 8.13 Favored 'Trans proline' 0 C--N 1.372 1.764 0 C-N-CA 123.024 2.483 . . . . 0.0 112.412 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.48 -47.83 0.43 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.21 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.447 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 97.1 m-85 -107.67 -3.35 19.29 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.03 178.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 79.7 m -93.91 -42.45 9.07 Favored 'General case' 0 C--O 1.235 0.338 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.574 -179.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.69 -56.42 0.52 Allowed Glycine 0 C--N 1.34 0.754 0 O-C-N 123.423 0.452 . . . . 0.0 112.521 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.418 -1.212 . . . . 0.0 112.548 179.996 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.303 0 CA-C-O 120.502 0.192 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.53 86.08 1.89 Allowed Glycine 0 C--N 1.338 0.653 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.578 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -128.67 145.71 51.08 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 123.609 0.241 . . . . 0.0 110.844 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.496 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 71.5 m -93.58 149.17 21.45 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.285 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.445 ' CG1' HH11 ' A' ' 6' ' ' ARG . 5.1 t -119.84 105.58 17.49 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.747 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . 0.445 HH11 ' CG1' ' A' ' 5' ' ' VAL . 8.3 mpt_? 55.99 27.18 10.84 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 123.848 0.859 . . . . 0.0 112.603 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 91.93 26.67 18.68 Favored Glycine 0 C--N 1.339 0.718 0 CA-C-N 115.809 -0.632 . . . . 0.0 113.435 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -136.11 117.68 14.88 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-O 120.682 0.277 . . . . 0.0 110.803 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.496 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 49.1 t -138.98 114.57 8.49 Favored Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.719 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -81.35 -161.87 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.717 0 C-N-CA 122.36 2.04 . . . . 0.0 112.844 179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.57 -30.85 7.34 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.447 0.467 . . . . 0.0 113.013 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.47 43.44 3.43 Favored Glycine 0 C--N 1.338 0.673 0 C-N-CA 121.697 -0.287 . . . . 0.0 112.707 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.587 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.41 -171.31 2.67 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 122.473 0.309 . . . . 0.0 110.807 -179.911 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.407 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 98.9 m -93.82 155.07 17.4 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -125.84 125.2 42.48 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.712 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 75.6 m -90.9 143.57 26.59 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.735 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -54.83 -21.15 10.38 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -178.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.1 m-85 -76.25 -6.81 53.09 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 122.381 0.273 . . . . 0.0 111.371 179.204 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.67 47.89 2.63 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.501 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -138.05 164.15 29.82 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 111.884 0.327 . . . . 0.0 111.884 -179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.455 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 20.0 m -126.93 151.57 48.3 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.634 179.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.587 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.11 158.6 20.71 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 120.977 -0.63 . . . . 0.0 112.843 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 51.9 m -112.91 144.03 43.17 Favored 'General case' 0 C--O 1.235 0.318 0 O-C-N 123.659 0.27 . . . . 0.0 110.969 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.21 -177.56 31.23 Favored Glycine 0 CA--C 1.529 0.925 0 CA-C-O 119.393 -0.671 . . . . 0.0 112.776 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -76.76 62.99 7.39 Favored 'Trans proline' 0 C--N 1.371 1.712 0 C-N-CA 122.996 2.464 . . . . 0.0 112.524 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -139.48 -46.36 0.46 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.25 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -116.72 -1.54 12.07 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.12 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 83.0 m -93.73 -42.75 8.98 Favored 'General case' 0 C--N 1.344 0.344 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.528 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.98 118.01 4.12 Favored Glycine 0 C--N 1.341 0.831 0 O-C-N 123.43 0.456 . . . . 0.0 112.513 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.068 0 CA-C-O 118.333 -1.259 . . . . 0.0 112.584 179.927 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.343 0 CA-C-O 120.481 0.181 . . . . 0.0 111.058 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.92 64.29 0.41 Allowed Glycine 0 C--N 1.336 0.568 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.498 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -128.33 151.23 49.57 Favored 'General case' 0 N--CA 1.466 0.366 0 O-C-N 123.618 0.246 . . . . 0.0 110.928 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.456 ' SG ' ' SG ' ' A' ' 9' ' ' CYS . 66.0 m -96.34 137.11 35.9 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.298 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.7 t -101.16 95.11 3.74 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 59.63 24.12 12.93 Favored 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 123.745 0.818 . . . . 0.0 112.234 -179.366 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.87 52.75 3.04 Favored Glycine 0 C--N 1.339 0.713 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.015 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 70.2 mtp180 -135.59 121.75 20.22 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 120.814 0.34 . . . . 0.0 111.507 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.543 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 26.0 m -143.71 152.39 55.91 Favored Pre-proline 0 N--CA 1.469 0.524 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.491 179.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -69.5 -159.39 0.05 OUTLIER 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 122.591 2.194 . . . . 0.0 113.075 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.59 37.46 3.8 Favored Glycine 0 C--N 1.341 0.829 0 O-C-N 123.324 0.39 . . . . 0.0 112.894 -179.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.67 -40.57 0.52 Allowed Glycine 0 C--N 1.337 0.6 0 C-N-CA 121.548 -0.358 . . . . 0.0 112.68 179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.495 HD12 ' N ' ' A' ' 22' ' ' GLY . 1.5 pt? -123.96 178.39 5.31 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 122.4 0.28 . . . . 0.0 110.884 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 21' ' ' CYS . 68.9 m -110.57 157.96 19.08 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.678 -0.237 . . . . 0.0 111.569 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.543 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 49.9 t -120.84 129.25 53.46 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.231 -179.798 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.415 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 38.5 p -94.61 144.56 25.5 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.435 179.226 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 58.9 mttp -56.0 -17.75 7.59 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 113.638 0.977 . . . . 0.0 113.638 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -76.4 -7.36 54.87 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.701 0.286 . . . . 0.0 111.282 179.132 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 95.07 46.84 2.76 Favored Glycine 0 C--N 1.343 0.943 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.629 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.415 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 95.0 m-85 -139.57 156.88 46.62 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.504 0.192 . . . . 0.0 111.489 -179.696 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.438 ' HA ' ' O ' ' A' ' 14' ' ' CYS . 0.7 OUTLIER -137.81 133.73 34.35 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.55 179.395 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.495 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -164.88 166.97 38.39 Favored Glycine 0 C--N 1.338 0.694 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.667 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.2 t -105.94 148.32 27.79 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 120.664 0.268 . . . . 0.0 111.063 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.22 177.81 25.3 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.405 -0.664 . . . . 0.0 112.807 179.83 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -79.57 64.51 8.86 Favored 'Trans proline' 0 C--N 1.372 1.788 0 C-N-CA 122.948 2.432 . . . . 0.0 112.468 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.61 -48.77 0.39 Allowed 'General case' 0 C--O 1.235 0.326 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.053 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 98.6 m-85 -103.66 -5.63 22.41 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.021 178.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 86.0 m -95.16 -41.2 9.21 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.491 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.2 -61.12 0.82 Allowed Glycine 0 C--N 1.341 0.828 0 CA-C-N 116.215 -0.448 . . . . 0.0 112.506 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.02 0 CA-C-O 118.367 -1.24 . . . . 0.0 112.613 179.978 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.327 0 CA-C-O 120.543 0.211 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 108.18 -54.8 0.54 Allowed Glycine 0 C--N 1.338 0.641 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.589 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -124.6 149.89 46.57 Favored 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 122.307 0.243 . . . . 0.0 110.931 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.526 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 93.0 m -91.52 150.26 21.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.276 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.3 t -121.95 112.53 35.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.922 179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 77.1 mtp180 57.62 25.84 12.16 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 123.859 0.863 . . . . 0.0 112.626 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.55 18.49 54.85 Favored Glycine 0 C--N 1.338 0.662 0 CA-C-N 115.779 -0.646 . . . . 0.0 113.531 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -133.02 124.39 27.59 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-O 120.634 0.254 . . . . 0.0 110.822 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.526 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 43.2 t -135.55 116.57 11.88 Favored Pre-proline 0 CA--C 1.54 0.571 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.844 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -80.82 -161.64 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 122.36 2.04 . . . . 0.0 112.859 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.05 -30.69 7.75 Favored Glycine 0 C--N 1.34 0.788 0 O-C-N 123.388 0.43 . . . . 0.0 113.013 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.93 42.27 3.11 Favored Glycine 0 C--N 1.338 0.639 0 C-N-CA 121.617 -0.325 . . . . 0.0 112.685 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.71 -171.24 2.73 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 122.578 0.351 . . . . 0.0 110.729 -179.952 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 99.6 m -96.08 156.76 16.2 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 111.895 0.331 . . . . 0.0 111.895 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.3 t -126.69 127.4 45.08 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.8 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.475 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 35.5 p -93.61 143.67 26.09 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.61 179.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -54.24 -20.43 6.97 Favored 'General case' 0 N--CA 1.481 1.086 0 N-CA-C 113.749 1.018 . . . . 0.0 113.749 -178.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -76.08 -6.88 53.17 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.356 0.263 . . . . 0.0 111.321 179.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.79 47.15 3.0 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.558 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.475 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 89.5 m-85 -138.25 161.98 35.49 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 111.876 0.324 . . . . 0.0 111.876 -179.483 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.44 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 15.1 m -123.54 151.68 42.61 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.685 179.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.59 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 176.31 155.32 12.97 Favored Glycine 0 C--N 1.34 0.804 0 C-N-CA 121.168 -0.539 . . . . 0.0 112.84 179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.7 t -110.67 145.1 38.56 Favored 'General case' 0 C--O 1.235 0.34 0 O-C-N 123.723 0.308 . . . . 0.0 110.822 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 100.58 -178.71 28.92 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-O 119.368 -0.684 . . . . 0.0 112.809 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.5 Cg_exo -76.83 62.75 7.38 Favored 'Trans proline' 0 C--N 1.371 1.721 0 C-N-CA 122.974 2.449 . . . . 0.0 112.508 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.9 -46.22 0.4 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.135 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.453 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.7 m-85 -114.32 -2.62 13.26 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.158 178.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 84.6 m -94.05 -41.98 9.26 Favored 'General case' 0 C--N 1.344 0.332 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.544 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -153.86 96.62 0.16 Allowed Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.293 -0.412 . . . . 0.0 112.51 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 118.394 -1.226 . . . . 0.0 112.484 179.966 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.516 0.198 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 100.52 70.83 0.93 Allowed Glycine 0 C--N 1.337 0.622 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.583 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -128.17 145.63 50.97 Favored 'General case' 0 N--CA 1.465 0.306 0 O-C-N 123.607 0.239 . . . . 0.0 110.849 -179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.414 ' SG ' ' SG ' ' A' ' 9' ' ' CYS . 58.2 m -98.64 130.89 45.17 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 123.675 0.61 . . . . 0.0 111.115 179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.4 t -101.76 95.26 3.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 97.4 mtt180 58.24 24.69 11.75 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 123.815 0.846 . . . . 0.0 112.322 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 87.41 47.44 4.62 Favored Glycine 0 C--N 1.34 0.796 0 CA-C-N 115.662 -0.699 . . . . 0.0 112.965 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -133.72 119.0 18.76 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 120.86 0.362 . . . . 0.0 111.28 -179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 54.8 m -141.25 151.78 62.53 Favored Pre-proline 0 CA--C 1.536 0.437 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.626 179.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -70.36 -159.23 0.06 OUTLIER 'Trans proline' 0 C--N 1.373 1.832 0 C-N-CA 122.46 2.107 . . . . 0.0 113.007 -179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -105.82 37.7 3.68 Favored Glycine 0 C--N 1.34 0.794 0 O-C-N 123.341 0.401 . . . . 0.0 112.864 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -121.97 -44.14 0.38 Allowed Glycine 0 C--N 1.338 0.647 0 C-N-CA 121.655 -0.307 . . . . 0.0 112.539 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.543 HD12 ' N ' ' A' ' 22' ' ' GLY . 1.3 pt? -118.62 178.84 4.32 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 122.478 0.311 . . . . 0.0 110.87 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 69.1 m -109.87 152.43 25.79 Favored 'General case' 0 N--CA 1.464 0.272 0 O-C-N 123.103 0.252 . . . . 0.0 111.43 -178.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.549 ' HB2' ' SG ' ' A' ' 9' ' ' CYS . 46.4 t -109.82 128.37 55.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.146 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 57.9 m -95.92 138.7 33.18 Favored 'General case' 0 C--O 1.239 0.541 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.529 179.307 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -54.3 -22.1 11.05 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 113.615 0.969 . . . . 0.0 113.615 -178.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -76.27 -6.81 53.11 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.418 0.287 . . . . 0.0 111.229 179.158 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.96 44.35 3.61 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-N 115.779 -0.646 . . . . 0.0 112.51 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -143.03 123.61 14.04 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.629 0.252 . . . . 0.0 111.373 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -106.05 140.41 39.08 Favored 'General case' 0 C--O 1.235 0.293 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.66 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.543 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -170.83 167.9 41.04 Favored Glycine 0 C--N 1.338 0.691 0 O-C-N 123.603 0.565 . . . . 0.0 112.668 -179.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 36.5 p -105.37 150.75 24.95 Favored 'General case' 0 C--O 1.235 0.299 0 CA-C-O 120.604 0.24 . . . . 0.0 111.369 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.77 176.35 26.96 Favored Glycine 0 CA--C 1.53 0.973 0 CA-C-O 119.276 -0.735 . . . . 0.0 112.876 179.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -78.53 63.79 8.5 Favored 'Trans proline' 0 C--N 1.371 1.754 0 C-N-CA 122.945 2.43 . . . . 0.0 112.375 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.4 -48.27 0.44 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.158 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -105.62 -3.7 21.97 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.026 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.2 m -94.96 -43.71 8.04 Favored 'General case' 0 C--N 1.343 0.298 0 CA-C-N 115.685 -0.688 . . . . 0.0 111.499 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.67 -88.01 0.5 Allowed Glycine 0 C--N 1.341 0.821 0 O-C-N 123.449 0.468 . . . . 0.0 112.486 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.121 0 CA-C-O 118.343 -1.254 . . . . 0.0 112.667 179.999 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.539 0.209 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 161.55 77.53 0.03 OUTLIER Glycine 0 C--N 1.337 0.627 0 CA-C-N 115.849 -0.614 . . . . 0.0 112.44 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -129.25 142.46 50.84 Favored 'General case' 0 C--O 1.235 0.308 0 C-N-CA 122.349 0.26 . . . . 0.0 110.845 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.539 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 97.5 m -92.02 150.12 21.16 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.339 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.5 t -123.46 110.62 26.57 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.785 179.785 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 57.46 25.76 11.79 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 123.88 0.872 . . . . 0.0 112.68 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.07 21.76 37.83 Favored Glycine 0 C--N 1.339 0.732 0 CA-C-N 115.748 -0.66 . . . . 0.0 113.524 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 -134.79 123.55 23.75 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 120.654 0.264 . . . . 0.0 110.787 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.539 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 48.2 t -136.82 116.96 10.77 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.815 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 83.3 Cg_endo -80.77 -161.84 0.16 Allowed 'Trans proline' 0 C--N 1.37 1.69 0 C-N-CA 122.37 2.047 . . . . 0.0 112.877 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 93.99 -30.39 7.62 Favored Glycine 0 C--N 1.341 0.815 0 O-C-N 123.344 0.403 . . . . 0.0 113.057 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.43 42.74 3.36 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 121.582 -0.342 . . . . 0.0 112.675 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.583 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.86 -170.26 2.47 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 122.532 0.333 . . . . 0.0 110.796 -179.958 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.9 m -95.42 154.55 17.15 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.766 0.317 . . . . 0.0 111.725 -178.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 42.8 t -123.89 128.95 50.21 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.792 179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.468 ' OG ' ' HB2' ' A' ' 20' ' ' PHE . 46.9 p -96.78 141.65 29.74 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.444 179.46 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -54.94 -19.32 6.45 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -178.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -76.33 -7.25 54.56 Favored 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.141 0.275 . . . . 0.0 111.239 179.116 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.58 46.64 2.92 Favored Glycine 0 C--N 1.342 0.901 0 CA-C-N 115.884 -0.598 . . . . 0.0 112.607 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.468 ' HB2' ' OG ' ' A' ' 16' ' ' SER . 93.3 m-85 -139.6 164.25 30.4 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.435 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 19.8 m -126.4 152.64 46.07 Favored 'General case' 0 C--O 1.237 0.416 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.752 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.583 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 179.51 153.41 11.77 Favored Glycine 0 C--N 1.341 0.806 0 C-N-CA 121.194 -0.527 . . . . 0.0 112.641 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 53.1 m -103.62 137.51 41.57 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 122.271 0.228 . . . . 0.0 111.324 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.59 179.95 22.14 Favored Glycine 0 CA--C 1.529 0.958 0 CA-C-O 119.36 -0.689 . . . . 0.0 112.953 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -80.13 65.94 8.85 Favored 'Trans proline' 0 C--N 1.37 1.706 0 C-N-CA 123.101 2.534 . . . . 0.0 112.378 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.06 -49.34 0.42 Allowed 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.124 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.561 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 94.1 m-85 -101.11 -5.88 25.08 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.087 178.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.6 -42.54 8.36 Favored 'General case' 0 C--N 1.343 0.305 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.484 -179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.37 -56.38 0.46 Allowed Glycine 0 C--N 1.34 0.799 0 O-C-N 123.445 0.466 . . . . 0.0 112.498 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.357 -1.246 . . . . 0.0 112.504 179.998 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.301 0 CA-C-O 120.52 0.2 . . . . 0.0 111.083 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -159.12 -53.72 0.01 OUTLIER Glycine 0 C--N 1.337 0.592 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.55 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -104.45 152.05 22.8 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 122.369 0.268 . . . . 0.0 110.937 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.52 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 72.4 m -90.38 148.89 22.53 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.239 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.4 t -117.68 112.1 37.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.889 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 57.04 25.87 11.27 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 123.912 0.885 . . . . 0.0 112.688 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.98 20.39 46.74 Favored Glycine 0 C--N 1.339 0.705 0 CA-C-N 115.764 -0.653 . . . . 0.0 113.478 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -133.91 123.68 25.1 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.594 0.235 . . . . 0.0 110.813 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.52 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 38.7 t -136.38 116.43 11.05 Favored Pre-proline 0 CA--C 1.54 0.589 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.7 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -80.73 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.369 1.634 0 C-N-CA 122.348 2.032 . . . . 0.0 112.883 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.04 -30.65 7.8 Favored Glycine 0 C--N 1.34 0.798 0 O-C-N 123.377 0.423 . . . . 0.0 113.038 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.51 42.97 3.04 Favored Glycine 0 C--N 1.339 0.695 0 C-N-CA 121.588 -0.339 . . . . 0.0 112.588 -179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.605 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -134.38 -171.68 2.82 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 122.649 0.38 . . . . 0.0 110.778 -179.86 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 74.9 m -97.03 158.36 15.46 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.685 0.279 . . . . 0.0 111.744 -178.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.434 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 43.0 t -128.6 127.2 41.79 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.735 -0.666 . . . . 0.0 111.089 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 22.6 t -89.22 144.85 25.8 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.394 179.102 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -53.94 -22.36 10.03 Favored 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 113.726 1.01 . . . . 0.0 113.726 -178.753 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -76.2 -5.72 48.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-O 120.622 0.248 . . . . 0.0 111.511 179.352 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.57 48.48 2.75 Favored Glycine 0 C--N 1.343 0.947 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.631 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.434 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 85.1 m-85 -136.23 160.96 37.1 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -179.503 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.441 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 15.4 m -121.9 151.15 41.02 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.776 179.729 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.605 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 175.98 150.09 7.87 Favored Glycine 0 C--N 1.341 0.857 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.658 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 16.5 t -108.85 145.53 35.14 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 123.628 0.251 . . . . 0.0 110.804 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 99.71 -177.49 29.33 Favored Glycine 0 CA--C 1.528 0.885 0 CA-C-O 119.369 -0.684 . . . . 0.0 112.77 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -77.16 62.76 7.6 Favored 'Trans proline' 0 C--N 1.37 1.707 0 C-N-CA 122.962 2.441 . . . . 0.0 112.596 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.54 -45.81 0.37 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.083 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.577 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.0 m-85 -114.7 -3.43 12.85 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.12 178.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 74.0 m -94.7 -44.48 7.78 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.568 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -154.37 124.46 1.55 Allowed Glycine 0 C--N 1.341 0.846 0 O-C-N 123.469 0.481 . . . . 0.0 112.403 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.416 -1.214 . . . . 0.0 112.581 179.993 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 120.478 0.18 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 151.22 -59.19 0.42 Allowed Glycine 0 C--N 1.337 0.607 0 CA-C-N 115.872 -0.603 . . . . 0.0 112.514 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -129.26 143.06 50.71 Favored 'General case' 0 C--O 1.235 0.321 0 O-C-N 123.649 0.264 . . . . 0.0 110.901 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 62.3 m -98.68 136.42 38.77 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.864 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.0 t -116.41 114.6 46.51 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.284 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.8 mtt180 54.97 26.25 7.76 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.953 0.901 . . . . 0.0 112.957 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 86.64 27.49 29.41 Favored Glycine 0 C--N 1.338 0.693 0 CA-C-N 115.974 -0.557 . . . . 0.0 113.515 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 73.1 mtp180 -129.59 113.96 15.47 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 120.89 0.376 . . . . 0.0 110.694 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 46.7 t -146.96 115.36 4.35 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.768 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_endo -81.04 -162.86 0.2 Allowed 'Trans proline' 0 C--N 1.369 1.649 0 C-N-CA 122.373 2.049 . . . . 0.0 112.626 179.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 91.84 -30.17 6.82 Favored Glycine 0 C--N 1.34 0.795 0 O-C-N 123.38 0.425 . . . . 0.0 112.975 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.2 46.1 2.67 Favored Glycine 0 C--N 1.339 0.717 0 C-N-CA 121.674 -0.298 . . . . 0.0 112.873 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.621 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.6 OUTLIER -134.19 -172.43 3.0 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 122.486 0.315 . . . . 0.0 110.81 179.951 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -104.86 170.18 8.02 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 -178.085 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.3 m -122.08 130.53 53.34 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.613 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 t -91.46 142.51 27.59 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.312 178.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -55.1 -20.97 11.19 Favored 'General case' 0 N--CA 1.481 1.117 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -77.65 -5.31 49.94 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 122.384 0.274 . . . . 0.0 111.461 179.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.07 46.64 3.04 Favored Glycine 0 C--N 1.343 0.924 0 CA-C-N 115.975 -0.557 . . . . 0.0 112.462 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.3 m-85 -136.92 169.62 17.46 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.6 0.238 . . . . 0.0 111.602 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -127.07 141.54 51.75 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.621 179.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.621 ' N ' HD12 ' A' ' 13' ' ' LEU . . . -179.54 150.84 9.6 Favored Glycine 0 C--N 1.339 0.748 0 O-C-N 123.514 0.509 . . . . 0.0 112.361 -179.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 15.4 t -100.94 143.38 31.16 Favored 'General case' 0 C--O 1.235 0.309 0 O-C-N 123.618 0.246 . . . . 0.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 98.38 -179.66 32.14 Favored Glycine 0 CA--C 1.529 0.965 0 CA-C-O 119.376 -0.68 . . . . 0.0 112.943 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -79.97 65.41 8.89 Favored 'Trans proline' 0 C--N 1.371 1.726 0 C-N-CA 123.007 2.471 . . . . 0.0 112.425 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -141.19 -49.54 0.42 Allowed 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 115.142 -0.936 . . . . 0.0 109.986 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.466 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 86.1 m-85 -106.52 -6.51 18.05 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.015 178.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -108.44 -42.58 4.53 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.355 -179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -100.39 142.57 15.92 Favored Glycine 0 C--N 1.34 0.794 0 O-C-N 123.501 0.501 . . . . 0.0 112.535 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.108 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.46 -179.938 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.249 0 CA-C-O 120.538 0.208 . . . . 0.0 111.04 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 155.58 -67.84 0.3 Allowed Glycine 0 C--N 1.337 0.627 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.455 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -110.33 149.13 30.64 Favored 'General case' 0 C--O 1.235 0.325 0 O-C-N 123.631 0.254 . . . . 0.0 110.962 -179.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.559 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 86.2 m -91.46 150.47 21.22 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.394 179.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 4.2 t -118.46 112.66 39.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.871 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 96.7 mtt180 56.86 26.03 11.13 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 123.891 0.876 . . . . 0.0 112.782 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 88.82 17.13 57.1 Favored Glycine 0 C--N 1.339 0.735 0 CA-C-N 115.817 -0.628 . . . . 0.0 113.581 179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -133.09 125.7 30.17 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.748 0.274 . . . . 0.0 110.824 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.559 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.7 t -134.94 117.92 12.97 Favored Pre-proline 0 CA--C 1.539 0.555 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.824 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -80.27 -161.73 0.16 Allowed 'Trans proline' 0 C--N 1.371 1.72 0 C-N-CA 122.43 2.087 . . . . 0.0 112.92 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 94.75 -30.37 8.01 Favored Glycine 0 C--N 1.34 0.8 0 O-C-N 123.437 0.46 . . . . 0.0 113.015 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.61 41.8 3.07 Favored Glycine 0 C--N 1.338 0.654 0 C-N-CA 121.559 -0.353 . . . . 0.0 112.637 -179.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.593 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.86 -170.96 2.61 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 122.644 0.377 . . . . 0.0 110.788 -179.938 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 73.2 m -98.36 160.03 14.56 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.648 0.261 . . . . 0.0 111.656 -178.515 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 50.9 t -127.73 128.6 45.67 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.058 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.9 t -90.26 143.66 26.56 Favored 'General case' 0 C--O 1.239 0.531 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.3 179.151 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -54.46 -21.55 10.24 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -178.67 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -76.99 -5.72 49.76 Favored 'General case' 0 N--CA 1.471 0.576 0 O-C-N 123.152 0.282 . . . . 0.0 111.47 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 93.78 48.72 2.65 Favored Glycine 0 C--N 1.341 0.839 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.622 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -136.78 160.99 37.2 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.718 0.294 . . . . 0.0 111.752 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 16.2 m -120.85 148.95 43.33 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.627 179.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.593 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 179.51 149.51 8.45 Favored Glycine 0 C--N 1.341 0.849 0 C-N-CA 121.067 -0.587 . . . . 0.0 112.55 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 40.3 p -103.83 134.13 47.65 Favored 'General case' 0 C--O 1.234 0.275 0 O-C-N 123.635 0.256 . . . . 0.0 111.225 -179.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 107.55 -178.89 21.9 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-O 119.358 -0.69 . . . . 0.0 112.908 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -80.03 65.2 8.91 Favored 'Trans proline' 0 C--N 1.371 1.735 0 C-N-CA 123.101 2.534 . . . . 0.0 112.417 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.75 -48.83 0.43 Allowed 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.129 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.512 ' CD1' ' HA3' ' A' ' 22' ' ' GLY . 91.6 m-85 -105.74 -5.5 19.87 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.029 178.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.9 -42.07 8.49 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.422 -179.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 102.98 129.79 6.78 Favored Glycine 0 C--N 1.34 0.783 0 O-C-N 123.351 0.407 . . . . 0.0 112.556 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.074 0 CA-C-O 118.501 -1.166 . . . . 0.0 112.52 179.98 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.288 0 CA-C-O 120.482 0.182 . . . . 0.0 111.06 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -147.23 -110.64 0.62 Allowed Glycine 0 C--N 1.338 0.661 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.482 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -130.86 152.93 49.65 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 123.654 0.267 . . . . 0.0 110.991 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.543 ' SG ' ' HB2' ' A' ' 9' ' ' CYS . 85.4 m -88.35 148.79 24.09 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.035 -0.529 . . . . 0.0 111.319 179.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 5.1 t -113.21 107.2 22.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ARG . . . . . . . . . . . . . 95.8 mtt180 56.12 26.71 10.5 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.932 0.893 . . . . 0.0 112.647 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 92.4 20.89 33.71 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.465 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 72.1 mtp180 -134.2 121.86 21.98 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 116.72 0.26 . . . . 0.0 110.771 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.543 ' HB2' ' SG ' ' A' ' 4' ' ' CYS . 30.2 t -137.06 115.72 10.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.824 -179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.93 -161.46 0.15 Allowed 'Trans proline' 0 C--N 1.37 1.68 0 C-N-CA 122.393 2.062 . . . . 0.0 112.912 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.69 -31.18 7.44 Favored Glycine 0 C--N 1.34 0.771 0 O-C-N 123.317 0.386 . . . . 0.0 113.016 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 98.15 42.56 2.99 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 121.575 -0.345 . . . . 0.0 112.544 -179.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.582 HD12 ' N ' ' A' ' 22' ' ' GLY . 0.7 OUTLIER -133.59 -169.45 2.29 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.588 0.355 . . . . 0.0 110.695 -179.883 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 58.7 m -98.0 155.61 17.02 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.715 0.293 . . . . 0.0 111.58 -178.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 40.4 t -126.38 127.98 46.33 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.934 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.7 m -92.07 141.82 28.19 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.419 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -55.22 -19.78 9.0 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -77.07 -6.16 51.7 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 122.458 0.303 . . . . 0.0 111.361 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.49 48.28 2.59 Favored Glycine 0 C--N 1.343 0.936 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.702 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -138.83 161.14 38.0 Favored 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 111.864 0.32 . . . . 0.0 111.864 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.435 ' SG ' ' SG ' ' A' ' 4' ' ' CYS . 14.5 m -123.96 151.15 43.96 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.65 179.623 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.582 ' N ' HD12 ' A' ' 13' ' ' LEU . . . 177.47 153.46 11.04 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.694 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 42.0 p -106.36 140.78 38.74 Favored 'General case' 0 C--O 1.234 0.282 0 C-N-CA 122.325 0.25 . . . . 0.0 111.253 -179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 104.53 -178.98 24.41 Favored Glycine 0 CA--C 1.529 0.923 0 CA-C-N 115.744 -0.662 . . . . 0.0 112.867 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.46 65.86 8.87 Favored 'Trans proline' 0 C--N 1.371 1.714 0 C-N-CA 123.086 2.524 . . . . 0.0 112.409 -179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -140.97 -49.45 0.43 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.996 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.521 ' CD2' ' HA3' ' A' ' 22' ' ' GLY . 95.4 m-85 -103.57 -7.24 20.95 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.958 178.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.92 -43.72 7.34 Favored 'General case' 0 C--N 1.343 0.314 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.414 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 118.84 117.56 2.72 Favored Glycine 0 C--N 1.341 0.822 0 O-C-N 123.447 0.467 . . . . 0.0 112.536 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.528 -1.151 . . . . 0.0 112.551 -179.989 . . . . . . . . 0 0 . 1 stop_ save_